[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Ralston Group\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":269},{"warningLetters":4,"total":268},[5,32,52,75,97,117,139,158,172,192,210,231,251],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},1456,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-05-14T13:20:00Z\">05\u002F14\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-17T04:00:00Z\">04\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgnr-group-co-ltd-679766-04172024\">G.N.R. Group Co., LTD.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Juice\u002FHACCP\u002FAdulterated\u003Cbr \u002F>\r\n","","Juice\u002FHACCP\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ritz Chalermchaicharn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>G.N.R. Group Co., LTD.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>273 Rama 3 Soi 53, Rama 3 Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yan Nawa\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bangkok\u003C\u002Fspan> \u003Cspan>10120\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thailand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@gnrgroup.co.th\"> info@gnrgroup.co.th\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 17, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nReference No. 679766\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chalermchaicharn:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your food manufacturing facility located at 273 Rama 3 Soi 53, Rama 3 Rd, Yan Nawa, Bangkok Thailand 10120 from January 22 to January 23, 2024. Your firm manufactures a frozen fruits, vegetables, and coconut juice. The inspection revealed serious deviations of the juice Hazard Analysis and Critical Control Point (HACCP) Systems regulation, Title 21, Code of Federal Regulations, Part 120 (21 CFR 120). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations, that lists the serious deviations found at your firm.\u003C\u002Fp>\n\n\u003Cp>In accordance with 21 CFR 120.9, failure of a processor to have and implement a HACCP system that complies with 21 CFR 120.6, 120.7, and 120.8, or otherwise to operate in accordance with the requirements of Part 120, renders the juice products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21U.S.C. § 342(a)(4). Accordingly, your juice products, which are subject to the requirements of 21 CFR Part 120 are adulterated in that they may have been prepared, packed, or held under conditions whereby it may have been rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>We received your email response to the FDA-483 on February 6, 2024, and address the details of your response below. Based on our review of the inspectional findings and the response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility.\u003C\u002Fp>\n\n\u003Cp>Your significant violation is as follows:\u003Cbr>\n\u003Cbr>\nYou must include in your HACCP plan control measures that will consistently produce, at a minimum, a 5-log reduction, for a period at least as long as the shelf life of the product when stored under normal and moderate abuse conditions, in the pertinent microorganism, as required by 21 CFR 120.24(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your HACCP plan for Frozen Coconut Juice lists the critical limits for pasteurization of \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Celsius for \u003Cstrong>(b)(4)\u003C\u002Fstrong> seconds at two critical control points: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to control pathogenic bacteria. However, your Frozen Coconut Juice is a low-acid juice product, and \u003Cem>Clostridium botulinum\u003C\u002Fem> is the pertinent microorganism. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> process for both the coconut meat and for the coconut water are not sufficient to produce a minimum 5-log reduction in non-proteolytic \u003Cem>Clostridium botulinum&nbsp;\u003C\u002Fem>(NPB), the pertinent microorganism. You have not provided documentation to demonstrate the identified control measures will consistently produce a 5-log reduction of the pertinent microorganisms in your Frozen Coconut Juice.\u003C\u002Fp>\n\n\u003Cp>In your response, you cited the article, “Thermal Pasteurization of RTE Foods and Vegetables,” as support for your critical limits for the pasteurization (i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong> process). However, we note that the article recognizes, “… for low-acid juices such as carrot juice, C. botulinum may be present and produce toxins, and therefore becomes the pathogen hazard of concern”. The article further states, “A severe pasteurization process of F90°C = 10.0 min aiming at a 6D process inactivation of nonproteolytic C. botulinum allows a product shelf life of up to 6 weeks at 5°C”. We recommend you engage with a process authority to develop a thermal process that will consistently produce a minimum 5-log reduction in non-proteolytic \u003Cem>Clostridium botulinum&nbsp;\u003C\u002Fem>(NPB). In your response to this letter, you should provide data demonstrating the efficacy of the proposed thermal treatment for Frozen Coconut Juice you produce (i.e., the treatment will repeatedly and reliably produce the required microbial reduction).\u003C\u002Fp>\n\n\u003Cp>This letter may not list all the violations at your facility. You are responsible for ensuring that your facility operates in compliance with the Act and all applicable regulations. You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations. If you do not believe your products are in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. Responding in English will help to assist us in our review of your documentation.\u003C\u002Fp>\n\n\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take action to refuse admission of your juice products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including subjecting it to detention without physical examination (DWPE). FDA's DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the juice HACCP regulation is Import Alert #20-07. You may view this alert at: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_761.html.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Victoria Wagoner, Compliance Officer, Office of Compliance, Division of Enforcement, Food Assessment and Adulteration Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Victoria Wagoner via email at Victoria.Wagoner@fda.hhs.gov. Please reference 679766 on any submissions and within the subject line of any emails to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Ritz Chalermchaicharn\n\nRecipient Title\n\nGeneral Manager\n\nG.N.R. Group Co., LTD.\n\n273 Rama 3 Soi 53, Rama 3 Rd\n\nYan Nawa\n\nBangkok 10120\n\nThailand\n\ninfo@gnrgroup.co.th\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nApril 17, 2024\n\nWARNING LETTER\n\nReference No. 679766\n\nDear Mr. Chalermchaicharn:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your food manufacturing facility located at 273 Rama 3 Soi 53, Rama 3 Rd, Yan Nawa, Bangkok Thailand 10120 from January 22 to January 23, 2024. Your firm manufactures a frozen fruits, vegetables, and coconut juice. The inspection revealed serious deviations of the juice Hazard Analysis and Critical Control Point (HACCP) Systems regulation, Title 21, Code of Federal Regulations, Part 120 (21 CFR 120). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations, that lists the serious deviations found at your firm.\n\nIn accordance with 21 CFR 120.9, failure of a processor to have and implement a HACCP system that complies with 21 CFR 120.6, 120.7, and 120.8, or otherwise to operate in accordance with the requirements of Part 120, renders the juice products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21U.S.C. § 342(a)(4). Accordingly, your juice products, which are subject to the requirements of 21 CFR Part 120 are adulterated in that they may have been prepared, packed, or held under conditions whereby it may have been rendered injurious to health.\n\nWe received your email response to the FDA-483 on February 6, 2024, and address the details of your response below. Based on our review of the inspectional findings and the response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility.\n\nYour significant violation is as follows:\n\nYou must include in your HACCP plan control measures that will consistently produce, at a minimum, a 5-log reduction, for a period at least as long as the shelf life of the product when stored under normal and moderate abuse conditions, in the pertinent microorganism, as required by 21 CFR 120.24(a).\n\nSpecifically, your HACCP plan for Frozen Coconut Juice lists the critical limits for pasteurization of (b)(4) degrees Celsius for (b)(4) seconds at two critical control points: “(b)(4)” and “(b)(4)” to control pathogenic bacteria. However, your Frozen Coconut Juice is a low-acid juice product, and Clostridium botulinum is the pertinent microorganism. Your (b)(4) process for both the coconut meat and for the coconut water are not sufficient to produce a minimum 5-log reduction in non-proteolytic Clostridium botulinum (NPB), the pertinent microorganism. You have not provided documentation to demonstrate the identified control measures will consistently produce a 5-log reduction of the pertinent microorganisms in your Frozen Coconut Juice.\n\nIn your response, you cited the article, “Thermal Pasteurization of RTE Foods and Vegetables,” as support for your critical limits for the pasteurization (i.e., (b)(4) process). However, we note that the article recognizes, “… for low-acid juices such as carrot juice, C. botulinum may be present and produce toxins, and therefore becomes the pathogen hazard of concern”. The article further states, “A severe pasteurization process of F90°C = 10.0 min aiming at a 6D process inactivation of nonproteolytic C. botulinum allows a product shelf life of up to 6 weeks at 5°C”. We recommend you engage with a process authority to develop a thermal process that will consistently produce a minimum 5-log reduction in non-proteolytic Clostridium botulinum (NPB). In your response to this letter, you should provide data demonstrating the efficacy of the proposed thermal treatment for Frozen Coconut Juice you produce (i.e., the treatment will repeatedly and reliably produce the required microbial reduction).\n\nThis letter may not list all the violations at your facility. You are responsible for ensuring that your facility operates in compliance with the Act and all applicable regulations. You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations. If you do not believe your products are in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. Responding in English will help to assist us in our review of your documentation.\n\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take action to refuse admission of your juice products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including subjecting it to detention without physical examination (DWPE). FDA's DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the juice HACCP regulation is Import Alert #20-07. You may view this alert at: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_761.html.\n\nPlease send your reply to the Food and Drug Administration, Attention: Victoria Wagoner, Compliance Officer, Office of Compliance, Division of Enforcement, Food Assessment and Adulteration Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Victoria Wagoner via email at Victoria.Wagoner@fda.hhs.gov. Please reference 679766 on any submissions and within the subject line of any emails to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition","G.N.R. Group Co., LTD.","gnr-group-co-ltd-679766-04172024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgnr-group-co-ltd-679766-04172024","2026-10-26T08:08:47.316352+00:00","Warning Letter","Issued","2024-05-14","679766","Food & Beverages","Mr. Ritz Chalermchaicharn","2026-08-20T00:05:33.548+00:00","Via Express Delivery","2024-04-17",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":20,"letter_url":45,"updated_at":46,"action_type":23,"case_status":24,"posted_date":47,"marcs_cms_no":48,"product_type":27,"closeout_date":20,"issuing_office":38,"recipient_name":49,"body_fetched_at":50,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":51,"medical_device_id":20,"response_letter_date":20},97,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fys-group-inc-731129-06082026\">YS Group Inc.\u003C\u002Fa>","Office of Inspections and Investigations","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yamato Miura, Co-Chief Executive Officer and Chief Financial Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Steve Tieu, Co-Chief Executive Officer and Secretary \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>YS Group Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1108 S Baldwin Ave Suite B6\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Arcadia\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91007\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS #731129\u003C\u002Fp>\u003Cp>Dear Mr. Miura and Mr. Tieu:\u003C\u002Fp>\u003Cp>On April 30, 2026 through May 12, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of YS Group Inc. located at 1108 S Baldwin Ave Suite B6, Arcadia, CA 91007. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import.\u003C\u002Fp>\u003Cp>Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your response dated June 2, 2026 in which you stated you developed the hazard analysis for the tofu skin imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and requested \u003Cstrong>(b)(4)\u003C\u002Fstrong> to provide a certificate of analysis for future shipments of tofu skin as documentation of your verification activity. You also clarified that the foreign supplier of the buckwheat flour listed on the Form FDA 483a was a distributor and you will update your database to the correct manufacturer. You included the hazard analysis for tofu skin imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the response. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Tofu Skin imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Dried Seaweed imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Buckwheat Flour imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During our inspection you provided the following:\u003C\u002Fp>\u003Cul>\u003Cli>Supplier HACCP Verification Records for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>HACCP plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You stated that you are not familiar with FSVP requirements and have just recently started to conduct and document FSVP activities. However, it is not clear how these documents would apply to your FSVP program as the HACCP records are for fish and fishery products, and you did not explain how they would apply to your FSVP program.\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the food from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Lydia Chan, Compliance Officer, 1201 Harbor Bay Parkway, Alameda, CA 94502. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Lydia Chan via email at lydia.chan@fda.hhs.gov. Please reference CMS #731129 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Dr. Kathleen Turner\u003Cbr>Program Division Director\u003Cbr>Division of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nYamato Miura, Co-Chief Executive Officer and Chief Financial Officer\n\nRecipient Title\n\nSteve Tieu, Co-Chief Executive Officer and Secretary\n\nYS Group Inc.\n\n1108 S Baldwin Ave Suite B6\n\nArcadia, CA 91007\n\nUnited States\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nRe: CMS #731129\nDear Mr. Miura and Mr. Tieu:\nOn April 30, 2026 through May 12, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of YS Group Inc. located at 1108 S Baldwin Ave Suite B6, Arcadia, CA 91007. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import.\nBecause of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe acknowledge receipt of your response dated June 2, 2026 in which you stated you developed the hazard analysis for the tofu skin imported from (b)(4) and requested (b)(4) to provide a certificate of analysis for future shipments of tofu skin as documentation of your verification activity. You also clarified that the foreign supplier of the buckwheat flour listed on the Form FDA 483a was a distributor and you will update your database to the correct manufacturer. You included the hazard analysis for tofu skin imported from (b)(4) with the response. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\nTofu Skin imported from (b)(4)\nDried Seaweed imported from (b)(4)\nBuckwheat Flour imported from (b)(4)\nDuring our inspection you provided the following:\nSupplier HACCP Verification Records for (b)(4), and (b)(4)\nHACCP plan for (b)(4)\nYou stated that you are not familiar with FSVP requirements and have just recently started to conduct and document FSVP activities. However, it is not clear how these documents would apply to your FSVP program as the HACCP records are for fish and fishery products, and you did not explain how they would apply to your FSVP program.\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the food from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Lydia Chan, Compliance Officer, 1201 Harbor Bay Parkway, Alameda, CA 94502. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Lydia Chan via email at lydia.chan@fda.hhs.gov. Please reference CMS #731129 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nDr. Kathleen Turner\nProgram Division Director\nDivision of West Coast Imports","YS Group Inc.","ys-group-inc-731129-06082026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fys-group-inc-731129-06082026","2026-10-26T08:10:37.57101+00:00","2026-06-16","731129","Yamato Miura, Co-Chief Executive Officer and Chief Financial Officer","2026-08-19T04:37:08.527+00:00","2026-06-08",{"id":53,"raw":54,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":20,"letter_url":65,"updated_at":66,"action_type":23,"case_status":24,"posted_date":67,"marcs_cms_no":68,"product_type":69,"closeout_date":20,"issuing_office":70,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":20,"reference_number":20,"action_taken_date":74,"medical_device_id":20,"response_letter_date":20},2165,[55,56,57,58,59,13,13,13],"\u003Ctime datetime=\"2023-03-14T13:20:00Z\">03\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-19T05:00:00Z\">01\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fb-j-group-641099-01192023\">B &amp; J Group\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Tilghman B. Frey\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>B &amp; J Group\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1001 New Ford Mill Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Morrisville\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19067\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 641099\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 19, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Frey:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers). FDA has reviewed the records you submitted in response to our January 25, 2022 and February 9, 2022 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 374(a)(4)) for your facility, B &amp; J Group, FEI 3010096700, at 1001 New Ford Mill Road, Morrisville, Pennsylvania.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs as described in your response to our 704(a)(4) request do not conform to CGMP regulations, your drug products are deemed adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B))\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>704(a)(4) Request for Records and Related CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and (b))\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your response to our request for records and other information under section 704(a)(4) indicated that you are a contract filler of OTC hand sanitizer drug products and that you did not test the finished drug products before release. Specifically, in response to our request to provide the finished product specifications and test methods for both analytical and microbiological tests for each hand sanitizer product manufactured for distribution in the United States, you stated that this is “Done by customer” and “We just filled the bottles.”\u003C\u002Fp>\n\n\u003Cp>Owners and contract manufacturing facilities are both responsible for CGMPs, which includes the implementation of oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.\u003C\u002Fp>\n\n\u003Cp>Full release testing, including for identity, strength, and impurities, must be performed prior to drug release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision:\u003Cbr>\n&nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; o A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not demonstrate adequate testing of the identity of incoming components used in the manufacture of your drug products. Specifically, your response stated that raw material identity testing for each lot of each component is “Not Applicable,” testing of ethanol or isopropyl alcohol and methanol is “Done by each customer,” and testing the potency (assay) of ethanol or isopropyl alcohol used for hand sanitizer is “Not Applicable.”\u003C\u002Fp>\n\n\u003Cp>You manufacture multiple drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19)\u003C\u002Fem> at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the information you provided, you did not demonstrate that your manufacturing processes are reproducible and controlled to yield a product of uniform character and quality. For example, we asked you to provide a copy of the most recent, completed batch production record for each hand sanitizer product manufactured. You stated in your response that batch production records are “Maintained by customers.”\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products distributed by your firm, and a full reconciliation of all material you distributed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov and CDER-OC-OMQ-Communications@fda.hhs.gov. Please also identify your response with FEI 3010096700.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u002F District Director\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOPQO Division I \u002F New Jersey District\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the&nbsp;guidance. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). Because B &amp; J Group hand sanitizer drug products were not prepared under the circumstances described in this guidance, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Tilghman B. Frey\n\nRecipient Title\n\nChief Operating Officer\n\nB & J Group\n\n1001 New Ford Mill Rd.\n\nMorrisville, PA 19067\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter 641099\n\nJanuary 19, 2023\n\nDear Mr. Frey:\n\nYour facility is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers). FDA has reviewed the records you submitted in response to our January 25, 2022 and February 9, 2022 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 374(a)(4)) for your facility, B & J Group, FEI 3010096700, at 1001 New Ford Mill Road, Morrisville, Pennsylvania.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs as described in your response to our 704(a)(4) request do not conform to CGMP regulations, your drug products are deemed adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B))1.\n\n704(a)(4) Request for Records and Related CGMP Violations\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and (b))\n\nYour response to our request for records and other information under section 704(a)(4) indicated that you are a contract filler of OTC hand sanitizer drug products and that you did not test the finished drug products before release. Specifically, in response to our request to provide the finished product specifications and test methods for both analytical and microbiological tests for each hand sanitizer product manufactured for distribution in the United States, you stated that this is “Done by customer” and “We just filled the bottles.”\n\nOwners and contract manufacturing facilities are both responsible for CGMPs, which includes the implementation of oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.\n\nFull release testing, including for identity, strength, and impurities, must be performed prior to drug release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\n\nIn response to this letter, provide:\n\n• A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision:\n\no An action plan and timelines for conducting full chemical and microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nBased on the records and information you provided, you did not demonstrate adequate testing of the identity of incoming components used in the manufacture of your drug products. Specifically, your response stated that raw material identity testing for each lot of each component is “Not Applicable,” testing of ethanol or isopropyl alcohol and methanol is “Done by each customer,” and testing the potency (assay) of ethanol or isopropyl alcohol used for hand sanitizer is “Not Applicable.”\n\nYou manufacture multiple drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nBased on the information you provided, you did not demonstrate that your manufacturing processes are reproducible and controlled to yield a product of uniform character and quality. For example, we asked you to provide a copy of the most recent, completed batch production record for each hand sanitizer product manufactured. You stated in your response that batch production records are “Maintained by customers.”\n\nIn response to this letter, provide:\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n• A list of all batches of any hand sanitizer drug products distributed by your firm, and a full reconciliation of all material you distributed.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov and CDER-OC-OMQ-Communications@fda.hhs.gov. Please also identify your response with FEI 3010096700.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\u002F District Director\n\nU.S. Food and Drug Administration\n\nOPQO Division I \u002F New Jersey District\n\n________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). Because B & J Group hand sanitizer drug products were not prepared under the circumstances described in this guidance, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.","B & J Group","b-j-group-641099-01192023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fb-j-group-641099-01192023","2026-10-26T08:08:00.033895+00:00","2023-03-14","641099","Drugs","Division of Pharmaceutical Quality Operations I","Mr. Tilghman B. Frey","2026-08-20T01:12:01.995+00:00","VIA UPS and Electronic Mail","2023-01-19",{"id":76,"raw":77,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":20,"letter_url":89,"updated_at":90,"action_type":23,"case_status":24,"posted_date":91,"marcs_cms_no":92,"product_type":69,"closeout_date":20,"issuing_office":81,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":20,"reference_number":20,"action_taken_date":96,"medical_device_id":20,"response_letter_date":20},3217,[78,79,80,81,82,13,13,13],"\u003Ctime datetime=\"2021-08-10T13:20:00Z\">08\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-04T04:00:00Z\">08\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbbc-group-limited-614659-08042021\">BBC Group Limited\u003C\u002Fa>","Center for Drug Evaluation and Research","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Alan Wong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BBC Group Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Yangxia Development Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pumei Town\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yunxiao County\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>363300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-21-53\u003C\u002Fp>\n\n\u003Cp>August 4, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Wong,\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, BBC Group Limited, FEI 3010165327, at Yangxia Development Zone, Pumei Town, Yunxiao County, Zhangzhou, China, from March 22 to March 26, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, your firm manufactures L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products that are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and are misbranded under sections 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 13, 2021 response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) drug products, including alcohol-based hand sanitizers\u003Csup>\u003Cem>\u003Cstrong>[1]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. During the inspection of your facility, our investigator attempted to review analytical data from your gas chromatograph (GC) supporting the release of drug products distributed to the United States. However, your firm stated that all testing data from 2018 to 2020 was lost approximately one month prior to the initiation of our inspection. The GC is used to analyze the identity and strength of active ingredients and impurities contained in your OTC drug products, as well as other critical parameters. According to firm management, the data is unrecoverable. While your firm retained a static copy of laboratory records for review (i.e., paper record), they were inadequate as they did not preserve the dynamic record format of the full chromatographs to support test results and they did not include system suitability documentation that are part of the complete, original record.\u003C\u002Fp>\n\n\u003Cp>Additionally, our investigator observed that the computerized system and software associated with your GC lacked restricted access. For example, your laboratory employees who used the GC to perform analyses of drug products all logged in as “System Administrator,” which does not require a password, and had full system administration rights. In addition, audit trails on your GC were not enabled.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you did not retain all original, dynamic records, obtained during the course of testing on other laboratory equipment. Your viscometer and UV-Vis spectrophotometer had the capability to save data from product\u002Fmaterial testing. Despite having this capability, your analysts failed to save the complete, dynamic testing data, and therefore the data was not available for review by the FDA investigator. The viscometer is used to measure the viscosity of finished drug products during release testing and the UV-Vis spectrophotometer is used to measure ethanol content during raw material testing.\u003C\u002Fp>\n\n\u003Cp>Your firm also utilizes electronic spreadsheets to input data for your stability program. However, these spreadsheets are not controlled and there is no protection to prevent data manipulation, overwriting, or erasure.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicated that you purchased and\u002For installed additional equipment to address this violation, including, but not limited to, an uninterrupted power source, remote hard drive, electrical equipment, and new software. Your response also states that you have updated and developed associated procedures, created individual accounts for all personnel that utilize laboratory equipment, and conducted accompanying trainings. However, your response is inadequate because it lacked supporting documentation, including evidence to support that the computer security controls were effective at preventing data and document manipulation. Additionally, you did not perform a retrospective risk assessment into how system vulnerabilities may have impacted data integrity.\u003C\u002Fp>\n\n\u003Cp>Your firm does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003Cbr>\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003Cbr>\n• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed Corrective Action and Preventive Action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003Cbr>\n• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory computer systems. This should include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A list of all hardware that includes all equipment, both standalone and network, in your laboratory.\u003Cbr>\n&nbsp; &nbsp; o Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\u003Cbr>\n&nbsp; &nbsp; o A list of all software configurations and versions, details of all user privileges, and oversight responsibilities for each of your laboratory systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory computer systems, and their organizational affiliations and titles. Also describe how you will ensure laboratory staff are not given administrative rights, or other permissions that compromise data retention or reliability.\u003Cbr>\n&nbsp; &nbsp; o System security provisions, including, but not limited to, whether unique user names\u002Fpasswords are always used, and their confidentiality safeguarded.\u003Cbr>\n&nbsp; &nbsp; o Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\u003Cbr>\n&nbsp; &nbsp; o Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\u003Cbr>\n&nbsp; &nbsp; o A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, appropriate user role assignments, secondary review of all analyses, and other system controls.\u003Cbr>\n&nbsp; &nbsp; o Provisions for oversight by QA managers, executives, and internal auditors with appropriate information technology (IT) expertise (e.g., to evaluate infrastructure, configuration, network requirements, data management practices, and segregation of duties including administrator rights).\u003Cbr>\n&nbsp; &nbsp; o A remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Include a full CAPA plan and any improvements made to date.\u003Cbr>\n&nbsp; &nbsp; o An independent, thorough retrospective assessment into the impact of laboratory system design, control, and staff practices on your data accuracy, completeness, and retention since January 1, 2018.\u003Cbr>\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your analytical test methods were not adequately validated, including those for the active ingredient ethanol, which is used to manufacture your alcohol-based hand sanitizers, and analysis for the impurity \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Specifically, no system suitability requirements were present and reference standards were not identified. Data must be available to establish that the analytical procedures used in testing meet proper standards of accuracy, sensitivity, specificity, and reproducibility and are suitable for their intended purpose.\u003Cbr>\n\u003Cbr>\nIn your response, you indicated that you updated test methods, established method validation protocols, and completed test method evaluation. However, your response is inadequate for the following reasons.\u003Cbr>\n• The response lacked information on the analyte reference standards used for the method validation.\u003Cbr>\n• The response lacked method validation details on identity of the tested analytes, system suitability, method specificity data, preparations of the analyte stock solutions, and accuracy and precision data from spike and recovery experiments at different concentration levels.\u003Cbr>\n• The response lacked an assessment of drug products manufactured utilizing the deficient methods.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003Cbr>\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• An independent assessment of all test methods and data review procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and validation to determine whether they are fit for intended purposes.\u003Cbr>\n• Your test results, using an adequately validated test method, of retains for all finished drug products, within expiry. You should test all appropriate quality attributes of each batch that you distributed into U.S. commerce to ensure that your drug products conform to appropriate standards of identity, strength, quality, and purity. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Analytical Procedures and Methods Validation for Drugs and Biologics\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of method validation at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F87801\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F87801\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our inspection, the investigator observed rust on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and product contact surfaces of four of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to manufacture drug products, including the manufacture of your OTC hand sanitizers. Upon request, you provided our investigator with manufacturing equipment maintenance logs for the aforementioned \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These documents were only available in Chinese. After the conclusion of the inspection, the FDA had the document translated and found that the document provided was for equipment identified as “liquid washing pan” with serial number WJB-001, which is located in Workshop \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> floor, and not the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with equipment ID’s 12 through 15 located in Workshop \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> floor that were observed with rust. FDA is concerned that you provided maintence records for different equipment than those requested during the inspection.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicated that you replaced all the \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response failed to address the rust documented in other parts of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, your response is inadequate as you failed to revise your cleaning and maintenance procedures to prevent recurrence of this issue, you failed to perform a risk assessment of drug products manufactured in the four \u003Cstrong>(b)(4)\u003C\u002Fstrong> that contained rust, and you did not determine the root cause of why employees who perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspections of manufacturing equipment did not observe the rust in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003Cbr>\n• Your plan for continued manufacture of drug products in the aforementioned \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing rust. Our inspection observed rust on and around the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and other parts of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n• A risk assessment for drug products manufactured in the four \u003Cstrong>(b)(4)\u003C\u002Fstrong> that contained rust to determine if a market action is warranted.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as a consumer topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“HAND SANTIZER. . .\u003Cstrong>Drug Facts\u003C\u002Fstrong>. . .\u003Cstrong>Uses\u003C\u002Fstrong>. . . to decrease bacteria on the skin that could cause disease. . . \u003Cstrong>Direction\u003C\u002Fstrong> – rub a dime sized drop into hands.”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under Section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exemptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER drug products are GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products have been the subject of rulemaking under FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use in a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act, addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products contain the active ingredient “chloroxylenol 0.015%.” Chloroxylenol is not permitted as an active ingredient for use as a consumer antiseptic hand rub drug product under the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>[2]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such products do not conform with the TFM, nor are they consistent with the formulations described in FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>[3]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, CHERRY) SCENTED HAND SANITIZER products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Disparities in Records Submitted to the Agency\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on September 30, 2020 as information you provided in your response to a FDA request for records pursuant to section 704(a)(4) of the FD&amp;C Act, 21 U.S.C. 374(a)(4), did not appear to conform to CGMP. Specifically, your response to the FDA records request demonstrated a lack of analytical data supporting drug product release, as required under 21 CFR 211.165. Subsequent to your placement on Import Alert, you submitted additional data to the agency, now including test results of drug products you distributed to the United States. To evaluate the disparity in the records provided, and in part to evaluate if your firm should be removed from import alert, FDA conducted an inspection of your facility. However, upon physical inspection of your facility, the raw data related to your submitted test results were unavailable. The records you submitted electronically prior to the inspection were not consistent with what was observed during the FDA inspection of your facility. Your firm will remain on import alert until FDA is satisfied that the appearance of violations observed have been resolved.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility\u002Fin connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on September 23, 2020.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP.We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at BBC Group Limited, FEI 3010165327, at Yangxia Development Zone; Pumei Town, Yunxiao County; Zhangzhou, China into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3010165327 and ATTN: CDR Frank Verni.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCC:\u003Cbr>\nMr. Richard Pecora, Consultant\u003Cbr>\nPecora Consulting LLC\u003Cbr>\n51 Sunnywood Drive\u003Cbr>\nWestfield, NJ 07090\u003Cbr>\npecoraconsulting@verizon.net\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rubs) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Are view of the purported formulations on the drug product’s labeling indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic handwashes and healthcare personnel handwashes an alcohol concentration of 60 to 95% by volume in an aqueous solution denatured in accordance with Bureau of Alcohol, Tobacco and Firearms regulations. 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products are not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Alan Wong\n\nRecipient Title\n\nGeneral Manager\n\nBBC Group Limited\n\nYangxia Development Zone\n\nPumei Town\n\nYunxiao County\n\n363300\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWarning Letter 320-21-53\n\nAugust 4, 2021\n\nDear Mr. Wong,\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, BBC Group Limited, FEI 3010165327, at Yangxia Development Zone, Pumei Town, Yunxiao County, Zhangzhou, China, from March 22 to March 26, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, your firm manufactures L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products that are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and are misbranded under sections 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe reviewed your April 13, 2021 response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\nCGMP Violations\n\n1. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\n\nYour firm manufactures over-the-counter (OTC) drug products, including alcohol-based hand sanitizers[1]. During the inspection of your facility, our investigator attempted to review analytical data from your gas chromatograph (GC) supporting the release of drug products distributed to the United States. However, your firm stated that all testing data from 2018 to 2020 was lost approximately one month prior to the initiation of our inspection. The GC is used to analyze the identity and strength of active ingredients and impurities contained in your OTC drug products, as well as other critical parameters. According to firm management, the data is unrecoverable. While your firm retained a static copy of laboratory records for review (i.e., paper record), they were inadequate as they did not preserve the dynamic record format of the full chromatographs to support test results and they did not include system suitability documentation that are part of the complete, original record.\n\nAdditionally, our investigator observed that the computerized system and software associated with your GC lacked restricted access. For example, your laboratory employees who used the GC to perform analyses of drug products all logged in as “System Administrator,” which does not require a password, and had full system administration rights. In addition, audit trails on your GC were not enabled.\n\nFurthermore, you did not retain all original, dynamic records, obtained during the course of testing on other laboratory equipment. Your viscometer and UV-Vis spectrophotometer had the capability to save data from product\u002Fmaterial testing. Despite having this capability, your analysts failed to save the complete, dynamic testing data, and therefore the data was not available for review by the FDA investigator. The viscometer is used to measure the viscosity of finished drug products during release testing and the UV-Vis spectrophotometer is used to measure ethanol content during raw material testing.\n\nYour firm also utilizes electronic spreadsheets to input data for your stability program. However, these spreadsheets are not controlled and there is no protection to prevent data manipulation, overwriting, or erasure.\n\nIn your response, you indicated that you purchased and\u002For installed additional equipment to address this violation, including, but not limited to, an uninterrupted power source, remote hard drive, electrical equipment, and new software. Your response also states that you have updated and developed associated procedures, created individual accounts for all personnel that utilize laboratory equipment, and conducted accompanying trainings. However, your response is inadequate because it lacked supporting documentation, including evidence to support that the computer security controls were effective at preventing data and document manipulation. Additionally, you did not perform a retrospective risk assessment into how system vulnerabilities may have impacted data integrity.\n\nYour firm does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload.\n\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide the following:\n\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed Corrective Action and Preventive Action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory computer systems. This should include, but not be limited to:\n\no A list of all hardware that includes all equipment, both standalone and network, in your laboratory.\n\no Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\n\no A list of all software configurations and versions, details of all user privileges, and oversight responsibilities for each of your laboratory systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory computer systems, and their organizational affiliations and titles. Also describe how you will ensure laboratory staff are not given administrative rights, or other permissions that compromise data retention or reliability.\n\no System security provisions, including, but not limited to, whether unique user names\u002Fpasswords are always used, and their confidentiality safeguarded.\n\no Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\n\no Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\n\no A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, appropriate user role assignments, secondary review of all analyses, and other system controls.\n\no Provisions for oversight by QA managers, executives, and internal auditors with appropriate information technology (IT) expertise (e.g., to evaluate infrastructure, configuration, network requirements, data management practices, and segregation of duties including administrator rights).\n\no A remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Include a full CAPA plan and any improvements made to date.\n\no An independent, thorough retrospective assessment into the impact of laboratory system design, control, and staff practices on your data accuracy, completeness, and retention since January 1, 2018.\n\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\n\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYour analytical test methods were not adequately validated, including those for the active ingredient ethanol, which is used to manufacture your alcohol-based hand sanitizers, and analysis for the impurity (b)(4). Specifically, no system suitability requirements were present and reference standards were not identified. Data must be available to establish that the analytical procedures used in testing meet proper standards of accuracy, sensitivity, specificity, and reproducibility and are suitable for their intended purpose.\n\nIn your response, you indicated that you updated test methods, established method validation protocols, and completed test method evaluation. However, your response is inadequate for the following reasons.\n\n• The response lacked information on the analyte reference standards used for the method validation.\n\n• The response lacked method validation details on identity of the tested analytes, system suitability, method specificity data, preparations of the analyte stock solutions, and accuracy and precision data from spike and recovery experiments at different concentration levels.\n\n• The response lacked an assessment of drug products manufactured utilizing the deficient methods.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• An independent assessment of all test methods and data review procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and validation to determine whether they are fit for intended purposes.\n\n• Your test results, using an adequately validated test method, of retains for all finished drug products, within expiry. You should test all appropriate quality attributes of each batch that you distributed into U.S. commerce to ensure that your drug products conform to appropriate standards of identity, strength, quality, and purity. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\nSee FDA’s guidance document Analytical Procedures and Methods Validation for Drugs and Biologics for general principles and approaches that FDA considers appropriate elements of method validation at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F87801\u002Fdownload.\n\n3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\nDuring our inspection, the investigator observed rust on (b)(4) and product contact surfaces of four of the (b)(4) used to manufacture drug products, including the manufacture of your OTC hand sanitizers. Upon request, you provided our investigator with manufacturing equipment maintenance logs for the aforementioned (b)(4). These documents were only available in Chinese. After the conclusion of the inspection, the FDA had the document translated and found that the document provided was for equipment identified as “liquid washing pan” with serial number WJB-001, which is located in Workshop (b)(4) on the (b)(4) floor, and not the (b)(4) with equipment ID’s 12 through 15 located in Workshop (b)(4) on the (b)(4) floor that were observed with rust. FDA is concerned that you provided maintence records for different equipment than those requested during the inspection.\n\nIn your response, you indicated that you replaced all the (b)(4) in your (b)(4). However, your response failed to address the rust documented in other parts of the (b)(4). Additionally, your response is inadequate as you failed to revise your cleaning and maintenance procedures to prevent recurrence of this issue, you failed to perform a risk assessment of drug products manufactured in the four (b)(4) that contained rust, and you did not determine the root cause of why employees who perform (b)(4) inspections of manufacturing equipment did not observe the rust in the (b)(4).\n\nIn response to this letter, provide the following:\n\n• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n• Your plan for continued manufacture of drug products in the aforementioned (b)(4) containing rust. Our inspection observed rust on and around the (b)(4) and other parts of the (b)(4).\n\n• A risk assessment for drug products manufactured in the four (b)(4) that contained rust to determine if a market action is warranted.\n\nUnapproved New Drug and Misbranding Violations\n\nL.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as a consumer topical antiseptic.\n\nExamples of claims observed on the L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n“HAND SANTIZER. . .Drug Facts. . .Uses. . . to decrease bacteria on the skin that could cause disease. . . Direction – rub a dime sized drop into hands.”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under Section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exemptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER drug products are GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products have been the subject of rulemaking under FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use in a consumer antiseptic rub.\n\nSection 505G of the FD&C Act, addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products contain the active ingredient “chloroxylenol 0.015%.” Chloroxylenol is not permitted as an active ingredient for use as a consumer antiseptic hand rub drug product under the 1994 TFM.[2] Such products do not conform with the TFM, nor are they consistent with the formulations described in FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.[3]\n\nAdditionally, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, CHERRY) SCENTED HAND SANITIZER products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nDisparities in Records Submitted to the Agency\n\nFDA placed your firm on Import Alert 66-40 on September 30, 2020 as information you provided in your response to a FDA request for records pursuant to section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4), did not appear to conform to CGMP. Specifically, your response to the FDA records request demonstrated a lack of analytical data supporting drug product release, as required under 21 CFR 211.165. Subsequent to your placement on Import Alert, you submitted additional data to the agency, now including test results of drug products you distributed to the United States. To evaluate the disparity in the records provided, and in part to evaluate if your firm should be removed from import alert, FDA conducted an inspection of your facility. However, upon physical inspection of your facility, the raw data related to your submitted test results were unavailable. The records you submitted electronically prior to the inspection were not consistent with what was observed during the FDA inspection of your facility. Your firm will remain on import alert until FDA is satisfied that the appearance of violations observed have been resolved.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility\u002Fin connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on September 23, 2020.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP.We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at BBC Group Limited, FEI 3010165327, at Yangxia Development Zone; Pumei Town, Yunxiao County; Zhangzhou, China into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3010165327 and ATTN: CDR Frank Verni.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nMr. Richard Pecora, Consultant\n\nPecora Consulting LLC\n\n51 Sunnywood Drive\n\nWestfield, NJ 07090\n\npecoraconsulting@verizon.net\n\n________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rubs) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Are view of the purported formulations on the drug product’s labeling indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic handwashes and healthcare personnel handwashes an alcohol concentration of 60 to 95% by volume in an aqueous solution denatured in accordance with Bureau of Alcohol, Tobacco and Firearms regulations. 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n3 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products are not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","BBC Group Limited","bbc-group-limited-614659-08042021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbbc-group-limited-614659-08042021","2026-10-26T08:08:01.938176+00:00","2021-08-10","614659","Mr. Alan Wong","2026-08-20T02:42:31.43+00:00","VIA UPS","2021-08-04",{"id":98,"raw":99,"subject":103,"body_html":104,"body_text":105,"firm_name":106,"letter_id":107,"created_at":108,"fei_number":20,"letter_url":109,"updated_at":110,"action_type":23,"case_status":24,"posted_date":111,"marcs_cms_no":112,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":113,"body_fetched_at":114,"delivery_method":115,"recipient_title":20,"reference_number":20,"action_taken_date":116,"medical_device_id":20,"response_letter_date":20},3520,[100,101,102,11,103,13,13,13],"\u003Ctime datetime=\"2021-02-19T17:00:00Z\">02\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-18T05:00:00Z\">02\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsana-group-llc-612256-02182021\">SANA Group LLC\u003C\u002Fa>","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason W. Harris\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>SANA Group LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1200 E. Woodhurst S-200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Springfield\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>65804\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>RE: [CMS:612256]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Dear Mr. Harris,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.sleepsana.com\u003Cspan>, \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>in December 2020 and has determined that you take orders there for your Sleep Sana “Sleep Drops” and “Sleep Shots” products. The claims on your website establish that your \u003Cspan>products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">\u003Cspan>\u003Cspan>www.fda.gov\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Examples of some of the\u003C\u002Fspan> \u003Cspan>website claims that provide evidence that your “Sleep Drops” and “Sleep Shots” are intended for use as drugs include:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>On the webpage for Sleep Sana “Sleep Drops” and “Sleep Shots” ingredients: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"GABA (an ingredient in your \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan>\u003Cspan> is taken by mouth for relieving anxiety, ... and treating attention deficit hyperactivity disorder (ADHD). It is also used for ... stabilizing blood pressure, and relieving pain.\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"L-tryptophan (an ingredient in your \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan>\u003Cspan> is used for insomnia, sleep apnea, depression, anxiety, facial pain, a severe form of premenstrual syndrome called premenstrual dysphoric disorder (PMDD), ... attention deficit-hyperactivity disorder (ADHD), Tourette's syndrome....\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>&nbsp;\"Valerian (an ingredient in your \u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan> is most commonly used for sleep disorders, especially the inability to sleep (insomnia).\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\"[Y]our body may produce melatonin (an ingredient in your \u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan> either earlier or later in the day than usual. This change can lead to symptoms of seasonal affective disorder (SAD), or winter depression.\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your “Sleep Drops” and “Sleep Shots” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. \u003Cspan>§§ \u003C\u002Fspan>331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. \u003Cspan>§ \u003C\u002Fspan>201.5).&nbsp; Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your “Sleep Drops” and “Sleep Shots” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for their intended purposes. Accordingly, your “Sleep Drops” and “Sleep Shots” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. \u003Cspan>§\u003C\u002Fspan> 331(a)]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take prompt action to address the violates cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations.&nbsp; Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.&nbsp; If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. Your reply should be sent via e-mail to \u003C\u002Fspan>\u003Ca href=\"mailto:FDAAdvisory@fda.hhs.gov\">\u003Cspan>FDAAdvisory@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>William A. Correll Jr.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Center for Food Safety and Applied Nutrition\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJason W. Harris\n\nRecipient Title\n\nOwner\n\nSANA Group LLC\n\n1200 E. Woodhurst S-200\n\nSpringfield, MO 65804\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nRE: [CMS:612256]\n\nDear Mr. Harris,\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.sleepsana.com, in December 2020 and has determined that you take orders there for your Sleep Sana “Sleep Drops” and “Sleep Shots” products. The claims on your website establish that your products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your “Sleep Drops” and “Sleep Shots” are intended for use as drugs include:\n\nOn the webpage for Sleep Sana “Sleep Drops” and “Sleep Shots” ingredients:\n\n\"GABA (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) is taken by mouth for relieving anxiety, ... and treating attention deficit hyperactivity disorder (ADHD). It is also used for ... stabilizing blood pressure, and relieving pain.\"\n\n\"L-tryptophan (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) is used for insomnia, sleep apnea, depression, anxiety, facial pain, a severe form of premenstrual syndrome called premenstrual dysphoric disorder (PMDD), ... attention deficit-hyperactivity disorder (ADHD), Tourette's syndrome....\"\n\n\"Valerian (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) is most commonly used for sleep disorders, especially the inability to sleep (insomnia).\"\n\n\"[Y]our body may produce melatonin (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) either earlier or later in the day than usual. This change can lead to symptoms of seasonal affective disorder (SAD), or winter depression.\"\n\nYour “Sleep Drops” and “Sleep Shots” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Sleep Drops” and “Sleep Shots” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for their intended purposes. Accordingly, your “Sleep Drops” and “Sleep Shots” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address the violates cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. Your reply should be sent via e-mail to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam A. Correll Jr.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration","SANA Group LLC","sana-group-llc-612256-02182021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsana-group-llc-612256-02182021","2026-10-26T08:09:53.390359+00:00","2021-02-19","612256","Jason W. Harris","2026-08-20T03:22:28.818+00:00","Via Overnight Delivery","2021-02-18",{"id":118,"raw":119,"subject":125,"body_html":126,"body_text":127,"firm_name":128,"letter_id":129,"created_at":130,"fei_number":20,"letter_url":131,"updated_at":132,"action_type":23,"case_status":24,"posted_date":133,"marcs_cms_no":134,"product_type":69,"closeout_date":20,"issuing_office":123,"recipient_name":135,"body_fetched_at":136,"delivery_method":137,"recipient_title":20,"reference_number":20,"action_taken_date":138,"medical_device_id":20,"response_letter_date":20},2605,[120,121,122,123,124,13,13,13],"\u003Ctime datetime=\"2022-06-28T13:20:00Z\">06\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-14T04:00:00Z\">06\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffagron-group-bv-624255-06142022\">Fagron Group B.V.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Rafael Padilla\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Fagron Group B.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Lichtenauerlaan 182\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Rotterdam Zuid\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>3062 ME\u003C\u002Fspan> \u003Cspan>Holland\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Netherlands\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 14, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL #624255\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Padilla:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fagron, Inc., FEI 1000174332, at 2400 Pilot Knob Road, Saint Paul, Minnesota (USA) from November 1 to November 18, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your December 10, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific deviations including, but not limited to, the following.\u003Cbr>\n\u003Cbr>\n1. Failure to perform repackaging of API under appropriate CGMP to avoid potential cross-contamination.\u003C\u002Fp>\n\n\u003Cp>During your API repackaging and relabeling operations, including highly potent drugs such as testosterone, estradiol, betamethasone, tamoxifen, and opioids, your firm failed to conduct adequate cleaning validation studies to demonstrate that your cleaning procedures for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> non-dedicated “cabins” (production rooms) are adequate to prevent potential cross-contamination.\u003C\u002Fp>\n\n\u003Cp>For example, your firm was unable to provide a completed cleaning validation study to support your current cleaning practices. During the inspection, you acknowledged that your 2008 cleaning validation study did not represent your current cleaning practices and your cleaning procedures needed to be revalidated. You provided your 2020 cleaning validation protocol’s cabin risk assessments in which Cabin \u003Cstrong>(b)(4)\u003C\u002Fstrong> was determined to be the worst case scenario for potential product carryover. Swabbing locations were identified based on risk level for contamination. You provided our investigators with preliminary results for niacin and progesterone (a potent compound) residue yielding carryover levels that significantly exceeded the allowable specification. Your firm informed investigators that you were in the process of conducting a supplemental validation.\u003C\u002Fp>\n\n\u003Cp>Your firm failed to ensure that your equipment is adequately cleaned. For example, during the inspection, after the cleaning activities were documented as complete, our investigators observed visible powder residue on non-dedicated equipment (\u003Cstrong>(b)(4)\u003C\u002Fstrong> of the containment hood) following the repackaging of progesterone. Investigators also observed that the cleaning log for Cabin \u003Cstrong>(b)(4)\u003C\u002Fstrong> was \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>during repackaging of lidocaine HCl, even though the cleaning activities had not been initiated. You later stated that an employee destroyed the cleaning log and were unable to provide a copy to our investigators.\u003C\u002Fp>\n\n\u003Cp>In your response, you provided a follow-up cleaning validation report in which you only assessed the carryover of niacin swab samples but not progesterone, which was included in your initial cleaning validation. The lack of progesterone \u003Cstrong>(b)(4)\u003C\u002Fstrong> is concerning considering the failing residue results you provided to investigators would yield unacceptable levels of progesterone cross-contamination. Additionally, the niacin sample data you provided was limited to only the surfaces of \u003Cstrong>(b)(4)\u003C\u002Fstrong> containers even though you had detected unacceptable levels of drug residue in other areas of production that were not included in your current validation. Further, you stated that you are in the process of revising cleaning procedures including destruction steps for cytotoxic compounds. You also stated that you commit to performing additional cleaning validation activities and will evaluate the segregation of certain materials repackaged in specific rooms.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you failed to demonstrate that your cleaning procedures are adequate to prevent cross-contamination of repackaged API. You did not conduct a comprehensive risk assessment to determine the potential cross-contamination of various API you distributed and failed to detail interim plans to ensure that your equipment is adequately cleaned while cleaning revalidation studies were in progress.\u003C\u002Fp>\n\n\u003Cp>Inadequate removal of active ingredients and residues from manufacturing equipment during cleaning can result in cross-contamination of your API.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fp>\n\n\u003Cp>• A corrective action and preventive action (CAPA) plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness, improved ongoing verification of proper cleaning execution for all products and equipment, and all other needed remediations.\u003C\u002Fp>\n\n\u003Cp>• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; o drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cp>• A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fp>\n\n\u003Cp>• A summary of all results obtained from testing retain samples from each batch for cross-contamination of potent compounds. If such testing reveals substandard quality drugs, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to adequately investigate and document out-of-specification results and implement appropriate corrective actions.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your investigations into out-of-specification (OOS) test results were inadequate. You failed to investigate OOS results or implement adequate CAPA. For example, your firm did not initiate an investigation into OOS bioburden counts from your water system (which is used as a drug component). Your test procedure stated that actions should include the review of historical data, \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling and testing frequency, identification of the microorganisms, and quarantine of the equipment used and drugs made since the last passing test result date. On June 5, 2020, production \u003Cstrong>(b)(4)\u003C\u002Fstrong> bioburden counts of approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> per milliliter (CFU\u002FmL), which exceeds your firm’s action limit of no more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002FmL. You did not initiate an investigation.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledged that CAPAs (including \u003Cstrong>(b)(4)\u003C\u002Fstrong> investigations) are \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" and stated that you would conduct a retrospective analysis of results and determine appropriate actions. You failed to perform an investigation into the failing results to evaluate potential root causes, assess risk to patient safety and product quality, determine the scope and magnitude of the discrepancies, and implement and verify effectiveness of CAPAs.\u003C\u002Fp>\n\n\u003Cp>Inadequate investigations may result in not identifying or mitigating the root causes of nonconformances and does not ensure consistent production of safe and effective drugs.\u003C\u002Fp>\n\n\u003Cp>For more information about handling failing, OOS, out-of-trend, or other unexpected analytical results and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-test-results-pharmaceutical-production\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-test-results-pharmaceutical-production\u003C\u002Fa>.\u003Cbr>\n\u003Cbr>\nIn response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>\n&nbsp; &nbsp; o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\n&nbsp; &nbsp; o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003C\u002Fp>\n\n\u003Cp>• For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>\n&nbsp; &nbsp; o Quality unit oversight of laboratory investigations\u003Cbr>\n&nbsp; &nbsp; o Identification of adverse laboratory control trends\u003Cbr>\n&nbsp; &nbsp; o Resolution of causes of laboratory variation\u003Cbr>\n&nbsp; &nbsp; o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\n&nbsp; &nbsp; o Adequately scoping of each investigation and its CAPA\u003Cbr>\n&nbsp; &nbsp; o Revised OOS investigation procedures with these and other remediations\u003Cbr>\n\u003Cbr>\n\u003Cstrong>3. Failure of your quality unit to exercise its responsibility to ensure the API manufactured at the facility are in compliance with CGMP.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) failed to perform several critical functions to ensure that the API you repackage and distribute meets CGMP requirements. For example, investigators observed computers connected to CGMP-related laboratory equipment that allowed changes to or deletion of data generated to support the release of drugs without restriction.\u003C\u002Fp>\n\n\u003Cp>In addition, during the inspection you acknowledged that your QU did not qualify the contract laboratories you used to support product release due to resource issues. This is a repeat observation from your 2017 inspection.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated you will evaluate and implement the necessary actions to ensure that your equipment used in CGMP-related operations is compliant with 21 CFR Part 11. We acknowledge your commitment to qualify your contract laboratories and immediately hire additional QU personnel to support supplier qualification.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because simply addressing laboratory equipment deficiencies is insufficient to achieve overall CGMP compliance. These steps are only effective if you establish and follow appropriate procedures and systems that ensure your QU reviews all production and control data and associated audit trails as part of the batch release process. Further, you failed to assess how the deficiencies noted above may have affected drug quality or identified how additional personnel will adequately remediate your QU deficiencies.\u003C\u002Fp>\n\n\u003Cp>An adequate QU overseeing all CGMP operations is necessary to ensure consistent drug quality.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003Cbr>\n&nbsp; &nbsp; o Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fp>\n\n\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as \u003Cstrong>(b)(4)\u003C\u002Fstrong> re-validation. In addition, include a commitment to always conduct at \u003Cstrong>(b)(4)\u003C\u002Fstrong> specific identity test for \u003Cstrong>(b)(4)\u003C\u002Fstrong> incoming component lot.\u003C\u002Fp>\n\n\u003Cp>• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fp>\n\n\u003Cp>• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional API CGMP Guidance\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document \u003Cem>Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients\u003C\u002Fem> for guidance regarding CGMP for the manufacture of API at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\n\n\u003Cp>Correct the deviations cited in this letter promptly. Failure to promptly correct these deviations may result in legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations in this warning letter may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of any new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed your corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviation and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Tina M. Pawlowski, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Case Number above (#624255). If you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jeffrey Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Cc: Ms. Belen Perez\u003Cbr>\nVice President of Operations\u003Cbr>\nFagron, Inc.\u003Cbr>\n2400 Pilot Knob Road\u003Cbr>\nSaint Paul, Minn., 55120\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Rafael Padilla\n\nRecipient Title\n\nChief Executive Officer\n\nFagron Group B.V.\n\nLichtenauerlaan 182\n\nRotterdam Zuid\n\n3062 ME Holland\n\nNetherlands\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nJune 14, 2022\n\nWARNING LETTER\n\nWL #624255\n\nDear Mr. Padilla:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fagron, Inc., FEI 1000174332, at 2400 Pilot Knob Road, Saint Paul, Minnesota (USA) from November 1 to November 18, 2021.\n\nThis warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your December 10, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific deviations including, but not limited to, the following.\n\n1. Failure to perform repackaging of API under appropriate CGMP to avoid potential cross-contamination.\n\nDuring your API repackaging and relabeling operations, including highly potent drugs such as testosterone, estradiol, betamethasone, tamoxifen, and opioids, your firm failed to conduct adequate cleaning validation studies to demonstrate that your cleaning procedures for your (b)(4) non-dedicated “cabins” (production rooms) are adequate to prevent potential cross-contamination.\n\nFor example, your firm was unable to provide a completed cleaning validation study to support your current cleaning practices. During the inspection, you acknowledged that your 2008 cleaning validation study did not represent your current cleaning practices and your cleaning procedures needed to be revalidated. You provided your 2020 cleaning validation protocol’s cabin risk assessments in which Cabin (b)(4) was determined to be the worst case scenario for potential product carryover. Swabbing locations were identified based on risk level for contamination. You provided our investigators with preliminary results for niacin and progesterone (a potent compound) residue yielding carryover levels that significantly exceeded the allowable specification. Your firm informed investigators that you were in the process of conducting a supplemental validation.\n\nYour firm failed to ensure that your equipment is adequately cleaned. For example, during the inspection, after the cleaning activities were documented as complete, our investigators observed visible powder residue on non-dedicated equipment ((b)(4) of the containment hood) following the repackaging of progesterone. Investigators also observed that the cleaning log for Cabin (b)(4) was (b)(4) during repackaging of lidocaine HCl, even though the cleaning activities had not been initiated. You later stated that an employee destroyed the cleaning log and were unable to provide a copy to our investigators.\n\nIn your response, you provided a follow-up cleaning validation report in which you only assessed the carryover of niacin swab samples but not progesterone, which was included in your initial cleaning validation. The lack of progesterone (b)(4) is concerning considering the failing residue results you provided to investigators would yield unacceptable levels of progesterone cross-contamination. Additionally, the niacin sample data you provided was limited to only the surfaces of (b)(4) containers even though you had detected unacceptable levels of drug residue in other areas of production that were not included in your current validation. Further, you stated that you are in the process of revising cleaning procedures including destruction steps for cytotoxic compounds. You also stated that you commit to performing additional cleaning validation activities and will evaluate the segregation of certain materials repackaged in specific rooms.\n\nYour response is inadequate because you failed to demonstrate that your cleaning procedures are adequate to prevent cross-contamination of repackaged API. You did not conduct a comprehensive risk assessment to determine the potential cross-contamination of various API you distributed and failed to detail interim plans to ensure that your equipment is adequately cleaned while cleaning revalidation studies were in progress.\n\nInadequate removal of active ingredients and residues from manufacturing equipment during cleaning can result in cross-contamination of your API.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\n• A corrective action and preventive action (CAPA) plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness, improved ongoing verification of proper cleaning execution for all products and equipment, and all other needed remediations.\n\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no drugs with higher toxicities\n\no drugs with higher drug potencies\n\no drugs of lower solubility in their cleaning solvents\n\no drugs with characteristics that make them difficult to clean\n\no swabbing locations for areas that are most difficult to clean\n\no maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\n• A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n• A summary of all results obtained from testing retain samples from each batch for cross-contamination of potent compounds. If such testing reveals substandard quality drugs, take rapid corrective actions, such as notifying customers and product recalls.\n\n2. Failure to adequately investigate and document out-of-specification results and implement appropriate corrective actions.\n\nYour investigations into out-of-specification (OOS) test results were inadequate. You failed to investigate OOS results or implement adequate CAPA. For example, your firm did not initiate an investigation into OOS bioburden counts from your water system (which is used as a drug component). Your test procedure stated that actions should include the review of historical data, (b)(4) sampling and testing frequency, identification of the microorganisms, and quarantine of the equipment used and drugs made since the last passing test result date. On June 5, 2020, production (b)(4) bioburden counts of approximately (b)(4) per milliliter (CFU\u002FmL), which exceeds your firm’s action limit of no more than (b)(4) CFU\u002FmL. You did not initiate an investigation.\n\nIn your response, you acknowledged that CAPAs (including (b)(4) investigations) are \"(b)(4)\" and stated that you would conduct a retrospective analysis of results and determine appropriate actions. You failed to perform an investigation into the failing results to evaluate potential root causes, assess risk to patient safety and product quality, determine the scope and magnitude of the discrepancies, and implement and verify effectiveness of CAPAs.\n\nInadequate investigations may result in not identifying or mitigating the root causes of nonconformances and does not ensure consistent production of safe and effective drugs.\n\nFor more information about handling failing, OOS, out-of-trend, or other unexpected analytical results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-test-results-pharmaceutical-production.\n\nIn response to this letter, provide:\n\n• A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\n• For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\n• A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\n\no Quality unit oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequately scoping of each investigation and its CAPA\n\no Revised OOS investigation procedures with these and other remediations\n\n3. Failure of your quality unit to exercise its responsibility to ensure the API manufactured at the facility are in compliance with CGMP.\n\nYour quality unit (QU) failed to perform several critical functions to ensure that the API you repackage and distribute meets CGMP requirements. For example, investigators observed computers connected to CGMP-related laboratory equipment that allowed changes to or deletion of data generated to support the release of drugs without restriction.\n\nIn addition, during the inspection you acknowledged that your QU did not qualify the contract laboratories you used to support product release due to resource issues. This is a repeat observation from your 2017 inspection.\n\nIn your response, you stated you will evaluate and implement the necessary actions to ensure that your equipment used in CGMP-related operations is compliant with 21 CFR Part 11. We acknowledge your commitment to qualify your contract laboratories and immediately hire additional QU personnel to support supplier qualification.\n\nYour response is inadequate because simply addressing laboratory equipment deficiencies is insufficient to achieve overall CGMP compliance. These steps are only effective if you establish and follow appropriate procedures and systems that ensure your QU reviews all production and control data and associated audit trails as part of the batch release process. Further, you failed to assess how the deficiencies noted above may have affected drug quality or identified how additional personnel will adequately remediate your QU deficiencies.\n\nAn adequate QU overseeing all CGMP operations is necessary to ensure consistent drug quality.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\no Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing (b)(4) for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as (b)(4) re-validation. In addition, include a commitment to always conduct at (b)(4) specific identity test for (b)(4) incoming component lot.\n\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n\n• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nAdditional API CGMP Guidance\n\nFDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\n\nCorrect the deviations cited in this letter promptly. Failure to promptly correct these deviations may result in legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations in this warning letter may also prevent other Federal agencies from awarding contracts.\n\nFailure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of any new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed your corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviation and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Tina M. Pawlowski, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nYour written notification should refer to the Warning Letter Case Number above (#624255). If you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\n\nSincerely,\n\n\u002FS\u002F\n\nJeffrey Meng\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\nCc: Ms. Belen Perez\n\nVice President of Operations\n\nFagron, Inc.\n\n2400 Pilot Knob Road\n\nSaint Paul, Minn., 55120","Fagron Group B.V.","fagron-group-bv-624255-06142022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffagron-group-bv-624255-06142022","2026-10-26T08:08:39.519572+00:00","2022-06-28","624255","Mr. Rafael Padilla","2026-08-20T01:48:42.012+00:00","UPS","2022-06-14",{"id":140,"raw":141,"subject":146,"body_html":147,"body_text":148,"firm_name":149,"letter_id":150,"created_at":44,"fei_number":20,"letter_url":151,"updated_at":152,"action_type":23,"case_status":24,"posted_date":153,"marcs_cms_no":154,"product_type":27,"closeout_date":20,"issuing_office":145,"recipient_name":20,"body_fetched_at":155,"delivery_method":156,"recipient_title":20,"reference_number":20,"action_taken_date":157,"medical_device_id":20,"response_letter_date":20},224,[142,143,144,145,146,13,13,13],"\u003Ctime datetime=\"2026-04-14T04:00:00Z\">04\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Focean-group-inc-715467-03032026\">Ocean Group Inc. \u003C\u002Fa>","Human Foods Program","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Ocean Group Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1100 S Sante Fe Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Los Angeles\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90021\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jason@oceanfreshinc.com\"> jason@oceanfreshinc.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 3, 2026\u003C\u002Fp>\u003Cp>Re: CMS # 715467\u003C\u002Fp>\u003Cp>Dear Mr. Kim:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected four (4) of your Ocean Group seafood processing facilities, during a period from May 2025 through September 2025 (exact dates are listed below). FDA initiated an inspection at the Los Angeles facility as a compliance follow-up to the previous Warning Letter issued to you on April 17, 2024, and further expanded the inspection scope after a surveillance inspection at your Oceanside facility found similar sanitation deficiencies.\u003C\u002Fp>\u003Cp>We are issuing this letter to you as the CEO of the corporation responsible for the facilities (i.e., referenced in this letter as your “facility” or “facilities”), because we found serious violations during our inspections of these facilities. During these inspections, FDA investigators found significant violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123 (21 CFR Part 123). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facilities. FDA laboratory analysis of the environmental swabs found the presence of \u003Cem>Listeria monocytogenes (L. monocytogenes)\u003C\u002Fem>, a human pathogen, in your Los Angeles, CA, Las Vegas, NV, and Dallas, TX facilities. At the conclusion of the inspections, the FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations, listing the violations found at each of your facilities.\u003C\u002Fp>\u003Cp>Based on FDA’s inspectional findings and the analytical results for samples collected from your Los Angeles, CA, Las Vegas, NV, and Dallas, TX production environments, we have determined that the ready-to-eat (RTE) salmon and tuna processed in these three facilities are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they have been prepared, packed or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health.\u003C\u002Fp>\u003Cp>Additionally, in accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your ready-to-eat (RTE) raw tuna and salmon processed at all four facilities are adulterated within the meaning of section 402(a)(4) of the Act You may find the Act, the seafood HACCP regulation, and the June 2022 Edition of the Fish and Fisheries Products Hazards &amp; Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>We are issuing this letter to advise you of FDA’s concerns with regard to four of the inspected facilities. This letter contains detailed information describing the inspectional findings, as well as your purported corrective actions taken at each of the facilities. Furthermore, FDA has determined that a Regulatory Meeting would be beneficial to discuss your firm’s corrective actions.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Facilities Inspected\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>FDA inspected the following four seafood processing facilities located throughout the country:\u003C\u002Fp>\u003Cp>1. Los Angeles- located at 1100 S Sante Fe Ave, Los Angeles, CA 90021 conducted from June 24, 2025 through July 16, 2025, which processes RTE salmon and tuna. We acknowledge receipt of your responses dated July 11, 18, August 11, 18, and 26, 2025, which include a description of the corrective actions taken by your firm.\u003C\u002Fp>\u003Cp>2. Las Vegas- located at 4630 W Post Road, Ste 105, Las Vegas, NV from August 25 through September 12, 2025, which processes RTE salmon and tuna. We acknowledge receipt of your responses dated October 9 and 29, 2025, which include a description of the corrective actions taken by your firm.\u003C\u002Fp>\u003Cp>3. Dallas- located at 10600 Boomer Cir, Dallas, TX 75238 conducted from September 8 through September 17, 2025, which processes RTE salmon and tuna. We acknowledge receipt of your responses dated October 24 and November 14, 2025, which include a description of the corrective actions taken by your firm.\u003C\u002Fp>\u003Cp>4. Oceanside- located at 1830 Ord Way, Oceanside, CA 92056 conducted from May 12 through May 28, 2025, which processes RTE salmon and tuna. We acknowledge receipt of your responses dated June 10, 2025 with additional photographs on August 21, 2025, which include a description of the corrective actions taken by your firm.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Pathogen Findings:\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>\u003Cem>L. monocytogenes\u003C\u002Fem> is a pathogenic bacterium that is widespread in the environment and may be introduced into a food processing facility from raw materials, humans, or equipment. Without proper controls, it can proliferate in food processing facilities where it may contaminate food. Therefore, it is essential to identify the areas of the food processing plant where this organism can grow and survive, and to apply controls or take corrective actions as necessary to eradicate the organism. Consuming foods contaminated with \u003Cem>L. monocytogenes\u003C\u002Fem> can lead to a severe, sometimes life-threatening, illness called listeriosis, which is a major public health concern due to the severity of the disease, its high case-fatality rate, its long incubation time, and its tendency to affect individuals with underlying conditions.\u003C\u002Fp>\u003Cp>Appropriate control of \u003Cem>L. monocytogenes\u003C\u002Fem> in a food processing environment requires knowledge of the unique characteristics of the organism and implementation of the hygienic practices necessary to control this pathogen. Once \u003Cem>L. monocytogenes\u003C\u002Fem> is established in a production area, personnel or equipment can facilitate the pathogen’s movement and contamination of food-contact surfaces and finished product. It is essential to identify the harborage sites in the food processing plant and equipment where this organism is able to grow and survive, and to apply controls or take corrective actions as necessary to eradicate the organism by rendering these areas unable to support the survival and growth of the organism and to prevent the organism from being re-established in such sites.\u003C\u002Fp>\u003Cp>FDA’s analysis identified the following:\u003C\u002Fp>\u003Cp>\u003Cu>Los Angeles, CA\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>In 2025, \u003Cstrong>(b)(4) \u003C\u002Fstrong>out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> swabs were positive for \u003Cem>L. monocytogenes\u003C\u002Fem>. The swabs were collected from non-food contact surfaces, including a hose handle, the bottom surface of a table, wheels of racks or other tables, and wooden broom bristles.\u003C\u002Fli>\u003Cli>In 2024, \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> swabs were positive for \u003Cem>L. monocytogenes\u003C\u002Fem>. The swabs were collected from a food contact surface (a cutting board) and a non-food contact surface drain in the processing room.\u003C\u002Fli>\u003Cli>In 2023, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> swabs were positive for \u003Cem>L. monocytogenes\u003C\u002Fem>. These swabs were collected food contact surfaces, such as a white cutting board and the interior of a grey plastic bin used to process RTE salmon and non-food contact surfaces.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The presence of the same strain of \u003Cem>L. monocytogenes\u003C\u002Fem> within that facility across multiple years is indicative of a resident pathogen. Whole genome sequencing (WGS) conducted on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>L. monocytogenes\u003C\u002Fem> isolates obtained from the 2025 FDA environmental swabs determined these isolates match isolates collected from your facility in 2023 and 2024 and a clinical isolate from an ill person in 2022. The presence of the same strain of \u003Cem>L. monocytogenes\u003C\u002Fem> that has caused illness across three different processing environments over multiple years suggests that strain has been within one or more of your facilities since at least 2023.\u003C\u002Fp>\u003Cp>The recurring presence of \u003Cem>L. monocytogenes\u003C\u002Fem> in your Los Angeles, CA facility demonstrates that your sanitation procedures have been inadequate to effectively control pathogens in your facility and prevent contamination of food. It also demonstrates that your previous corrective actions were inadequate.\u003C\u002Fp>\u003Cp>In your responses received July 11, 2025, August 11, 18 and 26, 2025 to these findings, you provided corrective actions that describe deep cleaning and sanitation, hiring of a third-party professional, industrial grade cleaning service to deep clean and sanitize the operating environments twice a month in addition to your daily deep clean. Your response also provided your own environmental sampling from \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples, which showed negative results for \u003Cem>Listeria\u003C\u002Fem> spp., a technical report provided by your third-party cleaning service, environmental monitoring procedure, and root cause analysis.\u003C\u002Fp>\u003Cp>Given the repeat history of the same strain of \u003Cem>L. monocytogenes\u003C\u002Fem> in your processing environments and most recent inspectional findings at the Los Angeles facility, we continue to be concerned about your ability to control \u003Cem>L. monocytogenes\u003C\u002Fem> within this facility.\u003C\u002Fp>\u003Cp>\u003Cu>Las Vegas, NV\u003C\u002Fu>\u003Cbr>FDA laboratory analysis of environmental swabs collected at your Las Vegas, NV facility, on August 27, 2025, confirmed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> swabs were positive for \u003Cem>L. monocytogenes\u003C\u002Fem>. The swabs were collected from the top of a cutting board, on handles and a hook for blue hoses, on a drain, on a wall, and on the table leg of a fillet table.\u003C\u002Fp>\u003Cp>WGS conducted on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>L. monocytogenes\u003C\u002Fem> isolates obtained from the 2025 FDA environmental swabs of your Las Vegas facility showed that the isolates belonged to a single strain that match \u003Cstrong>(b)(4)\u003C\u002Fstrong> clinical isolates from ill people and environmental isolates collected from your Los Angeles facility in 2023 and 2024.\u003C\u002Fp>\u003Cp>We received your response to the Las Vegas sample findings on October 9 and October 29, 2025, in which you provide a root cause analysis with a determination that lack of cleaning and sanitation for transportation trucks by a third-party then the lack of hygiene and safety when processing the product resulted in the spread of \u003Cem>L. monocytogenes\u003C\u002Fem> from your Los Angeles facility to your Las Vegas facility. In your “(RCA) Root Cause Analysis Report” dated September 26, 2025, you listed corrective actions, including information that equipment, tools, and other contaminated sources were discarded and replaced, employee training, testing results from two drain swabs that led you to conclude that the Las Vegas facility is \u003Cem>Listeria\u003C\u002Fem>-free, and third-party cleaning services. In addition, you identified that the company “needs to make a radical change on the company culture \u002F education and training staff \u002F enforcement of safety to the company.” However, your response did not include supporting documentation for substantial changes to food safety culture and training such as improved sanitation control procedures and training material with frequency of training.\u003C\u002Fp>\u003Cp>\u003Cu>Dallas, TX\u003C\u002Fu>\u003Cbr>FDA laboratory analysis of environmental swabs collected at your Dallas facility on September 15, 2025, confirmed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> swabs were positive for \u003Cem>L. monocytogenes\u003C\u002Fem>. These swabs were collected from hose handles, floor drains, an ice shovel handle, an exterior door flap to your cooler, the wheel of a pallet jack, and various sections of the floor in your staging room.\u003C\u002Fp>\u003Cp>WGS of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>L. monocytogenes\u003C\u002Fem> isolates obtained from the 2025 FDA environmental swabs of your Dallas facility determined there were three clusters for the isolates as follows.\u003C\u002Fp>\u003Cp>1. Isolates from \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the positive environmental swabs from the Dallas facility match environmental sample isolates from your Las Vegas facility collected in 2025 and Los Angeles facility collected in 2023 and also match four clinical isolates from ill people collected between 2017 and 2023.\u003C\u002Fp>\u003Cp>2. An isolate from \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the positive environmental swabs from the Dallas facility matches \u003Cstrong>(b)(4)\u003C\u002Fstrong> clinical isolates collected from ill people in 2013 and 2014.\u003C\u002Fp>\u003Cp>3. An isolate from \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the positive environmental swabs from the Dallas facility matches \u003Cstrong>(b)(4)\u003C\u002Fstrong> isolates from food samples collected in 2008, 2010 and 2011 by the Canadian Food Inspection Agency (CFIA).\u003C\u002Fp>\u003Cp>Your response received October 24, 2025, states you have hired a professional cleaning company to provide training on using chemicals to “eradicate Listeria” and you have continued to search for a laboratory to perform \u003Cem>Listeria\u003C\u002Fem> testing and sample affected areas. You also stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” dated October 20, 2025, mainly identified lack of employee training as a root cause and listed corrective actions taken such as discarding equipment and tools, fixing of walls and floors, updates to record and logs, and training. However, no environmental monitoring procedure and no documentation to support the implementation of these corrective actions was provided.\u003C\u002Fp>\u003Cp>Based on the above listed \u003Cem>Listeria monocytogenes\u003C\u002Fem> findings, inadequate corrective actions and lack of supporting documentation at all these facilities, we remain deeply concerned for your ability to implement and maintain sanitation controls for \u003Cem>L.\u003C\u002Fem> \u003Cem>monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Seafood HACCP (21 CFR Part 123)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Your significant violations were as follows:\u003C\u002Fp>\u003Cp>\u003Cem>Sanitation conditions and practices\u003C\u002Fem>\u003C\u002Fp>\u003Cp>1. You must monitor sanitation conditions and practices during processing with sufficient frequency to ensure compliance with current good manufacturing practice (CGMP) requirements under 21 CFR Part 117, subpart B that are appropriate to your plant and food products (21 CFR 123.11(b)). However, your firm did not monitor the following conditions and practices with sufficient frequency to ensure cGMP compliance, as evidenced by the following observations by FDA investigators at your facilities where you process raw, RTE salmon and tuna:\u003C\u002Fp>\u003Cp>a. Condition and cleanliness of food contact surfaces, including utensils, gloves, and outer garments, as required by 21 CFR 123.11(b)(2):\u003C\u002Fp>\u003Cp>i. Cutting boards used to process raw RTE tuna and\u002For salmon were discolored and had cuts, scratches, cracks and\u002For crevices at your Oceanside facility on May 12 through 15, 2025, at your Los Angeles facility on June 24, 2025, and at your Las Vegas facility on August 27, 2025. Additionally, one of the cutting boards swabbed at your Las Vegas facility tested positive for L. monocytogenes from a swab collected on August 27, 2025, and one of the cutting boards at the Oceanside facility tested positive for L. innocua in a swab collected on May 13, 2025.\u003C\u002Fp>\u003Cp>ii. At your Oceanside facility from May 12 through 15, a white bin used to hold raw RTE salmon and ice before descaling was discolored with pink, brown, and black residue on the interior and exterior surfaces. After production on May 13, 2025, the bin was moved outside to allow ice to melt and then the bin was used the next day to again hold salmon and ice. Also, at the Oceanside facility from May 12 through 15, 2025, two bins used to hold ice used for cooling raw RTE fish were deeply scratched with dark brown residue within the scratches and other food residue (e.g., fish scales) adhering to surfaces. Your Vice President\u002FCOO of the Oceanside facility stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>.&nbsp;\u003C\u002Fp>\u003Cp>iii. At the Los Angeles facility on June 25, 2025, a plastic ice pallet container was damaged with a cracked wall on the inside of the container exposing ice to its insulation, a material that cannot be properly cleaned and sanitized.\u003C\u002Fp>\u003Cp>iv. At your Las Vegas facility on August 25 through 27, 2025, blue ice shovels had frayed edges, cracks, and crevices.\u003C\u002Fp>\u003Cp>v. Employee aprons, which come into contact with raw, RTE fish during processing, were not kept clean or in good condition.\u003C\u002Fp>\u003Cp>1. At your Oceanside facility on May 13, 2025, employee aprons were observed to be visibly worn and discolored during processing. However, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” was clean and in good repair on May 13, 2025. Also, on May 14, 2025, after production, an employee was observed to drape an apron across a bush outside the facility and on May 15, 2025, after production, employee aprons were stored against a wall visibly soiled with food residue. Additionally, a swab collected from employee apron collected on May 13, 2025 was positive for \u003Cem>Listeria innocua\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>2. At your Las Vegas facility on August 25 through 27, 2025 employee aprons were discolored and visibly soiled and specifically on August 25, 2025, employees were washing and rinsing aprons directly on the production floor, where pooling water and trash were present, then were observed standing on the aprons with production boots during sanitizing. However, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” was clean and in good repair on August 27, 2025.\u003C\u002Fp>\u003Cp>3. At your Los Angeles facility on June 25, 2025, employees were using hoses to rinse their aprons of food debris which created splash onto the filleting tables. Employee aprons were observed to contact the fillet table leg and the wrapping table leg which were both found to have \u003Cem>L. monocytogenes\u003C\u002Fem> present in swabs collected on June 24, 2025.\u003C\u002Fp>\u003Cp>vi. Food contact surfaces were not adequately cleaned and sanitized during sanitation. On August 25, 2025, after post-operation daily cleaning at the Las Vegas facility, the tuna ice table (“tuna bed”) still had fish bones. Additionally, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” document dated August 25, 2025, was signed and verified as being scrubbed, rinsed, and sanitized for the tuna bed.\u003C\u002Fp>\u003Cp>b. Prevention of cross-contamination from insanitary objects to food, food packaging material, and other food contact surfaces, as required by 21 CFR 123.11(b)(3):\u003Cbr>i. Employees did not wash their hands and change their gloves after touching insanitary objects and prior to returning to work with raw RTE fish and\u002For handling food contact surfaces. Insanitary objects include:\u003C\u002Fp>\u003Cp>1. Blue plastic crates, bins and\u002For insulated foam boxes that were previously in contact with the floor at the Oceanside facility on May 12 and 13, 2025, and at the Los Angeles facility on June 25 and 26, 2025;\u003C\u002Fp>\u003Cp>2. The handle of a pallet jack that was also used by an employee from the cooler at the Los Angeles facility on June 26, 2025;\u003C\u002Fp>\u003Cp>3. Trash, fish scraps, and bones off the ground and out of floor drains at the Las Vegas facility on August 25, 2025;\u003C\u002Fp>\u003Cp>4. Face masks, glasses, and\u002For personal clothes (e.g. visibly soiled hat) at the Las Vegas facility on August 25 through 27, and on September 11, 2025;\u003C\u002Fp>\u003Cp>5. Hose handles that had fallen to the floor at the Las Vegas facility on August 26, 2025, which were swabbed on August 27, 2025, and tested positive for \u003Cem>L. monocytogenes\u003C\u002Fem>; and\u003C\u002Fp>\u003Cp>6. A paper towel roll that had fallen to the floor at the Dallas facility on September 8, 2025;\u003C\u002Fp>\u003Cp>7. In addition, on June 26, 2025, at your Los Angeles facility, an employee filleted raw RTE salmon, exited the Fillet Room while wearing a steel chain glove to dispose of broken Styrofoam boxes outside the facility, and then returned to the Fillet Room and sanitized hands with the steel chain glove in the hand dip without washing. The steel chain glove had gaps that allow debris to accumulate. Sanitizing equipment without cleaning and removing fish protein debris will render the sanitizer in the hand dip ineffective.\u003C\u002Fp>\u003Cp>ii. Plastic or vinyl curtains were a source of contamination.\u003C\u002Fp>\u003Cp>1. At your Oceanside facility on May 12, 2025, employees transported insulated boxes containing salmon through vinyl curtains that were worn, discolored with dark residue, and not cleaned during May 12 through 14, 2025. The employees touched the boxes, then the RTE salmon fillets without washing or sanitizing hands or changing gloves. Employees, pallet jacks, and product containers passed through these vinyl curtains when moving from the Cooler to the Fillet Room.\u003C\u002Fp>\u003Cp>2. At your Los Angeles facility on June 25, 2025, employees transported a large plastic ice pallet container filled with ice through plastic curtains into the Display\u002FStaging Room in front of raw RTE tuna. The bottom of the plastic curtains came into contact with the ice, which was then shoveled into boxes of raw RTE tuna. The bottom of the plastic curtains also came into contact with employees' aprons, boots, and other pallets.\u003C\u002Fp>\u003Cp>3. At your Las Vegas facility on August 25 to 27, 2025, RTE salmon and tuna and human by-product intended for animal food (i.e., cat food) came into direct contact with plastic curtains at the fillet room entrance. Employees also touched the plastic curtain with the same gloved hands that also handled raw, RTE salmon and tuna. These plastic curtains were found to have L. innocua present in an environmental swab collected on August 27, 2025, and they are not monitored or documented on either Daily Sanitation Control or Daily Sanitation Audit Form.\u003C\u002Fp>\u003Cp>iii. Hoses were a source of contamination.\u003C\u002Fp>\u003Cp>1. At your Oceanside facility on May 12, 2025, a water hose with a spray nozzle in the Fillet Room hung directly above a fillet table in direct contact with RTE salmon fillets. Employees used the hose to rinse food and food contact surfaces with pressurized water throughout production, in a manner that caused the hose to touch the floor multiple times, including the section that had previously touched the RTE salmon. The hose surface that came into contact with the RTE salmon showed black discoloration and was only cleaned and sanitized at the end of the production day.\u003C\u002Fp>\u003Cp>2. At your Dallas facility on September 9, 2025, employees were using hoses while processing raw salmon and tuna, then storing the hose handles on the side of blue plastic bins, which held waste materials.\u003C\u002Fp>\u003Cp>3. At your Los Angeles facility on June 25 and 26, 2025, employees were holding hose handles and using the hoses to spray water on raw RTE salmon, table tops and legs, aprons, gloves, and Styrofoam boxes. Employees returned to handling raw RTE salmon without washing and sanitizing their hands. Two hose handles were found to have \u003Cem>L. monocytogenes\u003C\u002Fem>, \u003Cem>L. innocua\u003C\u002Fem>, and \u003Cem>L. welshimeri\u003C\u002Fem> present from swabs collected on June 24, 2025.\u003C\u002Fp>\u003Cp>iv. Tools used for cleaning were not appropriate or maintained.\u003C\u002Fp>\u003Cp>1. At your Oceanside facility on May 13, 2025, two handheld squeegees used to remove water from cutting boards and tables in the Fillet Room were visibly worn with black discoloration along the wiper edges.\u003C\u002Fp>\u003Cp>2. At your Los Angeles facility, employees used a wooden broom to push dirty water and debris on the floor toward the drain and to scrub the walls and tables with soap. The bristles of the wooden broom in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> corner of your fillet room were swabbed on June 24, 2025, and was found positive for \u003Cem>L. monocytogenes\u003C\u002Fem>.&nbsp;\u003C\u002Fp>\u003Cp>3. At your Las Vegas facility on August 25 to 27, 2025, ice was packed in bags, which came into contact with employees’ visibly soiled aprons and\u002For personal clothes, then were stored on an apparently soiled Styrofoam container or other soiled surfaces in the fillet room and warehouse. These ice bags were stored directly on raw RTE tuna in the fillet room.\u003C\u002Fp>\u003Cp>4. At your Las Vegas facility on August 25, 2025, a descaler was in direct contact with the wall, and in direct contact with raw, RTE salmon on August 26, 2025. The investigator did not observe the yellow back of the descaler get a full wash, rinse and sanitize on August 25 or 26, 2025. The section of the wall was swabbed on August 27, 2025, which found \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>c. Maintenance of hand washing, hand sanitizing, and toilet facilities, as required by 21 CFR 123.11(b)(4):\u003C\u002Fp>\u003Cp>i. At your Oceanside facility, the hand washing station did not have hand sanitizer available for use. Further, the investigator did not observe employees washing hands or using hand sanitizer at any time during production from May 12 through 14, 2025. This lack of hand sanitizer was not reflected in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>” for May 12 through 14, 2025, which was check-marked for adequate supply with water, soap, paper towels and sanitizer at the handwashing and sanitizing facilities.\u003C\u002Fp>\u003Cp>ii. At your Las Vegas facility on August 25, 2025, the only handwashing sink in the fillet room did not have soap.\u003C\u002Fp>\u003Cp>d. Protection of food, food packaging material, and food contact surfaces from adulteration with condensate, and other chemical, physical, and biological contaminants, as required by 21 CFR 123.11(b)(5):\u003C\u002Fp>\u003Cp>i. Dripping condensate at multiple facilities.\u003C\u002Fp>\u003Cp>1. At your Oceanside facility on May 15, 2025, condensate dripped from the metal rack directly above and onto the exposed ice covering raw RTE tuna stored in the cooler.\u003C\u002Fp>\u003Cp>2. At your Los Angeles facility on June 25 and 26, 2025, condensate dripped from the air conditioning unit directly onto exposed RTE salmon that was being wrapped for distribution. The air conditioning unit was not cleaned or sanitized.\u003C\u002Fp>\u003Cp>ii. Employee handling of water with gloved hands and\u002For hoses resulted in backsplash and\u002For aerosolized water from wooden pallets, Styrofoam boxes and other insanitary surfaces, including the floor, onto employee’s aprons and gloves, exposed raw RTE fish, and\u002For open Styrofoam boxes with blue lining. This was observed at your Oceanside facility on May 12 through 14, 2025, at your Los Angeles facility on June 25 and 26, 2025 and at your Las Vegas facility on August 26 and 27, 2025.\u003C\u002Fp>\u003Cp>e. Proper labeling, storage, and use of toxic compounds, as required by 21 CFR 123.11(b)(6):\u003C\u002Fp>\u003Cp>i. You did not follow sanitizer instructions for use and\u002For your sanitation operating procedures at multiple facilities, including at your Oceanside facility on May 12, 2025, your Los Angeles facility on June 25, 2025, and at your Las Vegas facility on September 11, 2025.\u003C\u002Fp>\u003Cp>1. At your Las Vegas facility, an employee stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Employees then used this solution, which measured between \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm on the cutting boards later used to cut RTE salmon and tuna and on the gray ice bin used to store ice for the tuna tables.\u003C\u002Fp>\u003Cp>2. At your Oceanside and Las Vegas facilities, the label for the concentrated Germicidal Bleach and chlorine sanitizing solution, respectively, did not include instructions for sanitizing food contact surfaces. These solutions were used to clean food contact surfaces.\u003C\u002Fp>\u003Cp>ii. Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” did not include a section to verify the concentration of sanitizers, or did not accurately reflect sanitizer concentrations.\u003C\u002Fp>\u003Cp>1. At your Oceanside facility on May 12, 2025, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” but there is no section on your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to verify the concentration of chlorine; the investigator found that employees were not measuring the amount of concentrated hypochlorite bleach added, and used a chlorine sanitizer test strip that indicated a concentration above the maximum reading of 1000 ppm.\u003C\u002Fp>\u003Cp>2. At your Oceanside facility on May 12, 2025, and at your Los Angeles facility on June 25, 2025, the quaternary ammonium sanitizer in spray bottles or used in hand dips measured above \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm, but the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” for both facilities which list that the concentration should be “Quat&lt;200,” were both check-marked as verified for both days.\u003C\u002Fp>\u003Cp>As noted above, non-human pathogenic \u003Cem>Listeria\u003C\u002Fem> spp. were found in all four of your facilities, including \u003Cem>Listeria innocua\u003C\u002Fem>, \u003Cem>Listeria welshimeri\u003C\u002Fem>, and \u003Cem>Listeria seeligeri\u003C\u002Fem>. Findings of non-human pathogen Listeria spp. within the processing environment are an indicator of inadequate sanitation and conditions that can support growth of the human pathogen, \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>We have reviewed your responses to the above listed sanitation deficiencies from the following facilities and find them to be inadequate, as further discussed below.\u003C\u002Fp>\u003Cp>\u003Cem>Oceanside, CA\u003C\u002Fem>\u003Cbr>We reviewed your response received on June 10, 2025, to the above listed sanitation deficiencies found during the Oceanside facility inspection and find the response to be inadequate. Your response stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide the supporting documentation for these actions such as records that provide the specifics on the cleaning and sanitizing done such as where, what, when, how, and who. Also, the response did not include employee training material or employee training records. Furthermore, your response did not include corrective actions that are intended to prevent recurrence such as sanitation control procedures that are detailed with increased frequency of monitoring to ensure implementation and compliance with 21 CFR 123.11.\u003C\u002Fp>\u003Cp>\u003Cem>Los Angeles, CA\u003C\u002Fem>\u003Cbr>We reviewed your responses received on July 11 and 18, 2025, August 11, 18 and 26, 2025, to the above listed sanitation deficiencies found during the Los Angles facility inspection and find the responses to be inadequate. Your response stated that you replaced a cutting board, table, brooms, bins, roller carts and hose handles. You also stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You trained employees, adjusted the strength of hoses’ water pressure so that over spray does not occur, and have updated the sanitation form to include an area to write the exact reading of the sanitizer concentration. You indicated that the refrigeration unit was fixed and placed on a monthly maintenance schedule and any time there is an issue that the employees are to report it.\u003C\u002Fp>\u003Cp>However, you should be monitoring for condensation, splashing, and dripping frequently during processing to ensure adulteration of food does not occur rather than rely on employees notifying the supervisor. You stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response on July 18, 2025 also included a procedure prepared by your HACCP coordinator for preparing and use of Member’s Mark sanitizer a “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” quat based sanitizer that is not appropriate. It does not list the expected concentration of use and testing of the sanitizer concentration as verification. It indicates that individuals will rinse areas (i.e., cutting board, knives, gloves, aprons, etc.) and then spray a solution of 1oz sanitizer to 1 gallon water on to the area every four hours, wait two minutes, and quick rinse with water. However, the instructions for use of this sanitizer are to be used on food contact surfaces after removal of gross food particles and cleaning with a good detergent followed by a potable water before application of the sanitizer in a manner that the surfaces remain visibly wet for at least 1 minute and allowed to air dry before contact with food. Sanitizer efficacy is detrimentally reduced by organic matter such as fish protein, which makes cleaning before sanitizing crucial. Additionally, when used on food contact surfaces, quat based sanitizers at the recommended concentration of up to 200 ppm do not need to be rinsed. You also provided blank templates of your ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>” records for the processing and fillet rooms in your July 18, 2025 response that do not provide a specific place to write the actual concentration of sanitizer used, and the records did not include observations to demonstrate implementation.\u003C\u002Fp>\u003Cp>\u003Cem>Las Vegas, NV\u003C\u002Fem>\u003Cbr>We reviewed your response received on October 9, 2025, to the above listed sanitation deficiencies found during the Las Vegas facility inspection and find the response to be inadequate. Your response stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, you provided completed “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” records for September 29, 2025, through October 4, 2025, that do not record the actual concentration of sanitizer used.\u003C\u002Fp>\u003Cp>\u003Cem>Dallas, TX\u003C\u002Fem>\u003Cbr>We reviewed your response received on October 27, 2025, to the above listed sanitation deficiencies found during the Dallas facility inspection and find the response to be inadequate. Your response stated “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” As a result, you created several new forms, including a new daily sanitation verification form, and conducted employee training. You additionally provided supporting documentation through four emails on November 14, 2025. You provided completed “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” records for weeks that do not include the date of the observations and do not record the actual concentration of sanitizer used. We will discuss our continued concerns in the proposed regulatory meeting.\u003C\u002Fp>\u003Cp>2. You must maintain adequate sanitation control records that, at a minimum, document monitoring and corrections set out in 21 CFR 123.11(b), to comply with 21 CFR 123.11 (c). However, your firm did not maintain adequate sanitation monitoring records for conditions and cleanliness of food contact surfaces; prevention of cross-contamination from insanitary objects to food, food packaging material, and other food contact surfaces; maintenance of hand washing, hand sanitizing, and toilet facilities; protection of food, food packaging materials, and food contact surfaces from adulteration; and proper labeling, storage and use of toxic compounds; required for the processing of raw RTE salmon and tuna at both your Los Angeles, CA and Oceanside, CA facilities. The records are inadequate because processing and other information was not entered on records at the time that it was observed in accordance with 21 CFR 123.9(a)(4). Specifically:\u003C\u002Fp>\u003Cp>a. During production at your Los Angeles facility on June 25-26, 2025, and sanitation on June 25, 2025, an FDA investigator observed that your sanitation monitoring records were not filled out during the time they were observed. The investigator did not observe your employees enter information in the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” at \u003Cstrong>(b)(4)\u003C\u002Fstrong>AM on June 25, at \u003Cstrong>(b)(4)\u003C\u002Fstrong>AM on June 25, 2025, and at \u003Cstrong>(b)(4)\u003C\u002Fstrong>AM on June 26 as printed on the record. The investigator also did not observe your employee enter information in the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” during sanitation of the Fillet Room on June 25, 2025, at \u003Cstrong>(b)(4)\u003C\u002Fstrong>AM. These documents have a pre-filled out time for end of operations at \u003Cstrong>(b)(4)\u003C\u002Fstrong>PM.\u003C\u002Fp>\u003Cp>b. At your Oceanside facility, an FDA investigator reviewed your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” dated April 17, 2025, which was blank, but signed and dated on April 17, 2025, by both the sanitation manager and by the HACCP Administration Associate.\u003C\u002Fp>\u003Cp>We received your response to the Oceanside, CA inspection on June 10, 2025 and to your Los Angeles, CA inspection on August 11 and 18, 2025. Your response to the Oceanside findings included the \u003Cstrong>(b)(4)\u003C\u002Fstrong> form dated April 17, 2025 that had been check marked for the missing information on May 21, 2025. Your response is inadequate because you entered information onto records more than a month after the record was created and such retroactive recording is not a proper corrective action.\u003C\u002Fp>\u003Cp>Your response for the Los Angeles findings includes revisions to the forms so that individuals must write in their name and the time the monitoring was completed, and that the new HACCP coordinator will work closely with QC personnel. These responses are inadequate. You should provide at least five recent days of these records to demonstrate that they are consistently being filled in with the individuals initials and dates. Additionally, we will verify the effectiveness of your corrective actions during our next inspection by verifying that the information is entered on the record at the time of the observation.\u003C\u002Fp>\u003Cp>We remain deeply concerned that you have not provided evidence that you have successfully corrected the egregious insanitary conditions and practices in a manner that will prevent recurrence at each of these facilities. You should provide revised sanitation control procedures along with at least five days of monitoring records to demonstrate implementation and compliance with 21 CFR 123.11. Your sanitation controls procedures should provide the details that address the insanitary conditions and practices found at each facility and the frequency for monitoring should be increased to ensure compliance. For assistance with creating your sanitation control procedures and monitoring see the Sanitation Control Procedures for Processing Fish and Fishery Products document. The corresponding Sanitation Control Procedures course is offered though the Association of Food and Drug Officials (AFDO) training programs website.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\u003Cp>In addition, we have the following comments:\u003C\u002Fp>\u003Cp>Your response to this Warning Letter should at a minimum include records specific for each facility that includes a record with details for deep cleaning and sanitizing of equipment and facility intended to eliminate the resident strain of \u003Cem>L. monocytogenes\u003C\u002Fem>, revised environmental monitoring program for routine testing, results from environmental testing for \u003Cem>Listeria\u003C\u002Fem> spp., training material for employees, and employee training records. A written environmental monitoring program should include scientifically robust routine sampling to verify the successful exclusion of pathogens from areas where cross-contamination and adulteration are likely to occur and identify contamination when present. The plan should include processing area floor diagrams identifying equipment and collection sites, the type of sampling done, number of samples collected, frequency of collection, identification of sampling equipment, instructions for the collection of samples, timing of sample collection (e.g. several hours into production or prior to cleanup), specific analytical methods, the laboratory performing analysis, and corrective actions for \u003Cem>Listeria\u003C\u002Fem> spp. detected on food contact surfaces. Furthermore, we reviewed your environmental monitoring plan for Listeria signed and dated May 30, 2025, and recommend you consider adding the elements noted above. Your environmental monitoring plan also states you \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We recommend that you determine the appropriate number of food contact surface (FCS), and non-FCS sampling sites based on the size of your plant, plant features, product flow, characteristics of the RTE food, the processing methods used to produce the food, and previous sampling results. Additionally, because you process raw, RTE fish and you have the same pathogenic strain of \u003Cem>L. monocytogenes\u003C\u002Fem> present at multiple facilities, you should consider controls for the receiving of raw fish and additional controls within the facility. Recommendations for such controls can be found in FDA’s draft guidance to industry titled \u003Cu>Control of \u003C\u002Fu>\u003Cem>\u003Cu>Listeria monocytogenes\u003C\u002Fu>\u003C\u002Fem>\u003Cu> in Ready-To-Eat Foods\u003C\u002Fu>.\u003C\u002Fp>\u003Cp>We recommend that you consider incorporating WGS as a tool to investigate pathogen isolates obtained in your environmental monitoring program. The use of WGS to analyze and investigate any pathogen isolated from your production environment or RTE food products would provide the most complete information available to identify and implement appropriate and effective corrective actions, including steps to prevent the contamination from recurring and steps to ensure contaminated product does not enter commerce.\u003C\u002Fp>\u003Cp>Please notify FDA in writing within fifteen (15) working days of the receipt of this letter of the specific steps and corrections you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete correction actions within fifteen (15) working days, state the reason for the delay and the time frame within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>We have scheduled a ninety (90) minute regulatory meeting to be conducted in person at the Food and Drug Administration, Los Angeles District Office, 19701 Fairchild, Irvine, CA 92612 on April 1, 2026 at 10:00AM PT to discuss these violations and your corrective actions. Please contact us within five (5) business days from receipt of this letter to confirm your attendance or request an alternate date.\u003C\u002Fp>\u003Cp>To facilitate productive discussions, we encourage you to provide any supporting documentation of corrective actions in advance of the meeting. This may include revised HACCP plans, monitoring records, corrective action documentation, and verification records. Advance submission will allow agency personnel to review materials prior to the meeting and enable more focused discussions.\u003C\u002Fp>\u003Cp>Please send your reply to confirm the above meeting details to the Food and Drug Administration, Attention: Elodie Tong-Lin, Compliance Officer, via email at Elodie.Tong-Lin@fda.hhs.gov. If you have any questions regarding this letter, you may contact Elodie Tong-Lin, Compliance Officer, via email at Elodie.Tong-Lin@fda.hhs.gov. Please reference CMS #715467 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD MBA\u003Cbr>Acting Director\u003Cbr>Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nOcean Group Inc.\n\n1100 S Sante Fe Ave\n\nLos Angeles, CA 90021\n\nUnited States\n\njason@oceanfreshinc.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nMarch 3, 2026\nRe: CMS # 715467\nDear Mr. Kim:\nThe United States Food and Drug Administration (FDA) inspected four (4) of your Ocean Group seafood processing facilities, during a period from May 2025 through September 2025 (exact dates are listed below). FDA initiated an inspection at the Los Angeles facility as a compliance follow-up to the previous Warning Letter issued to you on April 17, 2024, and further expanded the inspection scope after a surveillance inspection at your Oceanside facility found similar sanitation deficiencies.\nWe are issuing this letter to you as the CEO of the corporation responsible for the facilities (i.e., referenced in this letter as your “facility” or “facilities”), because we found serious violations during our inspections of these facilities. During these inspections, FDA investigators found significant violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123 (21 CFR Part 123). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facilities. FDA laboratory analysis of the environmental swabs found the presence of Listeria monocytogenes (L. monocytogenes), a human pathogen, in your Los Angeles, CA, Las Vegas, NV, and Dallas, TX facilities. At the conclusion of the inspections, the FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations, listing the violations found at each of your facilities.\nBased on FDA’s inspectional findings and the analytical results for samples collected from your Los Angeles, CA, Las Vegas, NV, and Dallas, TX production environments, we have determined that the ready-to-eat (RTE) salmon and tuna processed in these three facilities are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they have been prepared, packed or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health.\nAdditionally, in accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your ready-to-eat (RTE) raw tuna and salmon processed at all four facilities are adulterated within the meaning of section 402(a)(4) of the Act You may find the Act, the seafood HACCP regulation, and the June 2022 Edition of the Fish and Fisheries Products Hazards & Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\nWe are issuing this letter to advise you of FDA’s concerns with regard to four of the inspected facilities. This letter contains detailed information describing the inspectional findings, as well as your purported corrective actions taken at each of the facilities. Furthermore, FDA has determined that a Regulatory Meeting would be beneficial to discuss your firm’s corrective actions.\nFacilities Inspected\nFDA inspected the following four seafood processing facilities located throughout the country:\n1. Los Angeles- located at 1100 S Sante Fe Ave, Los Angeles, CA 90021 conducted from June 24, 2025 through July 16, 2025, which processes RTE salmon and tuna. We acknowledge receipt of your responses dated July 11, 18, August 11, 18, and 26, 2025, which include a description of the corrective actions taken by your firm.\n2. Las Vegas- located at 4630 W Post Road, Ste 105, Las Vegas, NV from August 25 through September 12, 2025, which processes RTE salmon and tuna. We acknowledge receipt of your responses dated October 9 and 29, 2025, which include a description of the corrective actions taken by your firm.\n3. Dallas- located at 10600 Boomer Cir, Dallas, TX 75238 conducted from September 8 through September 17, 2025, which processes RTE salmon and tuna. We acknowledge receipt of your responses dated October 24 and November 14, 2025, which include a description of the corrective actions taken by your firm.\n4. Oceanside- located at 1830 Ord Way, Oceanside, CA 92056 conducted from May 12 through May 28, 2025, which processes RTE salmon and tuna. We acknowledge receipt of your responses dated June 10, 2025 with additional photographs on August 21, 2025, which include a description of the corrective actions taken by your firm.\nPathogen Findings:\nL. monocytogenes is a pathogenic bacterium that is widespread in the environment and may be introduced into a food processing facility from raw materials, humans, or equipment. Without proper controls, it can proliferate in food processing facilities where it may contaminate food. Therefore, it is essential to identify the areas of the food processing plant where this organism can grow and survive, and to apply controls or take corrective actions as necessary to eradicate the organism. Consuming foods contaminated with L. monocytogenes can lead to a severe, sometimes life-threatening, illness called listeriosis, which is a major public health concern due to the severity of the disease, its high case-fatality rate, its long incubation time, and its tendency to affect individuals with underlying conditions.\nAppropriate control of L. monocytogenes in a food processing environment requires knowledge of the unique characteristics of the organism and implementation of the hygienic practices necessary to control this pathogen. Once L. monocytogenes is established in a production area, personnel or equipment can facilitate the pathogen’s movement and contamination of food-contact surfaces and finished product. It is essential to identify the harborage sites in the food processing plant and equipment where this organism is able to grow and survive, and to apply controls or take corrective actions as necessary to eradicate the organism by rendering these areas unable to support the survival and growth of the organism and to prevent the organism from being re-established in such sites.\nFDA’s analysis identified the following:\nLos Angeles, CA\nIn 2025, (b)(4) out of (b)(4) swabs were positive for L. monocytogenes. The swabs were collected from non-food contact surfaces, including a hose handle, the bottom surface of a table, wheels of racks or other tables, and wooden broom bristles.\nIn 2024, (b)(4) out of (b)(4) swabs were positive for L. monocytogenes. The swabs were collected from a food contact surface (a cutting board) and a non-food contact surface drain in the processing room.\nIn 2023, (b)(4) of (b)(4) swabs were positive for L. monocytogenes. These swabs were collected food contact surfaces, such as a white cutting board and the interior of a grey plastic bin used to process RTE salmon and non-food contact surfaces.\nThe presence of the same strain of L. monocytogenes within that facility across multiple years is indicative of a resident pathogen. Whole genome sequencing (WGS) conducted on the (b)(4) L. monocytogenes isolates obtained from the 2025 FDA environmental swabs determined these isolates match isolates collected from your facility in 2023 and 2024 and a clinical isolate from an ill person in 2022. The presence of the same strain of L. monocytogenes that has caused illness across three different processing environments over multiple years suggests that strain has been within one or more of your facilities since at least 2023.\nThe recurring presence of L. monocytogenes in your Los Angeles, CA facility demonstrates that your sanitation procedures have been inadequate to effectively control pathogens in your facility and prevent contamination of food. It also demonstrates that your previous corrective actions were inadequate.\nIn your responses received July 11, 2025, August 11, 18 and 26, 2025 to these findings, you provided corrective actions that describe deep cleaning and sanitation, hiring of a third-party professional, industrial grade cleaning service to deep clean and sanitize the operating environments twice a month in addition to your daily deep clean. Your response also provided your own environmental sampling from (b)(4) samples, which showed negative results for Listeria spp., a technical report provided by your third-party cleaning service, environmental monitoring procedure, and root cause analysis.\nGiven the repeat history of the same strain of L. monocytogenes in your processing environments and most recent inspectional findings at the Los Angeles facility, we continue to be concerned about your ability to control L. monocytogenes within this facility.\nLas Vegas, NV\nFDA laboratory analysis of environmental swabs collected at your Las Vegas, NV facility, on August 27, 2025, confirmed that (b)(4) out of (b)(4) swabs were positive for L. monocytogenes. The swabs were collected from the top of a cutting board, on handles and a hook for blue hoses, on a drain, on a wall, and on the table leg of a fillet table.\nWGS conducted on the (b)(4) L. monocytogenes isolates obtained from the 2025 FDA environmental swabs of your Las Vegas facility showed that the isolates belonged to a single strain that match (b)(4) clinical isolates from ill people and environmental isolates collected from your Los Angeles facility in 2023 and 2024.\nWe received your response to the Las Vegas sample findings on October 9 and October 29, 2025, in which you provide a root cause analysis with a determination that lack of cleaning and sanitation for transportation trucks by a third-party then the lack of hygiene and safety when processing the product resulted in the spread of L. monocytogenes from your Los Angeles facility to your Las Vegas facility. In your “(RCA) Root Cause Analysis Report” dated September 26, 2025, you listed corrective actions, including information that equipment, tools, and other contaminated sources were discarded and replaced, employee training, testing results from two drain swabs that led you to conclude that the Las Vegas facility is Listeria-free, and third-party cleaning services. In addition, you identified that the company “needs to make a radical change on the company culture \u002F education and training staff \u002F enforcement of safety to the company.” However, your response did not include supporting documentation for substantial changes to food safety culture and training such as improved sanitation control procedures and training material with frequency of training.\nDallas, TX\nFDA laboratory analysis of environmental swabs collected at your Dallas facility on September 15, 2025, confirmed that (b)(4) of the (b)(4) swabs were positive for L. monocytogenes. These swabs were collected from hose handles, floor drains, an ice shovel handle, an exterior door flap to your cooler, the wheel of a pallet jack, and various sections of the floor in your staging room.\nWGS of the (b)(4) L. monocytogenes isolates obtained from the 2025 FDA environmental swabs of your Dallas facility determined there were three clusters for the isolates as follows.\n1. Isolates from (b)(4) of the positive environmental swabs from the Dallas facility match environmental sample isolates from your Las Vegas facility collected in 2025 and Los Angeles facility collected in 2023 and also match four clinical isolates from ill people collected between 2017 and 2023.\n2. An isolate from (b)(4) of the positive environmental swabs from the Dallas facility matches (b)(4) clinical isolates collected from ill people in 2013 and 2014.\n3. An isolate from (b)(4) of the positive environmental swabs from the Dallas facility matches (b)(4) isolates from food samples collected in 2008, 2010 and 2011 by the Canadian Food Inspection Agency (CFIA).\nYour response received October 24, 2025, states you have hired a professional cleaning company to provide training on using chemicals to “eradicate Listeria” and you have continued to search for a laboratory to perform Listeria testing and sample affected areas. You also stated (b)(4). Additionally, your “(b)(4)” dated October 20, 2025, mainly identified lack of employee training as a root cause and listed corrective actions taken such as discarding equipment and tools, fixing of walls and floors, updates to record and logs, and training. However, no environmental monitoring procedure and no documentation to support the implementation of these corrective actions was provided.\nBased on the above listed Listeria monocytogenes findings, inadequate corrective actions and lack of supporting documentation at all these facilities, we remain deeply concerned for your ability to implement and maintain sanitation controls for L. monocytogenes.\nSeafood HACCP (21 CFR Part 123)\nYour significant violations were as follows:\nSanitation conditions and practices\n1. You must monitor sanitation conditions and practices during processing with sufficient frequency to ensure compliance with current good manufacturing practice (CGMP) requirements under 21 CFR Part 117, subpart B that are appropriate to your plant and food products (21 CFR 123.11(b)). However, your firm did not monitor the following conditions and practices with sufficient frequency to ensure cGMP compliance, as evidenced by the following observations by FDA investigators at your facilities where you process raw, RTE salmon and tuna:\na. Condition and cleanliness of food contact surfaces, including utensils, gloves, and outer garments, as required by 21 CFR 123.11(b)(2):\ni. Cutting boards used to process raw RTE tuna and\u002For salmon were discolored and had cuts, scratches, cracks and\u002For crevices at your Oceanside facility on May 12 through 15, 2025, at your Los Angeles facility on June 24, 2025, and at your Las Vegas facility on August 27, 2025. Additionally, one of the cutting boards swabbed at your Las Vegas facility tested positive for L. monocytogenes from a swab collected on August 27, 2025, and one of the cutting boards at the Oceanside facility tested positive for L. innocua in a swab collected on May 13, 2025.\nii. At your Oceanside facility from May 12 through 15, a white bin used to hold raw RTE salmon and ice before descaling was discolored with pink, brown, and black residue on the interior and exterior surfaces. After production on May 13, 2025, the bin was moved outside to allow ice to melt and then the bin was used the next day to again hold salmon and ice. Also, at the Oceanside facility from May 12 through 15, 2025, two bins used to hold ice used for cooling raw RTE fish were deeply scratched with dark brown residue within the scratches and other food residue (e.g., fish scales) adhering to surfaces. Your Vice President\u002FCOO of the Oceanside facility stated (b)(4).\niii. At the Los Angeles facility on June 25, 2025, a plastic ice pallet container was damaged with a cracked wall on the inside of the container exposing ice to its insulation, a material that cannot be properly cleaned and sanitized.\niv. At your Las Vegas facility on August 25 through 27, 2025, blue ice shovels had frayed edges, cracks, and crevices.\nv. Employee aprons, which come into contact with raw, RTE fish during processing, were not kept clean or in good condition.\n1. At your Oceanside facility on May 13, 2025, employee aprons were observed to be visibly worn and discolored during processing. However, your “(b)(4)” was clean and in good repair on May 13, 2025. Also, on May 14, 2025, after production, an employee was observed to drape an apron across a bush outside the facility and on May 15, 2025, after production, employee aprons were stored against a wall visibly soiled with food residue. Additionally, a swab collected from employee apron collected on May 13, 2025 was positive for Listeria innocua.\n2. At your Las Vegas facility on August 25 through 27, 2025 employee aprons were discolored and visibly soiled and specifically on August 25, 2025, employees were washing and rinsing aprons directly on the production floor, where pooling water and trash were present, then were observed standing on the aprons with production boots during sanitizing. However, your “(b)(4)” was clean and in good repair on August 27, 2025.\n3. At your Los Angeles facility on June 25, 2025, employees were using hoses to rinse their aprons of food debris which created splash onto the filleting tables. Employee aprons were observed to contact the fillet table leg and the wrapping table leg which were both found to have L. monocytogenes present in swabs collected on June 24, 2025.\nvi. Food contact surfaces were not adequately cleaned and sanitized during sanitation. On August 25, 2025, after post-operation daily cleaning at the Las Vegas facility, the tuna ice table (“tuna bed”) still had fish bones. Additionally, your “(b)(4)” document dated August 25, 2025, was signed and verified as being scrubbed, rinsed, and sanitized for the tuna bed.\nb. Prevention of cross-contamination from insanitary objects to food, food packaging material, and other food contact surfaces, as required by 21 CFR 123.11(b)(3):\ni. Employees did not wash their hands and change their gloves after touching insanitary objects and prior to returning to work with raw RTE fish and\u002For handling food contact surfaces. Insanitary objects include:\n1. Blue plastic crates, bins and\u002For insulated foam boxes that were previously in contact with the floor at the Oceanside facility on May 12 and 13, 2025, and at the Los Angeles facility on June 25 and 26, 2025;\n2. The handle of a pallet jack that was also used by an employee from the cooler at the Los Angeles facility on June 26, 2025;\n3. Trash, fish scraps, and bones off the ground and out of floor drains at the Las Vegas facility on August 25, 2025;\n4. Face masks, glasses, and\u002For personal clothes (e.g. visibly soiled hat) at the Las Vegas facility on August 25 through 27, and on September 11, 2025;\n5. Hose handles that had fallen to the floor at the Las Vegas facility on August 26, 2025, which were swabbed on August 27, 2025, and tested positive for L. monocytogenes; and\n6. A paper towel roll that had fallen to the floor at the Dallas facility on September 8, 2025;\n7. In addition, on June 26, 2025, at your Los Angeles facility, an employee filleted raw RTE salmon, exited the Fillet Room while wearing a steel chain glove to dispose of broken Styrofoam boxes outside the facility, and then returned to the Fillet Room and sanitized hands with the steel chain glove in the hand dip without washing. The steel chain glove had gaps that allow debris to accumulate. Sanitizing equipment without cleaning and removing fish protein debris will render the sanitizer in the hand dip ineffective.\nii. Plastic or vinyl curtains were a source of contamination.\n1. At your Oceanside facility on May 12, 2025, employees transported insulated boxes containing salmon through vinyl curtains that were worn, discolored with dark residue, and not cleaned during May 12 through 14, 2025. The employees touched the boxes, then the RTE salmon fillets without washing or sanitizing hands or changing gloves. Employees, pallet jacks, and product containers passed through these vinyl curtains when moving from the Cooler to the Fillet Room.\n2. At your Los Angeles facility on June 25, 2025, employees transported a large plastic ice pallet container filled with ice through plastic curtains into the Display\u002FStaging Room in front of raw RTE tuna. The bottom of the plastic curtains came into contact with the ice, which was then shoveled into boxes of raw RTE tuna. The bottom of the plastic curtains also came into contact with employees' aprons, boots, and other pallets.\n3. At your Las Vegas facility on August 25 to 27, 2025, RTE salmon and tuna and human by-product intended for animal food (i.e., cat food) came into direct contact with plastic curtains at the fillet room entrance. Employees also touched the plastic curtain with the same gloved hands that also handled raw, RTE salmon and tuna. These plastic curtains were found to have L. innocua present in an environmental swab collected on August 27, 2025, and they are not monitored or documented on either Daily Sanitation Control or Daily Sanitation Audit Form.\niii. Hoses were a source of contamination.\n1. At your Oceanside facility on May 12, 2025, a water hose with a spray nozzle in the Fillet Room hung directly above a fillet table in direct contact with RTE salmon fillets. Employees used the hose to rinse food and food contact surfaces with pressurized water throughout production, in a manner that caused the hose to touch the floor multiple times, including the section that had previously touched the RTE salmon. The hose surface that came into contact with the RTE salmon showed black discoloration and was only cleaned and sanitized at the end of the production day.\n2. At your Dallas facility on September 9, 2025, employees were using hoses while processing raw salmon and tuna, then storing the hose handles on the side of blue plastic bins, which held waste materials.\n3. At your Los Angeles facility on June 25 and 26, 2025, employees were holding hose handles and using the hoses to spray water on raw RTE salmon, table tops and legs, aprons, gloves, and Styrofoam boxes. Employees returned to handling raw RTE salmon without washing and sanitizing their hands. Two hose handles were found to have L. monocytogenes, L. innocua, and L. welshimeri present from swabs collected on June 24, 2025.\niv. Tools used for cleaning were not appropriate or maintained.\n1. At your Oceanside facility on May 13, 2025, two handheld squeegees used to remove water from cutting boards and tables in the Fillet Room were visibly worn with black discoloration along the wiper edges.\n2. At your Los Angeles facility, employees used a wooden broom to push dirty water and debris on the floor toward the drain and to scrub the walls and tables with soap. The bristles of the wooden broom in the (b)(4) corner of your fillet room were swabbed on June 24, 2025, and was found positive for L. monocytogenes.\n3. At your Las Vegas facility on August 25 to 27, 2025, ice was packed in bags, which came into contact with employees’ visibly soiled aprons and\u002For personal clothes, then were stored on an apparently soiled Styrofoam container or other soiled surfaces in the fillet room and warehouse. These ice bags were stored directly on raw RTE tuna in the fillet room.\n4. At your Las Vegas facility on August 25, 2025, a descaler was in direct contact with the wall, and in direct contact with raw, RTE salmon on August 26, 2025. The investigator did not observe the yellow back of the descaler get a full wash, rinse and sanitize on August 25 or 26, 2025. The section of the wall was swabbed on August 27, 2025, which found L. monocytogenes.\nc. Maintenance of hand washing, hand sanitizing, and toilet facilities, as required by 21 CFR 123.11(b)(4):\ni. At your Oceanside facility, the hand washing station did not have hand sanitizer available for use. Further, the investigator did not observe employees washing hands or using hand sanitizer at any time during production from May 12 through 14, 2025. This lack of hand sanitizer was not reflected in your (b)(4)” for May 12 through 14, 2025, which was check-marked for adequate supply with water, soap, paper towels and sanitizer at the handwashing and sanitizing facilities.\nii. At your Las Vegas facility on August 25, 2025, the only handwashing sink in the fillet room did not have soap.\nd. Protection of food, food packaging material, and food contact surfaces from adulteration with condensate, and other chemical, physical, and biological contaminants, as required by 21 CFR 123.11(b)(5):\ni. Dripping condensate at multiple facilities.\n1. At your Oceanside facility on May 15, 2025, condensate dripped from the metal rack directly above and onto the exposed ice covering raw RTE tuna stored in the cooler.\n2. At your Los Angeles facility on June 25 and 26, 2025, condensate dripped from the air conditioning unit directly onto exposed RTE salmon that was being wrapped for distribution. The air conditioning unit was not cleaned or sanitized.\nii. Employee handling of water with gloved hands and\u002For hoses resulted in backsplash and\u002For aerosolized water from wooden pallets, Styrofoam boxes and other insanitary surfaces, including the floor, onto employee’s aprons and gloves, exposed raw RTE fish, and\u002For open Styrofoam boxes with blue lining. This was observed at your Oceanside facility on May 12 through 14, 2025, at your Los Angeles facility on June 25 and 26, 2025 and at your Las Vegas facility on August 26 and 27, 2025.\ne. Proper labeling, storage, and use of toxic compounds, as required by 21 CFR 123.11(b)(6):\ni. You did not follow sanitizer instructions for use and\u002For your sanitation operating procedures at multiple facilities, including at your Oceanside facility on May 12, 2025, your Los Angeles facility on June 25, 2025, and at your Las Vegas facility on September 11, 2025.\n1. At your Las Vegas facility, an employee stated (b)(4). Employees then used this solution, which measured between (b)(4) ppm on the cutting boards later used to cut RTE salmon and tuna and on the gray ice bin used to store ice for the tuna tables.\n2. At your Oceanside and Las Vegas facilities, the label for the concentrated Germicidal Bleach and chlorine sanitizing solution, respectively, did not include instructions for sanitizing food contact surfaces. These solutions were used to clean food contact surfaces.\nii. Your “(b)(4)” did not include a section to verify the concentration of sanitizers, or did not accurately reflect sanitizer concentrations.\n1. At your Oceanside facility on May 12, 2025, your “(b)(4)” but there is no section on your “(b)(4)” to verify the concentration of chlorine; the investigator found that employees were not measuring the amount of concentrated hypochlorite bleach added, and used a chlorine sanitizer test strip that indicated a concentration above the maximum reading of 1000 ppm.\n2. At your Oceanside facility on May 12, 2025, and at your Los Angeles facility on June 25, 2025, the quaternary ammonium sanitizer in spray bottles or used in hand dips measured above (b)(4) ppm, but the “(b)(4),” for both facilities which list that the concentration should be “Quat\u003C200,” were both check-marked as verified for both days.\nAs noted above, non-human pathogenic Listeria spp. were found in all four of your facilities, including Listeria innocua, Listeria welshimeri, and Listeria seeligeri. Findings of non-human pathogen Listeria spp. within the processing environment are an indicator of inadequate sanitation and conditions that can support growth of the human pathogen, L. monocytogenes.\nWe have reviewed your responses to the above listed sanitation deficiencies from the following facilities and find them to be inadequate, as further discussed below.\nOceanside, CA\nWe reviewed your response received on June 10, 2025, to the above listed sanitation deficiencies found during the Oceanside facility inspection and find the response to be inadequate. Your response stated (b)(4). However, you did not provide the supporting documentation for these actions such as records that provide the specifics on the cleaning and sanitizing done such as where, what, when, how, and who. Also, the response did not include employee training material or employee training records. Furthermore, your response did not include corrective actions that are intended to prevent recurrence such as sanitation control procedures that are detailed with increased frequency of monitoring to ensure implementation and compliance with 21 CFR 123.11.\nLos Angeles, CA\nWe reviewed your responses received on July 11 and 18, 2025, August 11, 18 and 26, 2025, to the above listed sanitation deficiencies found during the Los Angles facility inspection and find the responses to be inadequate. Your response stated that you replaced a cutting board, table, brooms, bins, roller carts and hose handles. You also stated (b)(4). You trained employees, adjusted the strength of hoses’ water pressure so that over spray does not occur, and have updated the sanitation form to include an area to write the exact reading of the sanitizer concentration. You indicated that the refrigeration unit was fixed and placed on a monthly maintenance schedule and any time there is an issue that the employees are to report it.\nHowever, you should be monitoring for condensation, splashing, and dripping frequently during processing to ensure adulteration of food does not occur rather than rely on employees notifying the supervisor. You stated (b)(4). Your response on July 18, 2025 also included a procedure prepared by your HACCP coordinator for preparing and use of Member’s Mark sanitizer a “(b)(4)” quat based sanitizer that is not appropriate. It does not list the expected concentration of use and testing of the sanitizer concentration as verification. It indicates that individuals will rinse areas (i.e., cutting board, knives, gloves, aprons, etc.) and then spray a solution of 1oz sanitizer to 1 gallon water on to the area every four hours, wait two minutes, and quick rinse with water. However, the instructions for use of this sanitizer are to be used on food contact surfaces after removal of gross food particles and cleaning with a good detergent followed by a potable water before application of the sanitizer in a manner that the surfaces remain visibly wet for at least 1 minute and allowed to air dry before contact with food. Sanitizer efficacy is detrimentally reduced by organic matter such as fish protein, which makes cleaning before sanitizing crucial. Additionally, when used on food contact surfaces, quat based sanitizers at the recommended concentration of up to 200 ppm do not need to be rinsed. You also provided blank templates of your ‘(b)(4)” records for the processing and fillet rooms in your July 18, 2025 response that do not provide a specific place to write the actual concentration of sanitizer used, and the records did not include observations to demonstrate implementation.\nLas Vegas, NV\nWe reviewed your response received on October 9, 2025, to the above listed sanitation deficiencies found during the Las Vegas facility inspection and find the response to be inadequate. Your response stated (b)(4).” However, you provided completed “(b)(4)” records for September 29, 2025, through October 4, 2025, that do not record the actual concentration of sanitizer used.\nDallas, TX\nWe reviewed your response received on October 27, 2025, to the above listed sanitation deficiencies found during the Dallas facility inspection and find the response to be inadequate. Your response stated “(b)(4).” As a result, you created several new forms, including a new daily sanitation verification form, and conducted employee training. You additionally provided supporting documentation through four emails on November 14, 2025. You provided completed “(b)(4)” records for weeks that do not include the date of the observations and do not record the actual concentration of sanitizer used. We will discuss our continued concerns in the proposed regulatory meeting.\n2. You must maintain adequate sanitation control records that, at a minimum, document monitoring and corrections set out in 21 CFR 123.11(b), to comply with 21 CFR 123.11 (c). However, your firm did not maintain adequate sanitation monitoring records for conditions and cleanliness of food contact surfaces; prevention of cross-contamination from insanitary objects to food, food packaging material, and other food contact surfaces; maintenance of hand washing, hand sanitizing, and toilet facilities; protection of food, food packaging materials, and food contact surfaces from adulteration; and proper labeling, storage and use of toxic compounds; required for the processing of raw RTE salmon and tuna at both your Los Angeles, CA and Oceanside, CA facilities. The records are inadequate because processing and other information was not entered on records at the time that it was observed in accordance with 21 CFR 123.9(a)(4). Specifically:\na. During production at your Los Angeles facility on June 25-26, 2025, and sanitation on June 25, 2025, an FDA investigator observed that your sanitation monitoring records were not filled out during the time they were observed. The investigator did not observe your employees enter information in the “(b)(4)” at (b)(4)AM on June 25, at (b)(4)AM on June 25, 2025, and at (b)(4)AM on June 26 as printed on the record. The investigator also did not observe your employee enter information in the “(b)(4)” during sanitation of the Fillet Room on June 25, 2025, at (b)(4)AM. These documents have a pre-filled out time for end of operations at (b)(4)PM.\nb. At your Oceanside facility, an FDA investigator reviewed your “(b)(4)” dated April 17, 2025, which was blank, but signed and dated on April 17, 2025, by both the sanitation manager and by the HACCP Administration Associate.\nWe received your response to the Oceanside, CA inspection on June 10, 2025 and to your Los Angeles, CA inspection on August 11 and 18, 2025. Your response to the Oceanside findings included the (b)(4) form dated April 17, 2025 that had been check marked for the missing information on May 21, 2025. Your response is inadequate because you entered information onto records more than a month after the record was created and such retroactive recording is not a proper corrective action.\nYour response for the Los Angeles findings includes revisions to the forms so that individuals must write in their name and the time the monitoring was completed, and that the new HACCP coordinator will work closely with QC personnel. These responses are inadequate. You should provide at least five recent days of these records to demonstrate that they are consistently being filled in with the individuals initials and dates. Additionally, we will verify the effectiveness of your corrective actions during our next inspection by verifying that the information is entered on the record at the time of the observation.\nWe remain deeply concerned that you have not provided evidence that you have successfully corrected the egregious insanitary conditions and practices in a manner that will prevent recurrence at each of these facilities. You should provide revised sanitation control procedures along with at least five days of monitoring records to demonstrate implementation and compliance with 21 CFR 123.11. Your sanitation controls procedures should provide the details that address the insanitary conditions and practices found at each facility and the frequency for monitoring should be increased to ensure compliance. For assistance with creating your sanitation control procedures and monitoring see the Sanitation Control Procedures for Processing Fish and Fishery Products document. The corresponding Sanitation Control Procedures course is offered though the Association of Food and Drug Officials (AFDO) training programs website.\nThe violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\nIn addition, we have the following comments:\nYour response to this Warning Letter should at a minimum include records specific for each facility that includes a record with details for deep cleaning and sanitizing of equipment and facility intended to eliminate the resident strain of L. monocytogenes, revised environmental monitoring program for routine testing, results from environmental testing for Listeria spp., training material for employees, and employee training records. A written environmental monitoring program should include scientifically robust routine sampling to verify the successful exclusion of pathogens from areas where cross-contamination and adulteration are likely to occur and identify contamination when present. The plan should include processing area floor diagrams identifying equipment and collection sites, the type of sampling done, number of samples collected, frequency of collection, identification of sampling equipment, instructions for the collection of samples, timing of sample collection (e.g. several hours into production or prior to cleanup), specific analytical methods, the laboratory performing analysis, and corrective actions for Listeria spp. detected on food contact surfaces. Furthermore, we reviewed your environmental monitoring plan for Listeria signed and dated May 30, 2025, and recommend you consider adding the elements noted above. Your environmental monitoring plan also states you (b)(4). We recommend that you determine the appropriate number of food contact surface (FCS), and non-FCS sampling sites based on the size of your plant, plant features, product flow, characteristics of the RTE food, the processing methods used to produce the food, and previous sampling results. Additionally, because you process raw, RTE fish and you have the same pathogenic strain of L. monocytogenes present at multiple facilities, you should consider controls for the receiving of raw fish and additional controls within the facility. Recommendations for such controls can be found in FDA’s draft guidance to industry titled Control of Listeria monocytogenes in Ready-To-Eat Foods.\nWe recommend that you consider incorporating WGS as a tool to investigate pathogen isolates obtained in your environmental monitoring program. The use of WGS to analyze and investigate any pathogen isolated from your production environment or RTE food products would provide the most complete information available to identify and implement appropriate and effective corrective actions, including steps to prevent the contamination from recurring and steps to ensure contaminated product does not enter commerce.\nPlease notify FDA in writing within fifteen (15) working days of the receipt of this letter of the specific steps and corrections you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete correction actions within fifteen (15) working days, state the reason for the delay and the time frame within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nWe have scheduled a ninety (90) minute regulatory meeting to be conducted in person at the Food and Drug Administration, Los Angeles District Office, 19701 Fairchild, Irvine, CA 92612 on April 1, 2026 at 10:00AM PT to discuss these violations and your corrective actions. Please contact us within five (5) business days from receipt of this letter to confirm your attendance or request an alternate date.\nTo facilitate productive discussions, we encourage you to provide any supporting documentation of corrective actions in advance of the meeting. This may include revised HACCP plans, monitoring records, corrective action documentation, and verification records. Advance submission will allow agency personnel to review materials prior to the meeting and enable more focused discussions.\nPlease send your reply to confirm the above meeting details to the Food and Drug Administration, Attention: Elodie Tong-Lin, Compliance Officer, via email at Elodie.Tong-Lin@fda.hhs.gov. If you have any questions regarding this letter, you may contact Elodie Tong-Lin, Compliance Officer, via email at Elodie.Tong-Lin@fda.hhs.gov. Please reference CMS #715467 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD MBA\nActing Director\nOffice of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Ocean Group Inc.","ocean-group-inc-715467-03032026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Focean-group-inc-715467-03032026","2026-10-26T08:09:36.753247+00:00","2026-04-14","715467","2026-08-19T04:48:02.351+00:00","VIA Electronic Mail","2026-03-03",{"id":159,"raw":160,"subject":146,"body_html":163,"body_text":164,"firm_name":149,"letter_id":165,"created_at":19,"fei_number":20,"letter_url":166,"updated_at":167,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":168,"product_type":27,"closeout_date":20,"issuing_office":162,"recipient_name":169,"body_fetched_at":170,"delivery_method":171,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},1461,[8,9,161,162,146,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Focean-group-inc-675713-04172024\">Ocean Group Inc.\u003C\u002Fa>","Division of Human and Animal Food Operations West V","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jason Y. Kim\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ocean Group Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1100 S Sante Fe Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Los Angeles\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90021\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 17, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WL 675713&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kim:\u003C\u002Fp>\n\n\u003Cp>The Food and Drug Administration (FDA) conducted an inspection of your seafood processing facility, located at 1100 S Sante Fe Ave, Los Angeles, CA 90021 from December 11 -December 21, 2023. The inspection revealed serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123 (21 CFR Part 123). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facility. FDA laboratory analysis of the environmental swabs found the presence of \u003Cem>Listeria monocytogenes\u003C\u002Fem> (\u003Cem>L. monocytogenes\u003C\u002Fem>), a human pathogen, in your facility. At the conclusion of the inspection, the FDA investigators issued your facility a Form FDA 483 (FDA-483), Inspectional Observations.\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings and the analytical results for samples collected from your production environment, we have determined that the ready-to-eat (RTE) salmon and tuna processed in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the June 2022 Edition of the Fish and Fishery Products Hazards and Controls Guidance through links on the FDA’s homepage at www.fda.gov and https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F80637\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>We received your responses to FDA’s environmental sample findings via email on December 28, 2023, to the FDA-483 via email on January 4, 2024 and a follow-up email on January 13, 2024. Further, you recalled your RTE salmon and RTE tuna processed in your facility between December 11 through December 28, 2023 and voluntarily ceased processing of RTE seafood until you conducted your own environmental monitoring. We have addressed the details of your response in the letter below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Pathogen Findings\u003C\u002Fstrong>\u003Cbr>\n\u003Cem>L. monocytogenes\u003C\u002Fem> is a pathogenic bacterium that is widespread in the environment and may be introduced into a food processing facility from raw materials, humans, or equipment. Without proper controls, it can proliferate in food processing facilities where it may contaminate food. Therefore, it is essential to identify the areas of the food processing plant where this organism is able to grow and survive and to apply controls or take corrective actions as necessary to eradicate the organism. Consuming foods contaminated with \u003Cem>L. monocytogenes\u003C\u002Fem> can lead to a severe, sometimes life-threatening illness called listeriosis, which is a major public health concern due to the severity of the disease, its high case-fatality rate, its long incubation time, and its tendency to affect individuals with underlying conditions. FDA investigators collected environmental samples from your processing facility on December 11, 2023 and December 12, 2023. FDA analysis of the environmental samples (1195789 and 1239088) confirmed that thirty-four (34) of one hundred (100) environmental swabs were positive for pathogenic\u003Cem> L. monocytogenes\u003C\u002Fem>. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Two (2) swabs were collected from direct food contact surfaces in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> room including the food contact surfaces of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to process ready-to-eat salmon and \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to process ready-to-eat salmon.\u003C\u002Fli>\n\t\u003Cli>Multiple swabs collected from processing areas in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> room:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4), (b)(6), (b)(7)(C)\u003C\u002Fstrong> table that employees were observed handling.\u003Cbr>\n&nbsp; &nbsp; o \u003Cstrong>(b)(4), (b)(6), (b)(7)(C)\u003C\u002Fstrong> table.\u003Cbr>\n&nbsp; &nbsp; o Employee’s yellow-orange plastic apron hung on the left swinging door of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> room,” \u003Cstrong>(b)(4),&nbsp;(b)(6), (b)(7)(C)\u003C\u002Fstrong> table.\u003Cbr>\n&nbsp; &nbsp; o Underside of \u003Cstrong>(b)(4), (b)(6), (b)(7)(C)\u003C\u002Fstrong> table.\u003Cbr>\n&nbsp; &nbsp; o \u003Cstrong>(b)(4)\u003C\u002Fstrong> the red shutoff valve handle, \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4),&nbsp;(b)(6), (b)(7)(C)\u003C\u002Fstrong> table.\u003Cbr>\n&nbsp; &nbsp; o Stainless steel wall \u003Cstrong>(b)(4),&nbsp;(b)(6), (b)(7)(C)&nbsp;\u003C\u002Fstrong>table.\u003Cbr>\n&nbsp; &nbsp; o \u003Cstrong>(b)(4)\u003C\u002Fstrong> where employees store RTE packaged tuna.\u003Cbr>\n&nbsp; &nbsp; o Floor section \u003Cstrong>(b)(4)\u003C\u002Fstrong> where investigators observed standing water, and high employee and equipment traffic.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Multiple swabs collected \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o \u003Cstrong>(b)(4)\u003C\u002Fstrong> that was stacked on top of other bins. There were no distinguishing features for which bins are placed on the floor and which bins are used for holding products.\u003Cbr>\n&nbsp; &nbsp; o Rim of the floor drench in front of the fillet room where investigators observed high foot and equipment traffic during operations.\u003Cbr>\n&nbsp; &nbsp; o \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that employees use to move pallets of unprocessed and processed fish and equipment throughout the plant.\u003Cbr>\n&nbsp; &nbsp; o Plastic brush on the wood push broom used to push standing liquid on the floor to floor drains throughout the production area.\u003C\u002Fp>\n\n\u003Cp>Whole genome sequencing (WGS) was conducted on the above referenced \u003Cem>L. monocytogenes\u003C\u002Fem> isolates. The analysis of the WGS data of the referenced samples showed three (3) strains of \u003Cem>L. monocytogenes\u003C\u002Fem> are present in your facility. Most notably, one of these strains was identified in twenty-eight (28) isolates and matched four (4) clinical isolates (2017, 2018, 2019, and 2023), indicating that this strain is known to cause human illness, however, no epidemiological data was available to link the clinical isolate to your facility. Two other strains were identified in one (1) and four (4) isolates, respectively, which matched various product isolates collected from other firm(s) located in Wisconsin, Tennessee, the Netherlands, and the United Kingdom, but no clinical isolates. We advised you of these WGS results via a conference call on January 5, 2024.\u003C\u002Fp>\n\n\u003Cp>The presence of \u003Cem>L. monocytogenes\u003C\u002Fem> in your facility and your products is significant in that it demonstrates your sanitation efforts are inadequate to effectively control pathogens in your facility to prevent contamination of food. Appropriate control of \u003Cem>L. monocytogenes\u003C\u002Fem> in a food processing environment requires knowledge of the unique characteristics of the organism and implementing the corresponding hygienic practices necessary to control this pathogen. Our findings indicate that your firm is neither achieving satisfactory control against the presence of \u003Cem>L. monocytogenes\u003C\u002Fem> within your facility nor implementing effective methods and controls to eliminate this human pathogen or minimize exposure to food and food-contact surfaces. Once it is established in a production area, personnel or equipment can facilitate the pathogen’s movement and contamination of food-contact surfaces and finished product. It is essential to identify the harborage sites in the food processing plant and equipment where this organism is able to grow and survive and to take such corrective actions as are necessary to eradicate the organism.\u003C\u002Fp>\n\n\u003Cp>We note that FDA environmental samples (1195789 and 1239088) also isolated thirty (30) swabs with non-pathogenic Listeria species including \u003Cem>L. innocua, L. seeligeri,\u003C\u002Fem> and \u003Cem>L. welshimeri\u003C\u002Fem>. Some of these positive swabs were found on direct food contact surfaces, and other areas where you process RTE seafood products in your fillet room. The presence of non-pathogenic Listeria species is indicative of conditions that are suitable for the survival and\u002For growth of the pathogen \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>Your response to the findings included voluntary product recall; voluntarily cessation of production; cleaning and sanitizing and environmental sampling; updated sanitation procedures; and cessation of the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response cannot be fully evaluated due to of a lack of supporting documentation, such as environmental swab results for the staging room\u002Fwarehouse areas that were found positive and sanitation monitoring records.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Seafood HACCP Violations (21 CFR Part 123):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You must monitor sanitation conditions and practices during processing with sufficient frequency to ensure, at a minimum, conformance with current good manufacturing practice requirements in 21 CFR Part 117, Subpart B (CGMPs), that are both appropriate to your plant and the food being processed and relate to one of the areas specified in 21 CFR § 123.11(b)(1)-(8), to comply with 21 CFR § 123.11(b). However, you failed to monitor persons working in direct contact with food, food-contact surfaces and food-packaging materials with sufficient frequency to ensure that such persons took necessary precautions to protect against contamination of food, food-contact surfaces, or food-packaging materials, as required by 21 CFR § 117.10(b)(9). This is related to the prevention of cross-contamination from insanitary objects to food, food packaging material, and other food contact surfaces, including utensils, gloves, and outer garments, and from raw product to cooked product, 21 CFR § 123.11(b)(3). Specifically, the following observations occurred on 12\u002F11-13\u002F2023 in the fillet room, where you process RTE tuna and RTE salmon:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Employees were observed using \u003Cstrong>(b)(4)\u003C\u002Fstrong> to spray gray plastic bins, Styrofoam boxes, cutting boards, walls, and table drains, in a manner that resulted in backsplash from these items and the floor into the air and onto surrounding areas, including the production room tables with cutting boards, onto exposed RTE salmon, the ice table, aprons of employees, and other surfaces in the vicinity. Additionally, the floor was observed to be pitted with cracks, with standing pools of water.\u003C\u002Fli>\n\t\u003Cli>Employees were observed handling a scaler rod to turn on\u002Foff the scaler, then handling RTE salmon without washing or sanitizing their hands.\u003C\u002Fli>\n\t\u003Cli>Investigators observed a black residue on the wall joints that came into frequent contact with the blue plastic liner used to wrap processed salmon fillets for sushi.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We evaluated your responses received on December 28, 2023, January 4, 2024 and January 13, 2024, in which you informed us that you destroyed and discarded all fresh salmon products that entered your facility prior to December 23, 2023, ceased production of RTE salmon and RTE tuna until your environmental sampling resulted in negative findings, conducted a deep cleaning and sanitizing, ceased the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and stated that you would train employees, install new scalers, replace the blue plastic liner, designate the gray bins, fill the pits and cracks in the floor and create new sanitation procedures. However, we are unable to fully evaluate your response as you did not provide all supporting documents, such as sanitation monitoring records and other evidence that demonstrates that planned actions have been completed (e.g., training documents, photographs of corrections).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n19701 Fairchild\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number 675713 when replying.\u003C\u002Fp>\n\n\u003Cp>If you would prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification Number in the title of the e-mail message.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at Elodie.Tong-Lin@fda.hhs.gov or 510-337-6870.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Jason Y. Kim\n\nRecipient Title\n\nCEO\n\nOcean Group Inc.\n\n1100 S Sante Fe Ave\n\nLos Angeles, CA 90021\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nApril 17, 2024\n\nWL 675713\n\nDear Mr. Kim:\n\nThe Food and Drug Administration (FDA) conducted an inspection of your seafood processing facility, located at 1100 S Sante Fe Ave, Los Angeles, CA 90021 from December 11 -December 21, 2023. The inspection revealed serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123 (21 CFR Part 123). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facility. FDA laboratory analysis of the environmental swabs found the presence of Listeria monocytogenes (L. monocytogenes), a human pathogen, in your facility. At the conclusion of the inspection, the FDA investigators issued your facility a Form FDA 483 (FDA-483), Inspectional Observations.\n\nBased on FDA’s inspectional findings and the analytical results for samples collected from your production environment, we have determined that the ready-to-eat (RTE) salmon and tuna processed in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the June 2022 Edition of the Fish and Fishery Products Hazards and Controls Guidance through links on the FDA’s homepage at www.fda.gov and https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F80637\u002Fdownload.\n\nWe received your responses to FDA’s environmental sample findings via email on December 28, 2023, to the FDA-483 via email on January 4, 2024 and a follow-up email on January 13, 2024. Further, you recalled your RTE salmon and RTE tuna processed in your facility between December 11 through December 28, 2023 and voluntarily ceased processing of RTE seafood until you conducted your own environmental monitoring. We have addressed the details of your response in the letter below.\n\nPathogen Findings\n\nL. monocytogenes is a pathogenic bacterium that is widespread in the environment and may be introduced into a food processing facility from raw materials, humans, or equipment. Without proper controls, it can proliferate in food processing facilities where it may contaminate food. Therefore, it is essential to identify the areas of the food processing plant where this organism is able to grow and survive and to apply controls or take corrective actions as necessary to eradicate the organism. Consuming foods contaminated with L. monocytogenes can lead to a severe, sometimes life-threatening illness called listeriosis, which is a major public health concern due to the severity of the disease, its high case-fatality rate, its long incubation time, and its tendency to affect individuals with underlying conditions. FDA investigators collected environmental samples from your processing facility on December 11, 2023 and December 12, 2023. FDA analysis of the environmental samples (1195789 and 1239088) confirmed that thirty-four (34) of one hundred (100) environmental swabs were positive for pathogenic L. monocytogenes. For example:\n\nTwo (2) swabs were collected from direct food contact surfaces in your (b)(4) room including the food contact surfaces of (b)(4) used to process ready-to-eat salmon and (b)(4) used to process ready-to-eat salmon.\n\nMultiple swabs collected from processing areas in your (b)(4) room:\n\no (b)(4) of the (b)(4), (b)(6), (b)(7)(C) table that employees were observed handling.\n\no (b)(4), (b)(6), (b)(7)(C) table.\n\no Employee’s yellow-orange plastic apron hung on the left swinging door of the “(b)(4) room,” (b)(4), (b)(6), (b)(7)(C) table.\n\no Underside of (b)(4), (b)(6), (b)(7)(C) table.\n\no (b)(4) the red shutoff valve handle, (b)(4) to (b)(4), (b)(6), (b)(7)(C) table.\n\no Stainless steel wall (b)(4), (b)(6), (b)(7)(C) table.\n\no (b)(4) where employees store RTE packaged tuna.\n\no Floor section (b)(4) where investigators observed standing water, and high employee and equipment traffic.\n\nMultiple swabs collected (b)(4):\n\no (b)(4) that was stacked on top of other bins. There were no distinguishing features for which bins are placed on the floor and which bins are used for holding products.\n\no Rim of the floor drench in front of the fillet room where investigators observed high foot and equipment traffic during operations.\n\no (b)(4) of (b)(4) that employees use to move pallets of unprocessed and processed fish and equipment throughout the plant.\n\no Plastic brush on the wood push broom used to push standing liquid on the floor to floor drains throughout the production area.\n\nWhole genome sequencing (WGS) was conducted on the above referenced L. monocytogenes isolates. The analysis of the WGS data of the referenced samples showed three (3) strains of L. monocytogenes are present in your facility. Most notably, one of these strains was identified in twenty-eight (28) isolates and matched four (4) clinical isolates (2017, 2018, 2019, and 2023), indicating that this strain is known to cause human illness, however, no epidemiological data was available to link the clinical isolate to your facility. Two other strains were identified in one (1) and four (4) isolates, respectively, which matched various product isolates collected from other firm(s) located in Wisconsin, Tennessee, the Netherlands, and the United Kingdom, but no clinical isolates. We advised you of these WGS results via a conference call on January 5, 2024.\n\nThe presence of L. monocytogenes in your facility and your products is significant in that it demonstrates your sanitation efforts are inadequate to effectively control pathogens in your facility to prevent contamination of food. Appropriate control of L. monocytogenes in a food processing environment requires knowledge of the unique characteristics of the organism and implementing the corresponding hygienic practices necessary to control this pathogen. Our findings indicate that your firm is neither achieving satisfactory control against the presence of L. monocytogenes within your facility nor implementing effective methods and controls to eliminate this human pathogen or minimize exposure to food and food-contact surfaces. Once it is established in a production area, personnel or equipment can facilitate the pathogen’s movement and contamination of food-contact surfaces and finished product. It is essential to identify the harborage sites in the food processing plant and equipment where this organism is able to grow and survive and to take such corrective actions as are necessary to eradicate the organism.\n\nWe note that FDA environmental samples (1195789 and 1239088) also isolated thirty (30) swabs with non-pathogenic Listeria species including L. innocua, L. seeligeri, and L. welshimeri. Some of these positive swabs were found on direct food contact surfaces, and other areas where you process RTE seafood products in your fillet room. The presence of non-pathogenic Listeria species is indicative of conditions that are suitable for the survival and\u002For growth of the pathogen L. monocytogenes.\n\nYour response to the findings included voluntary product recall; voluntarily cessation of production; cleaning and sanitizing and environmental sampling; updated sanitation procedures; and cessation of the use of (b)(4). However, your response cannot be fully evaluated due to of a lack of supporting documentation, such as environmental swab results for the staging room\u002Fwarehouse areas that were found positive and sanitation monitoring records.\n\nSeafood HACCP Violations (21 CFR Part 123):\n\nYou must monitor sanitation conditions and practices during processing with sufficient frequency to ensure, at a minimum, conformance with current good manufacturing practice requirements in 21 CFR Part 117, Subpart B (CGMPs), that are both appropriate to your plant and the food being processed and relate to one of the areas specified in 21 CFR § 123.11(b)(1)-(8), to comply with 21 CFR § 123.11(b). However, you failed to monitor persons working in direct contact with food, food-contact surfaces and food-packaging materials with sufficient frequency to ensure that such persons took necessary precautions to protect against contamination of food, food-contact surfaces, or food-packaging materials, as required by 21 CFR § 117.10(b)(9). This is related to the prevention of cross-contamination from insanitary objects to food, food packaging material, and other food contact surfaces, including utensils, gloves, and outer garments, and from raw product to cooked product, 21 CFR § 123.11(b)(3). Specifically, the following observations occurred on 12\u002F11-13\u002F2023 in the fillet room, where you process RTE tuna and RTE salmon:\n\nEmployees were observed using (b)(4) to spray gray plastic bins, Styrofoam boxes, cutting boards, walls, and table drains, in a manner that resulted in backsplash from these items and the floor into the air and onto surrounding areas, including the production room tables with cutting boards, onto exposed RTE salmon, the ice table, aprons of employees, and other surfaces in the vicinity. Additionally, the floor was observed to be pitted with cracks, with standing pools of water.\n\nEmployees were observed handling a scaler rod to turn on\u002Foff the scaler, then handling RTE salmon without washing or sanitizing their hands.\n\nInvestigators observed a black residue on the wall joints that came into frequent contact with the blue plastic liner used to wrap processed salmon fillets for sushi.\n\nWe evaluated your responses received on December 28, 2023, January 4, 2024 and January 13, 2024, in which you informed us that you destroyed and discarded all fresh salmon products that entered your facility prior to December 23, 2023, ceased production of RTE salmon and RTE tuna until your environmental sampling resulted in negative findings, conducted a deep cleaning and sanitizing, ceased the use of (b)(4), and stated that you would train employees, install new scalers, replace the blue plastic liner, designate the gray bins, fill the pits and cracks in the floor and create new sanitation procedures. However, we are unable to fully evaluate your response as you did not provide all supporting documents, such as sanitation monitoring records and other evidence that demonstrates that planned actions have been completed (e.g., training documents, photographs of corrections).\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nPlease notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n19701 Fairchild\n\nIrvine, CA 92612\n\nRefer to Unique Identification Number 675713 when replying.\n\nIf you would prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification Number in the title of the e-mail message.\n\nIf you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at Elodie.Tong-Lin@fda.hhs.gov or 510-337-6870.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 5","ocean-group-inc-675713-04172024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Focean-group-inc-675713-04172024","2026-10-26T08:09:36.69787+00:00","675713","Mr. Jason Y. Kim","2026-08-20T00:06:01.568+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED",{"id":173,"raw":174,"subject":179,"body_html":180,"body_text":181,"firm_name":182,"letter_id":183,"created_at":184,"fei_number":20,"letter_url":185,"updated_at":186,"action_type":23,"case_status":24,"posted_date":187,"marcs_cms_no":188,"product_type":69,"closeout_date":20,"issuing_office":178,"recipient_name":189,"body_fetched_at":190,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":191,"medical_device_id":20,"response_letter_date":20},1714,[175,176,177,178,179,13,13,13],"\u003Ctime datetime=\"2023-12-12T14:20:00Z\">12\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-07T05:00:00Z\">12\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnovid-group-inc-672251-12072023\">Novid Group, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Marc Kerner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Novid Group, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>18350 Roscoe Blvd. Suite 318\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Northridge\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91325-4164\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@getnovid.com\"> hello@getnovid.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 7, 2023\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Re: Case # 672251\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Kerner:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of the over-the-counter (OTC) combination antihistamine and nasal decongestant drug product novid NASAL SPRAY.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The United States Food and Drug Administration (FDA) reviewed your website on October 12, 2023 at the Internet address https:\u002F\u002Fgetnovid.com\u002F where the product is available for purchase.\u003C\u002Fp>\n\n\u003Cp>novid NASAL SPRAY is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, &amp; Cosmetic Act (FD&amp;C Act,) 21 U.S.C. 355(a) and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>novid NASAL SPRAY is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a combination antihistamine and nasal decongestant drug product.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your website https:\u002F\u002Fgetnovid.com\u002F that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . ■ temporarily relieves symptoms of upper airway allergies and infections which include: ■ runny nose ■ nasal congestion ■ sinus pressure” [from your website https:\u002F\u002Fgetnovid.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Benefits\u003C\u002Fstrong> • Relieves runny, itchy nose • Controls nasal congestion • Reduces or eliminates the symptoms of allergies, colds, and sinus infections caused by viruses or bacteria.” [from your website https:\u002F\u002Fgetnovid.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>How can I use Novid for nasal protection?\u003C\u002Fstrong> This is a concept of providing yourself individual protection from catching colds or other viral infections when in a large crowd or in close contact with potentially infected individuals. If you know that you are going to be in a large crowd, you can use Novid™ nasal spray prior to exposure and afterwards to provide some personal protection.” [from your website https:\u002F\u002Fgetnovid.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“The Doctor recommended and approved Nasal and Sinus Protection spray that fights and defends where viruses and bacteria attack” [from your website https:\u002F\u002Fgetnovid.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“The only nasal spray that is effective in reducing inflammation. Likely the #1 cause for symptoms resulting from disease.” [from your website https:\u002F\u002Fgetnovid.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“Novid™ is formulated with a patented ingredient, Fulvic Gold, which enhances the immune-enhancing activity of the nasal spray. It is a safe and effective ingredient that augments our immune cellular activity.” [from your website https:\u002F\u002Fgetnovid.com\u002F]\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, novid NASAL SPRAY is intended for use as a combination antihistamine and nasal decongestant drug product. As described below, novid NASAL SPRAY is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product identified above.\u003C\u002Fp>\n\n\u003Cp>Your novid NASAL SPRAY drug product is subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “OTC monograph drugs”— may be legally marketed if they meet applicable requirements. With respect to OTC antihistamine and nasal decongestant drug products, such products are deemed to be generally recognized as safe and effective (GRASE) and not a new drug if, among other things, they conform to the conditions of use set forth in monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use (henceforth “M012” or the cold, cough monograph).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>However, novid NASAL SPRAY does not conform to the conditions of use specified in M012 for the reasons described below.\u003C\u002Fp>\n\n\u003Cp>novid NASAL SPRAY is neither formulated, nor labeled in conformance with M012. For example, novid NASAL SPRAY’s labeled active ingredients (i.e., sodium chloride and organic fulvic acids) do not comply with M012. Specifically, sodium chloride and organic fulvic acids are not permitted active ingredients under M012 when used in combination, or as sole ingredients, for any OTC antihistamine or nasal decongestant drug product.\u003C\u002Fp>\n\n\u003Cp>In addition, the labeling for novid NASAL SPRAY includes intended use claims that are not permitted under M012. For example, the labeling for your drug product states that novid NASAL SPRAY, “…fights and defends where viruses and bacteria attack,” provides “…individual protection from catching colds or other viral infections when in a large crowd or in close contact with potentially infected individuals,” and that, “If you know that you are going to be in a large crowd, you can use Novid™ nasal spray prior to exposure and afterwards to provide some personal protection.” Such claims that suggest novid NASAL SPRAY protects and\u002For prevents consumers from getting sick are not permitted under M012. Furthermore, the labeling for novid NASAL SPRAY also includes additional intended use claims that are not permitted under M012, such as “The only nasal spray that is effective in reducing inflammation,” “Novid™ is formulated with a patented ingredient, Fulvic Gold, which enhances the immune-enhancing activity of the nasal spray,” and your product contains “…a safe and effective ingredient that augments our immune cellular activity.”\u003C\u002Fp>\n\n\u003Cp>Therefore, your novid NASAL SPRAY drug product does not comply with the cold, cough monograph described above or any other final order.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Thus, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Additionally, novid NASAL SPRAY is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent by email to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance at FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nOffice Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your firm markets this product to contain the active ingredients sodium chloride and organic fulvic acids.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR 330 prior to enactment of the CARES Act. In the case of OTC antihistamine and nasal decongestant drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000026, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that novid NASAL SPRAY is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMarc Kerner\n\nRecipient Title\n\nPresident\n\nNovid Group, Inc.\n\n18350 Roscoe Blvd. Suite 318\n\nNorthridge, CA 91325-4164\n\nUnited States\n\nhello@getnovid.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDecember 7, 2023\n\nRe: Case # 672251\n\nDear Dr. Kerner:\n\nThis letter concerns your firm’s distribution of the over-the-counter (OTC) combination antihistamine and nasal decongestant drug product novid NASAL SPRAY.1 The United States Food and Drug Administration (FDA) reviewed your website on October 12, 2023 at the Internet address https:\u002F\u002Fgetnovid.com\u002F where the product is available for purchase.\n\nnovid NASAL SPRAY is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, & Cosmetic Act (FD&C Act,) 21 U.S.C. 355(a) and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug Violations\n\nnovid NASAL SPRAY is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a combination antihistamine and nasal decongestant drug product.\n\nExamples of claims from your website https:\u002F\u002Fgetnovid.com\u002F that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\n\n“Drug Facts . . . Uses . . . ■ temporarily relieves symptoms of upper airway allergies and infections which include: ■ runny nose ■ nasal congestion ■ sinus pressure” [from your website https:\u002F\u002Fgetnovid.com\u002F]\n\n“Benefits • Relieves runny, itchy nose • Controls nasal congestion • Reduces or eliminates the symptoms of allergies, colds, and sinus infections caused by viruses or bacteria.” [from your website https:\u002F\u002Fgetnovid.com\u002F]\n\n“How can I use Novid for nasal protection? This is a concept of providing yourself individual protection from catching colds or other viral infections when in a large crowd or in close contact with potentially infected individuals. If you know that you are going to be in a large crowd, you can use Novid™ nasal spray prior to exposure and afterwards to provide some personal protection.” [from your website https:\u002F\u002Fgetnovid.com\u002F]\n\n“The Doctor recommended and approved Nasal and Sinus Protection spray that fights and defends where viruses and bacteria attack” [from your website https:\u002F\u002Fgetnovid.com\u002F]\n\n“The only nasal spray that is effective in reducing inflammation. Likely the #1 cause for symptoms resulting from disease.” [from your website https:\u002F\u002Fgetnovid.com\u002F]\n\n“Novid™ is formulated with a patented ingredient, Fulvic Gold, which enhances the immune-enhancing activity of the nasal spray. It is a safe and effective ingredient that augments our immune cellular activity.” [from your website https:\u002F\u002Fgetnovid.com\u002F]\n\nBased on the above labeling claims, novid NASAL SPRAY is intended for use as a combination antihistamine and nasal decongestant drug product. As described below, novid NASAL SPRAY is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\n\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product identified above.\n\nYour novid NASAL SPRAY drug product is subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “OTC monograph drugs”— may be legally marketed if they meet applicable requirements. With respect to OTC antihistamine and nasal decongestant drug products, such products are deemed to be generally recognized as safe and effective (GRASE) and not a new drug if, among other things, they conform to the conditions of use set forth in monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use (henceforth “M012” or the cold, cough monograph).2\n\nHowever, novid NASAL SPRAY does not conform to the conditions of use specified in M012 for the reasons described below.\n\nnovid NASAL SPRAY is neither formulated, nor labeled in conformance with M012. For example, novid NASAL SPRAY’s labeled active ingredients (i.e., sodium chloride and organic fulvic acids) do not comply with M012. Specifically, sodium chloride and organic fulvic acids are not permitted active ingredients under M012 when used in combination, or as sole ingredients, for any OTC antihistamine or nasal decongestant drug product.\n\nIn addition, the labeling for novid NASAL SPRAY includes intended use claims that are not permitted under M012. For example, the labeling for your drug product states that novid NASAL SPRAY, “…fights and defends where viruses and bacteria attack,” provides “…individual protection from catching colds or other viral infections when in a large crowd or in close contact with potentially infected individuals,” and that, “If you know that you are going to be in a large crowd, you can use Novid™ nasal spray prior to exposure and afterwards to provide some personal protection.” Such claims that suggest novid NASAL SPRAY protects and\u002For prevents consumers from getting sick are not permitted under M012. Furthermore, the labeling for novid NASAL SPRAY also includes additional intended use claims that are not permitted under M012, such as “The only nasal spray that is effective in reducing inflammation,” “Novid™ is formulated with a patented ingredient, Fulvic Gold, which enhances the immune-enhancing activity of the nasal spray,” and your product contains “…a safe and effective ingredient that augments our immune cellular activity.”\n\nTherefore, your novid NASAL SPRAY drug product does not comply with the cold, cough monograph described above or any other final order.3 Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Thus, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMisbranded Drug Violations\n\nAdditionally, novid NASAL SPRAY is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent by email to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance at FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nOffice Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n______________________\n\n1 Your firm markets this product to contain the active ingredients sodium chloride and organic fulvic acids.\n\n2 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR 330 prior to enactment of the CARES Act. In the case of OTC antihistamine and nasal decongestant drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000026, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.)\n\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that novid NASAL SPRAY is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling.","Novid Group, Inc.","novid-group-inc-672251-12072023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnovid-group-inc-672251-12072023","2026-10-26T08:09:35.237436+00:00","2023-12-12","672251","Marc Kerner","2026-08-20T00:28:00.24+00:00","2023-12-07",{"id":193,"raw":194,"subject":39,"body_html":199,"body_text":200,"firm_name":201,"letter_id":202,"created_at":130,"fei_number":20,"letter_url":203,"updated_at":204,"action_type":23,"case_status":24,"posted_date":205,"marcs_cms_no":206,"product_type":27,"closeout_date":20,"issuing_office":198,"recipient_name":207,"body_fetched_at":208,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":209,"medical_device_id":20,"response_letter_date":20},2809,[195,196,197,198,39,13,13,13],"\u003Ctime datetime=\"2022-03-15T13:20:00Z\">03\u002F15\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-25T05:00:00Z\">02\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffella-group-llc-625512-02252022\">Fella Group LLC\u003C\u002Fa>","Division of West Coast Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jesus F. Felix Miranda\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Fella Group LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>24 Seedling\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618-8860\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 25, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 625512\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Felix:\u003C\u002Fp>\n\n\u003Cp>On December 10, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Programs (FSVP) inspection at FELLA GROUP LLC, 24 Seedling, Irvine, CA 92618-8860. We also conducted an inspection on July 28, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response dated January 6, 2022, and we address your response below.\u003C\u002Fp>\n\n\u003Cp>Your response stated that you would develop an FSVP plan for all imported food products imported by Fella Group LLC, and the time required to develop the FSVP plan would be between January 6, 2022 to December 15, 2022. You provided the same response to your initial inspection in which you provided a time frame of August 8, 2020 to July 31, 2021. To date, you have not made adequate corrective actions or provided sufficient FSVP documentation for the foods you import.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for each of the following foods:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Mayocoba Beans imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Chick Peas (Garbanzo Beans) imported from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Rustic Salad Dressing imported from \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>and\u003C\u002Fli>\n\t\u003Cli>any other foods you import\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The above violation is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms%20ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003Cbr>\n\u003Cbr>\nPlease send your reply to Food and Drug Administration, Attention: William Park, Compliance Officer, Division of West Coast Imports, One World Trade Center, Ste 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact William Park via email at william.park@fda.hhs.gov. Please reference CMS # 625512 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Kathleen Turner\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJesus F. Felix Miranda\n\nRecipient Title\n\nOwner\n\nFella Group LLC\n\n24 Seedling\n\nIrvine, CA 92618-8860\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nFebruary 25, 2022\n\nWARNING LETTER\n\nRe: CMS # 625512\n\nDear Mr. Felix:\n\nOn December 10, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Programs (FSVP) inspection at FELLA GROUP LLC, 24 Seedling, Irvine, CA 92618-8860. We also conducted an inspection on July 28, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\n\nWe acknowledge receipt of your response dated January 6, 2022, and we address your response below.\n\nYour response stated that you would develop an FSVP plan for all imported food products imported by Fella Group LLC, and the time required to develop the FSVP plan would be between January 6, 2022 to December 15, 2022. You provided the same response to your initial inspection in which you provided a time frame of August 8, 2020 to July 31, 2021. To date, you have not made adequate corrective actions or provided sufficient FSVP documentation for the foods you import.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for each of the following foods:\n\nMayocoba Beans imported from (b)(4)\n\nChick Peas (Garbanzo Beans) imported from (b)(4)\n\nRustic Salad Dressing imported from (b)(4) and\n\nany other foods you import\n\nThe above violation is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: William Park, Compliance Officer, Division of West Coast Imports, One World Trade Center, Ste 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact William Park via email at william.park@fda.hhs.gov. Please reference CMS # 625512 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Kathleen Turner\n\nProgram Division Director\n\nDivision of West Coast Imports","Fella Group LLC","fella-group-llc-625512-02252022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffella-group-llc-625512-02252022","2026-10-26T08:08:40.435139+00:00","2022-03-15","625512","Jesus F. Felix Miranda","2026-08-20T02:06:01.616+00:00","2022-02-25",{"id":211,"raw":212,"subject":217,"body_html":219,"body_text":220,"firm_name":221,"letter_id":222,"created_at":64,"fei_number":20,"letter_url":223,"updated_at":224,"action_type":23,"case_status":225,"posted_date":226,"marcs_cms_no":227,"product_type":27,"closeout_date":226,"issuing_office":216,"recipient_name":228,"body_fetched_at":229,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":230,"medical_device_id":20,"response_letter_date":20},2396,[213,214,215,216,217,13,218,13],"\u003Ctime datetime=\"2022-10-18T13:20:00Z\">10\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-20T04:00:00Z\">04\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthai-union-group-plc-630100-04202022\">Thai Union Group PLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthai-union-group-plc-630100-09082022\">\u003Ctime datetime=\"2022-10-18T04:00:00Z\">10\u002F18\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Wachira Katueang-Ngan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Quality Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Thai Union Group PLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>72\u002F1 Moo 7 Sethakit 1 Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tambon Tarsrai\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Amphoe\u003C\u002Fspan>, \u003Cspan>Mueang\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Samut Sakhon\u003C\u002Fspan> \u003Cspan>74000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thailand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 20, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Reference # 630100\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Wachira Katueang-Ngan:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted a Foreign Remote Regulatory Assessment (FRRA) of your seafood processing facility, Thai Union Group PLC, located at 72\u002F1 Moo 7 Sethakit 1 Road, Tambon Tarsrai, Amphoe Mueang Samutsakhon, Samutsakhon, 74000, Thailand on January 18-20 &amp; 25, 2022. An on-site inspection was not possible due to travel restrictions during the COVID-19 pandemic. During the remote assessment, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). At the conclusion of the assessment, the FDA investigator discussed items of concern. We acknowledge your email responses dated, February 1, 2022, and March 1, 2022, to the discussion items identified during the FRRA.\u003C\u002Fp>\n\n\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your frozen, pre-cooked tuna loin products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You must have a HACCP plan that at minimum lists the critical limits that must be met, to comply with 21 CFR 123.6 (c)(3). A critical limit is defined in 21 CFR 123.3 (c) as the “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard. However, your firm’s HACCP Plan for frozen precooked tuna loins lists a critical limit of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” at the Precooking critical control point (CCP 11) that is not adequate to control scombrotoxin (histamine) formation. FDA recommends you establish critical limits for the minimum or maximum values for the critical factors established by a scientific study, which may include length of the cook cycle, speed of the belt for a continuous cooker, temperature of the steam or water used for cooking, initial temperature of the product, product form (loin, whole fish, etc.), and any other critical factors that affect the rate of heating the product. Alternatively, you may establish a value for the end product internal product temperature (EPIPT), established by a scientific study.\u003C\u002Fp>\n\n\u003Cp>Your Temperature Distribution Testing Report and Heat Penetration Testing Report provided during the inspection do not support the listed critical limit of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>\na. The Temperature Distribution Testing Report documents the result of temperature distribution within “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” located at “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” but the Heat Penetration Testing Report documents results for “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” located at “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” In order to scientifically validate the cooking process, the scientific studies used to establish critical limits should be conducted for and applied to each individual cook tunnel.\u003Cbr>\nb. Although the “Test Procedure” section of the Heat Penetration Testing Report states that the thermocouples (TC) should be placed in the geometric center of the product at the thickest point near the backbone,” the photos on page 3 of the report show temperature sensors placed in tuna loins and not in whole, headed and gutted or any tunas with backbones. It does not appear that the heat penetration study is representative of the whole tuna processed under the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” HACCP plan, which lists the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step as occurring after the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step.\u003C\u002Fp>\n\n\u003Cp>Additionally, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” is identified as the scheduled process of precooked tuna (For USA) and includes Skipjack, Bigeye, Yellowfin, and Albacore tuna. The document lists multiple sizes for each species and a corresponding “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” It is unclear how this document relates to the listed critical limit of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” or how it relates to the Heat Penetration Testing Report. Since multiple sized batches are processed, the critical limit should include ensuring each fish of each batch weighs less than a specific maximum size to ensure that all fish are processed to achieve a uniform heat penetration with a minimum internal temperature of 60°C.\u003C\u002Fp>\n\n\u003Cp>2. You must have a HACCP Plan that at minimum lists monitoring procedures and their frequency for each critical control point, to comply with 21 CFR 123.6(c)(4). However, your firm’s HACCP plan for frozen precooked tuna loins lists a monitoring frequency at the following critical control points that is not adequate. Specifically:\u003Cbr>\n\u003Cbr>\na. The unrefrigerated processing critical control points for steps “3-19” (CCP 10) lists a monitoring frequency of “-Every bin of raw material -Every trolley of precooked fish” that is not adequate to control scombrotoxin (histamine) formation because it does not include a unit of time between measurements. FDA recommends monitoring cumulative exposure time at a frequency of every 2 hours.\u003Cbr>\nb. The unrefrigerated processing critical control point for steps “19-33, 44” (CCP 12) lists a monitoring frequency of “-Every precooked fish trolley” that is not adequate to control scombrotoxin (histamine) formation because it does not include a unit of time between measurements. FDA recommends monitoring cumulative exposure time at a frequency of every 2 hours.\u003Cbr>\nc. The unrefrigerated processing critical control point for steps “22-33,40” (CCP13) lists a monitoring frequency of “-Every precooked fish trolley” that is not adequate to control \u003Cem>Staphylococcus aureus\u003C\u002Fem> growth and toxin formation because it does not include a unit of time between measurements. FDA recommends monitoring cumulative exposure time at a frequency of every 2 hours.\u003C\u002Fp>\n\n\u003Cp>3. You must implement the monitoring procedures and frequency that you have listed in your HACCP Plan, to comply with 21 CFR 123.6(b) and (c)(4). However, your firm did not follow the monitoring procedure of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” at the unrefrigerated processing critical control point for steps “3-19” (CCP 10) to control scombrotoxin (histamine) formation. FDA recommends continuous ambient temperature monitoring (air and water surrounding fish) from the time a lot of fish exits cold storage until the time a lot of fish enters the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step.\u003C\u002Fp>\n\n\u003Cp>According to your submitted Corrective Action report, [the] “production department has designated PD Staffs to check temperature of water in the fish tank by thermometer at the end of \u003Cstrong>(b)(4)\u003C\u002Fstrong> step. PD staffs has recorded its temperature for monitoring the temperature control at \u003Cstrong>(b)(4)\u003C\u002Fstrong> step.” Monitoring the water temperature at the end of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step is not consistent with your listed monitoring procedure of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and does not ensure that the fish were not exposed to temperatures above 4.4°C (40°F) during tempering (or thawing).\u003C\u002Fp>\n\n\u003Cp>Your “Attach No.3 – Validation of temperature from the each step.xlsx,” document showed that the total time fish are exposed to temperatures above 4.4°C (40°F) between the start of step 3 until step 19 (raw material transportation to precooking) take over 19 hours (1166 minutes). We acknowledge that the water temperature during tempering and thawing varies. It appears you are using thermocouples to monitor the water temperature during tempering and thawing. If the thermocouples are connected to continuous temperature monitoring device that produces a history of the water temperature during these steps, this would allow for continuous monitoring and documentation of the actual amount of time fish are exposed to water temperatures above 4.4°C (40°F) (see “Attach No.1 – Temperature control at \u003Cstrong>(b)(4)\u003C\u002Fstrong> step.pdf”).\u003C\u002Fp>\n\n\u003Cp>4. Since you chose to include corrective actions in your HACCP Plan, your described corrective actions must be appropriate, to comply with 21 CFR 123.7(b). However, your corrective action plan listed at the following critical control points are not appropriate. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. The metal detecting critical control point (CCP 2) lists a corrective actions of “If any product was rejected by metal detector, action shall be taken one as following: 1) the fish shall be rejected, or 2) the fish shall be separated for sorting out the metal fragments and after removed the metal fragment, re-pass the fish through metal detector again before releasing” is not adequate because it does not address the cause of the critical limit deviation. In order to regain control over the operation, FDA also recommends you attempt to locate and correct the source of the fragments found in the product by the metal detector.\u003Cbr>\nb. The unrefrigerated processing critical control point for steps 3-19 (CCP 10) does not ensure unsafe product doesn’t reach the consumer or correct the cause of the critical limit deviation. To ensure unsafe product does not reach the consumer, in addition to your listed corrective action of “perform histamine analysis on the fish lot by analyzing minimum of 60 fish, including all fish that show evidence of decomposition,” FDA recommends you also add instructions to destroy the lot or divert it to a non-food use if any fish is found with histamine greater than or equal to 50ppm. To correct the cause of the critical limit deviation, FDA recommends you modify the process as needed to reduce exposure time. Note that the listed corrective action to “reject the lot which is all raw material bins that take longer than control time and greater than control temperature at each step” is not appropriate because it represents an action taken for a critical limit deviation for processing temperatures, but the CCP does not contain a temperature critical limit.\u003Cbr>\nc. The unrefrigerated processing critical control point for steps 19-33,40 (CCP 12) lists a corrective action of “If cumulative time from after precooking until start of freezing exceeds 12 hours, then specifically identify the involved trolley of tuna, segregate and immediately expedite processing, then conduct histamine analysis at cleaning for 60 tuna randomly selected from the identified racks based on composites from 3 tuna (20 composites) If any composite exceeds 10ppm histamine, then reject all identified rack.- Depending on evidence, each of the 60 individual fish can be analyzed whereby all identified tuna are rejected if any one fish exceeds 30ppm. – Determine and correct cause for the excessive exposure time”. This corrective action is not adequate to ensure unsafe product does not reach the consumer or correct the cause of the critical limit deviation.\u003C\u002Fp>\n\n\u003Cp>To ensure unsafe product does not reach the consumer, FDA recommends you:\u003Cbr>\n• chill and hold the affected product until histamine analysis is performed on a minimum of 60 fish representatively collected from throughout the affected lot and destroy the lot or divert it to a non-food use if any fish is found with histamine greater than or equal to 50 ppm. The fish collected for analysis may be composited if the action plan is reduced accordingly. For example, a sample of 60 fish may be composited into 20 units of 3 fish each, provided the action point is reduced from 50 ppm to 17 ppm for each unit;\u003Cbr>\nOR\u003Cbr>\n• Destroy the product;\u003Cbr>\nOR\u003Cbr>\n• Divert the product to a non-food use.\u003Cbr>\nAND: to regain control over the operation and correct the cause of the critical limit deviation, FDA recommends you:\u003Cbr>\n• Add ice to the product;\u003Cbr>\nOR\u003Cbr>\n• Return the affected product to the cooler;\u003Cbr>\nAND\u003Cbr>\n• Modify the process as needed to reduce the time and temperature exposure.\u003Cbr>\nd. The Unrefrigerated Processing critical control point for steps 22-33,40 (CCP 13) lists a corrective action of “If the accumulated time is more than the critical limits reject the products” that is not adequate to ensure unsafe product does not reach the consumer or correct the cause of the critical limit deviation.\u003Cbr>\nTo ensure unsafe product does not reach the consumer, FDA recommends you:\u003Cbr>\n• Chill and hold the affected product until an evaluation of total time and temperature exposures is performed;\u003Cbr>\nOR\u003Cbr>\n• Destroy the product;\u003Cbr>\nOR\u003Cbr>\n• Divert the product to a non-food use.\u003Cbr>\nAND: to regain control over the operation and correct the cause of the critical limit deviation, FDA recommends you:\u003Cbr>\n• Determine cause of deviation\u003Cbr>\nAND\u003Cbr>\n• Modify the process as needed to reduce time and temperature exposure.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your revised HACCP plan dated “22\u002F02\u002F22”. This HACCP plan outlines a process where tuna is loined after the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step. The technical review conducted was based upon the updated flowchart provided with the updated HACCP Plan. However, your description of the traditional process for vacuum-packed frozen tuna loins outlines processing steps that conflict with the steps outlined in the updated HACCP plan dated 22\u002F02\u002F22. Clarification is needed to determine which is utilized during production, the actual process outlined in the updated flowchart and updated HACCP plan dated “22\u002F02\u002F22”. If the actual process, the updated flowchart, and updated HACCP plan do not align with actual processing taking place, hazards might not be identified and\u002For adequately controlled during processing.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan or plans, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. You may view this alert at: \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>You should direct your written reply to Rosemary Sexton, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact Rosemary Sexton via email at Rosemary.Sexton@fda.hhs.gov. Please reference CMS #630100 on any submissions and on the subject line of any emails to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Wachira Katueang-Ngan\n\nRecipient Title\n\nQuality Manager\n\nThai Union Group PLC\n\n72\u002F1 Moo 7 Sethakit 1 Road\n\nTambon Tarsrai\n\nAmphoe, Mueang\n\nSamut Sakhon 74000\n\nThailand\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nApril 20, 2022\n\nWARNING LETTER\n\nReference # 630100\n\nDear Ms. Wachira Katueang-Ngan:\n\nThe United States Food and Drug Administration (FDA) conducted a Foreign Remote Regulatory Assessment (FRRA) of your seafood processing facility, Thai Union Group PLC, located at 72\u002F1 Moo 7 Sethakit 1 Road, Tambon Tarsrai, Amphoe Mueang Samutsakhon, Samutsakhon, 74000, Thailand on January 18-20 & 25, 2022. An on-site inspection was not possible due to travel restrictions during the COVID-19 pandemic. During the remote assessment, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). At the conclusion of the assessment, the FDA investigator discussed items of concern. We acknowledge your email responses dated, February 1, 2022, and March 1, 2022, to the discussion items identified during the FRRA.\n\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your frozen, pre-cooked tuna loin products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\n\nYour significant deviations are as follows:\n\n1. You must have a HACCP plan that at minimum lists the critical limits that must be met, to comply with 21 CFR 123.6 (c)(3). A critical limit is defined in 21 CFR 123.3 (c) as the “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard. However, your firm’s HACCP Plan for frozen precooked tuna loins lists a critical limit of “(b)(4)” at the Precooking critical control point (CCP 11) that is not adequate to control scombrotoxin (histamine) formation. FDA recommends you establish critical limits for the minimum or maximum values for the critical factors established by a scientific study, which may include length of the cook cycle, speed of the belt for a continuous cooker, temperature of the steam or water used for cooking, initial temperature of the product, product form (loin, whole fish, etc.), and any other critical factors that affect the rate of heating the product. Alternatively, you may establish a value for the end product internal product temperature (EPIPT), established by a scientific study.\n\nYour Temperature Distribution Testing Report and Heat Penetration Testing Report provided during the inspection do not support the listed critical limit of “(b)(4).”\n\na. The Temperature Distribution Testing Report documents the result of temperature distribution within “(b)(4)” located at “(b)(4)” but the Heat Penetration Testing Report documents results for “(b)(4)” and “(b)(4)” located at “(b)(4).” In order to scientifically validate the cooking process, the scientific studies used to establish critical limits should be conducted for and applied to each individual cook tunnel.\n\nb. Although the “Test Procedure” section of the Heat Penetration Testing Report states that the thermocouples (TC) should be placed in the geometric center of the product at the thickest point near the backbone,” the photos on page 3 of the report show temperature sensors placed in tuna loins and not in whole, headed and gutted or any tunas with backbones. It does not appear that the heat penetration study is representative of the whole tuna processed under the “(b)(4)” HACCP plan, which lists the “(b)(4)” step as occurring after the “(b)(4)” step.\n\nAdditionally, your “(b)(4)” is identified as the scheduled process of precooked tuna (For USA) and includes Skipjack, Bigeye, Yellowfin, and Albacore tuna. The document lists multiple sizes for each species and a corresponding “(b)(4).” It is unclear how this document relates to the listed critical limit of “(b)(4)” or how it relates to the Heat Penetration Testing Report. Since multiple sized batches are processed, the critical limit should include ensuring each fish of each batch weighs less than a specific maximum size to ensure that all fish are processed to achieve a uniform heat penetration with a minimum internal temperature of 60°C.\n\n2. You must have a HACCP Plan that at minimum lists monitoring procedures and their frequency for each critical control point, to comply with 21 CFR 123.6(c)(4). However, your firm’s HACCP plan for frozen precooked tuna loins lists a monitoring frequency at the following critical control points that is not adequate. Specifically:\n\na. The unrefrigerated processing critical control points for steps “3-19” (CCP 10) lists a monitoring frequency of “-Every bin of raw material -Every trolley of precooked fish” that is not adequate to control scombrotoxin (histamine) formation because it does not include a unit of time between measurements. FDA recommends monitoring cumulative exposure time at a frequency of every 2 hours.\n\nb. The unrefrigerated processing critical control point for steps “19-33, 44” (CCP 12) lists a monitoring frequency of “-Every precooked fish trolley” that is not adequate to control scombrotoxin (histamine) formation because it does not include a unit of time between measurements. FDA recommends monitoring cumulative exposure time at a frequency of every 2 hours.\n\nc. The unrefrigerated processing critical control point for steps “22-33,40” (CCP13) lists a monitoring frequency of “-Every precooked fish trolley” that is not adequate to control Staphylococcus aureus growth and toxin formation because it does not include a unit of time between measurements. FDA recommends monitoring cumulative exposure time at a frequency of every 2 hours.\n\n3. You must implement the monitoring procedures and frequency that you have listed in your HACCP Plan, to comply with 21 CFR 123.6(b) and (c)(4). However, your firm did not follow the monitoring procedure of “(b)(4)” at the unrefrigerated processing critical control point for steps “3-19” (CCP 10) to control scombrotoxin (histamine) formation. FDA recommends continuous ambient temperature monitoring (air and water surrounding fish) from the time a lot of fish exits cold storage until the time a lot of fish enters the (b)(4) step.\n\nAccording to your submitted Corrective Action report, [the] “production department has designated PD Staffs to check temperature of water in the fish tank by thermometer at the end of (b)(4) step. PD staffs has recorded its temperature for monitoring the temperature control at (b)(4) step.” Monitoring the water temperature at the end of the (b)(4) step is not consistent with your listed monitoring procedure of “(b)(4)” and does not ensure that the fish were not exposed to temperatures above 4.4°C (40°F) during tempering (or thawing).\n\nYour “Attach No.3 – Validation of temperature from the each step.xlsx,” document showed that the total time fish are exposed to temperatures above 4.4°C (40°F) between the start of step 3 until step 19 (raw material transportation to precooking) take over 19 hours (1166 minutes). We acknowledge that the water temperature during tempering and thawing varies. It appears you are using thermocouples to monitor the water temperature during tempering and thawing. If the thermocouples are connected to continuous temperature monitoring device that produces a history of the water temperature during these steps, this would allow for continuous monitoring and documentation of the actual amount of time fish are exposed to water temperatures above 4.4°C (40°F) (see “Attach No.1 – Temperature control at (b)(4) step.pdf”).\n\n4. Since you chose to include corrective actions in your HACCP Plan, your described corrective actions must be appropriate, to comply with 21 CFR 123.7(b). However, your corrective action plan listed at the following critical control points are not appropriate. Specifically:\n\na. The metal detecting critical control point (CCP 2) lists a corrective actions of “If any product was rejected by metal detector, action shall be taken one as following: 1) the fish shall be rejected, or 2) the fish shall be separated for sorting out the metal fragments and after removed the metal fragment, re-pass the fish through metal detector again before releasing” is not adequate because it does not address the cause of the critical limit deviation. In order to regain control over the operation, FDA also recommends you attempt to locate and correct the source of the fragments found in the product by the metal detector.\n\nb. The unrefrigerated processing critical control point for steps 3-19 (CCP 10) does not ensure unsafe product doesn’t reach the consumer or correct the cause of the critical limit deviation. To ensure unsafe product does not reach the consumer, in addition to your listed corrective action of “perform histamine analysis on the fish lot by analyzing minimum of 60 fish, including all fish that show evidence of decomposition,” FDA recommends you also add instructions to destroy the lot or divert it to a non-food use if any fish is found with histamine greater than or equal to 50ppm. To correct the cause of the critical limit deviation, FDA recommends you modify the process as needed to reduce exposure time. Note that the listed corrective action to “reject the lot which is all raw material bins that take longer than control time and greater than control temperature at each step” is not appropriate because it represents an action taken for a critical limit deviation for processing temperatures, but the CCP does not contain a temperature critical limit.\n\nc. The unrefrigerated processing critical control point for steps 19-33,40 (CCP 12) lists a corrective action of “If cumulative time from after precooking until start of freezing exceeds 12 hours, then specifically identify the involved trolley of tuna, segregate and immediately expedite processing, then conduct histamine analysis at cleaning for 60 tuna randomly selected from the identified racks based on composites from 3 tuna (20 composites) If any composite exceeds 10ppm histamine, then reject all identified rack.- Depending on evidence, each of the 60 individual fish can be analyzed whereby all identified tuna are rejected if any one fish exceeds 30ppm. – Determine and correct cause for the excessive exposure time”. This corrective action is not adequate to ensure unsafe product does not reach the consumer or correct the cause of the critical limit deviation.\n\nTo ensure unsafe product does not reach the consumer, FDA recommends you:\n\n• chill and hold the affected product until histamine analysis is performed on a minimum of 60 fish representatively collected from throughout the affected lot and destroy the lot or divert it to a non-food use if any fish is found with histamine greater than or equal to 50 ppm. The fish collected for analysis may be composited if the action plan is reduced accordingly. For example, a sample of 60 fish may be composited into 20 units of 3 fish each, provided the action point is reduced from 50 ppm to 17 ppm for each unit;\n\nOR\n\n• Destroy the product;\n\nOR\n\n• Divert the product to a non-food use.\n\nAND: to regain control over the operation and correct the cause of the critical limit deviation, FDA recommends you:\n\n• Add ice to the product;\n\nOR\n\n• Return the affected product to the cooler;\n\nAND\n\n• Modify the process as needed to reduce the time and temperature exposure.\n\nd. The Unrefrigerated Processing critical control point for steps 22-33,40 (CCP 13) lists a corrective action of “If the accumulated time is more than the critical limits reject the products” that is not adequate to ensure unsafe product does not reach the consumer or correct the cause of the critical limit deviation.\n\nTo ensure unsafe product does not reach the consumer, FDA recommends you:\n\n• Chill and hold the affected product until an evaluation of total time and temperature exposures is performed;\n\nOR\n\n• Destroy the product;\n\nOR\n\n• Divert the product to a non-food use.\n\nAND: to regain control over the operation and correct the cause of the critical limit deviation, FDA recommends you:\n\n• Determine cause of deviation\n\nAND\n\n• Modify the process as needed to reduce time and temperature exposure.\n\nWe acknowledge your revised HACCP plan dated “22\u002F02\u002F22”. This HACCP plan outlines a process where tuna is loined after the (b)(4) step. The technical review conducted was based upon the updated flowchart provided with the updated HACCP Plan. However, your description of the traditional process for vacuum-packed frozen tuna loins outlines processing steps that conflict with the steps outlined in the updated HACCP plan dated 22\u002F02\u002F22. Clarification is needed to determine which is utilized during production, the actual process outlined in the updated flowchart and updated HACCP plan dated “22\u002F02\u002F22”. If the actual process, the updated flowchart, and updated HACCP plan do not align with actual processing taking place, hazards might not be identified and\u002For adequately controlled during processing.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan or plans, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\n\nYou should direct your written reply to Rosemary Sexton, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact Rosemary Sexton via email at Rosemary.Sexton@fda.hhs.gov. Please reference CMS #630100 on any submissions and on the subject line of any emails to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition","Thai Union Group PLC","thai-union-group-plc-630100-04202022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthai-union-group-plc-630100-04202022","2026-10-26T08:10:10.946439+00:00","Closed Out","2022-10-18","630100","Ms. Wachira Katueang-Ngan","2026-08-20T01:30:24.318+00:00","2022-04-20",{"id":232,"raw":233,"subject":238,"body_html":239,"body_text":240,"firm_name":241,"letter_id":242,"created_at":44,"fei_number":20,"letter_url":243,"updated_at":244,"action_type":23,"case_status":24,"posted_date":245,"marcs_cms_no":246,"product_type":69,"closeout_date":20,"issuing_office":237,"recipient_name":247,"body_fetched_at":248,"delivery_method":95,"recipient_title":20,"reference_number":249,"action_taken_date":250,"medical_device_id":20,"response_letter_date":20},117,[234,235,236,237,238,13,13,13],"\u003Ctime datetime=\"2026-06-09T04:00:00Z\">06\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frevlon-group-holdings-llc-722596-06022026\">Revlon Group Holdings, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FOTC Finished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-89\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. David Hamilton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President of Operations  \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Revlon Group Holdings, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1501 Williamsboro St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Oxford\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27565\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-89\u003C\u002Fp>\u003Cp>June 2, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Hamilton:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 8, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Revlon – Oxford Facility, FEI 1021184, at 1501 Williamsboro St., Oxford, as well as subsequent correspondence.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violation were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactured \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product labeled to contain the active drug ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You currently manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> OTC drug product labeled to contain the active drug ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These drug products listed above are labeled to contain the inactive ingredient talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.\u003Cem>\u003Cstrong>\u003Csup>1,2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is considered a higher-risk drug as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation.\u003C\u002Fp>\u003Cp>You have not demonstrated that you appropriately tested incoming talc drug components used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products for identity, purity, strength, and quality. In response to our 704(a)(4) request, you originally indicated that you did perform testing for asbestos in talc before release for use in drug product manufacturing. In subsequent correspondence, the data you provided only clarified that your talc components were tested for asbestos by the supplier and not by you. Evidence was not provided that your firm conducts asbestos testing at your facility. You failed to provide records indicating that you established the reliability of your supplier’s analyses through appropriate validation of the supplier’s test results. Although 21 CFR 211.84(d)(2) provides for some reliance on a certificate of analysis (COA) from the supplier of the component, such reliance is permissible only if the drug product manufacturer establishes the reliability of the supplier’s test results through appropriate validation of the test results at appropriate intervals.\u003C\u002Fp>\u003Cp>Additionally, you provided records to demonstrate you had conducted identity testing pursuant to the applicable United States Pharmacopeia (USP) test to satisfy the requirements for identity testing in 211.84(d)(1) and (2), but the testing does not conform to the current USP testing method, in that it is incomplete (i.e., lacks identification B and C). Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>As a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Identity, assay and impurity test results from testing retains for all lots of talc (drug component) used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate written specifications for identity, purity, strength, and quality. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A gap analysis for specifications for drug components (active and inactive) between your current specifications and test procedures against the USP, where applicable. Based on your gap analysis, provide a comprehensive plan for conformance of your drug component specifications and testing to USP standards, where applicable.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that your test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). The current USP talc monograph could be used to meet this requirement for talc; however, your specifications for talc components did not include testing for assay, and multiple impurities (e.g., limits of \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Beyond the deficiencies in testing detailed above, your talc microbiological specifications for “yeast and mold” of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fg exceeds USP specification for total combined molds and yeasts of Not More Than (NMT) \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fg for talc used in \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. Your COA reports microbiological test results as \"CONFORM\" without including a quantitative value, which would not be sufficient for the QU to make an informed release decision or determine if the result meets the USP requirement. Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>A determination of whether procedures used by your firm are robust and appropriate\u003C\u002Fli>\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003C\u002Fli>\u003Cli>A complete and final review of representative batches within expiry and their related information before the QU disposition decision\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Practice of Releasing Drug Products Close to Expiration\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on a review of documents you provided, you released multiple lots of OTC drug products within a few months of expiry, including one released with only 1 month before the drug product expiry. Of note, FDA documented instances of drug products that you discontinued, and past your expiration date, for sale online well after they expired, which could be attributed to your practice of distributing drugs close to expiry.\u003C\u002Fp>\u003Cp>\u003Cstrong>Reformulation to No Longer Use Talc in High-Risk Dosage Forms\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In your response to our additional request for records you indicated that you would be reformulating your drug products containing talc. In response to this letter provide an update on your reformulation efforts to move to an alternative not associated with risks of talc.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Specifications Regarding Talc\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Talc is a USP article, whose specification can be found in the current USP talc monograph. As\u003Cbr>mentioned above, the specific test for asbestos is included in the talc monograph. Be advised that\u003Cbr>drugs including components, such as talc, that are recognized in the USP are generally required\u003Cbr>to meet the current applicable USP monograph under section 501(b) of the FD&amp;C Act. FDA\u003Cbr>reviewed your specifications for talc components and they are incomplete when compared to the\u003Cbr>current USP specification. We note that the USP has recently revised its monograph for talc\u003Cbr>which includes updated technical requirements for asbestos testing in talc and is currently\u003Cbr>scheduled to be official in June 2026.&nbsp;\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1021184 and ATTN: Nancy Espinal.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cstrong>1\u003C\u002Fstrong> https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\u003C\u002Fp>\u003Cp>\u003Cstrong>2\u003C\u002Fstrong> https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-89\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. David Hamilton\n\nRecipient Title\n\nVice President of Operations\n\nRevlon Group Holdings, LLC\n\n1501 Williamsboro St.\n\nOxford, NC 27565\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-89\nJune 2, 2026\nDear Mr. Hamilton:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 8, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Revlon – Oxford Facility, FEI 1021184, at 1501 Williamsboro St., Oxford, as well as subsequent correspondence.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violation were observed including, but not limited to, the following:\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\nYour firm manufactured (b)(4), an OTC (b)(4) drug product labeled to contain the active drug ingredient (b)(4). You currently manufacture (b)(4) OTC drug product labeled to contain the active drug ingredient (b)(4). These drug products listed above are labeled to contain the inactive ingredient talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.1,2 Your (b)(4) drug product, (b)(4), is considered a higher-risk drug as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation.\nYou have not demonstrated that you appropriately tested incoming talc drug components used in the manufacture of your (b)(4) drug products for identity, purity, strength, and quality. In response to our 704(a)(4) request, you originally indicated that you did perform testing for asbestos in talc before release for use in drug product manufacturing. In subsequent correspondence, the data you provided only clarified that your talc components were tested for asbestos by the supplier and not by you. Evidence was not provided that your firm conducts asbestos testing at your facility. You failed to provide records indicating that you established the reliability of your supplier’s analyses through appropriate validation of the supplier’s test results. Although 21 CFR 211.84(d)(2) provides for some reliance on a certificate of analysis (COA) from the supplier of the component, such reliance is permissible only if the drug product manufacturer establishes the reliability of the supplier’s test results through appropriate validation of the test results at appropriate intervals.\nAdditionally, you provided records to demonstrate you had conducted identity testing pursuant to the applicable United States Pharmacopeia (USP) test to satisfy the requirements for identity testing in 211.84(d)(1) and (2), but the testing does not conform to the current USP testing method, in that it is incomplete (i.e., lacks identification B and C). Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\nAs a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\nIn response to this letter, provide:\nIdentity, assay and impurity test results from testing retains for all lots of talc (drug component) used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.\nA description of how you will test each component lot for conformity with all appropriate written specifications for identity, purity, strength, and quality. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\nThe chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.\nA gap analysis for specifications for drug components (active and inactive) between your current specifications and test procedures against the USP, where applicable. Based on your gap analysis, provide a comprehensive plan for conformance of your drug component specifications and testing to USP standards, where applicable.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that your test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). The current USP talc monograph could be used to meet this requirement for talc; however, your specifications for talc components did not include testing for assay, and multiple impurities (e.g., limits of (b)(4)). Beyond the deficiencies in testing detailed above, your talc microbiological specifications for “yeast and mold” of (b)(4) cfu\u002Fg exceeds USP specification for total combined molds and yeasts of Not More Than (NMT) (b)(4) cfu\u002Fg for talc used in (b)(4) drug products. Your COA reports microbiological test results as \"CONFORM\" without including a quantitative value, which would not be sufficient for the QU to make an informed release decision or determine if the result meets the USP requirement. Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.\nYour QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\nA determination of whether procedures used by your firm are robust and appropriate\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\nA complete and final review of representative batches within expiry and their related information before the QU disposition decision\nPractice of Releasing Drug Products Close to Expiration\nBased on a review of documents you provided, you released multiple lots of OTC drug products within a few months of expiry, including one released with only 1 month before the drug product expiry. Of note, FDA documented instances of drug products that you discontinued, and past your expiration date, for sale online well after they expired, which could be attributed to your practice of distributing drugs close to expiry.\nReformulation to No Longer Use Talc in High-Risk Dosage Forms\nIn your response to our additional request for records you indicated that you would be reformulating your drug products containing talc. In response to this letter provide an update on your reformulation efforts to move to an alternative not associated with risks of talc.\nQuality Specifications Regarding Talc\nTalc is a USP article, whose specification can be found in the current USP talc monograph. As\nmentioned above, the specific test for asbestos is included in the talc monograph. Be advised that\ndrugs including components, such as talc, that are recognized in the USP are generally required\nto meet the current applicable USP monograph under section 501(b) of the FD&C Act. FDA\nreviewed your specifications for talc components and they are incomplete when compared to the\ncurrent USP specification. We note that the USP has recently revised its monograph for talc\nwhich includes updated technical requirements for asbestos testing in talc and is currently\nscheduled to be official in June 2026.\n\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1021184 and ATTN: Nancy Espinal.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________________\n1 https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\n2 https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F","Revlon Group Holdings, LLC","revlon-group-holdings-llc-722596-06022026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frevlon-group-holdings-llc-722596-06022026","2026-10-26T08:09:49.211168+00:00","2026-06-09","722596","Mr. David Hamilton","2026-08-19T04:38:12.564+00:00","320-26-89","2026-06-02",{"id":252,"raw":253,"subject":59,"body_html":257,"body_text":258,"firm_name":259,"letter_id":260,"created_at":64,"fei_number":20,"letter_url":261,"updated_at":262,"action_type":23,"case_status":24,"posted_date":263,"marcs_cms_no":264,"product_type":69,"closeout_date":20,"issuing_office":70,"recipient_name":265,"body_fetched_at":266,"delivery_method":95,"recipient_title":20,"reference_number":20,"action_taken_date":267,"medical_device_id":20,"response_letter_date":20},2135,[254,255,256,58,59,13,13,13],"\u003Ctime datetime=\"2023-04-18T13:20:00Z\">04\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-04-05T04:00:00Z\">04\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchemical-services-group-incroyal-chemical-company-648378-04052023\">Chemical Services Group, Inc.\u002FRoyal Chemical Company\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Matt Dailey\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chemical Services Group, Inc.\u002FRoyal Chemical Company\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8679 South Freeway Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Macedonia\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>44056-1535\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:matt.dailey@royalchemical.com\"> matt.dailey@royalchemical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 648378\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 5, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Dailey:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Royal Chemical Company, FEI 2517008, at 1336 Crowe Road, East Stroudsburg, Pennsylvania 18301, from October 31 to November 8, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 22, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactured over-the-counter (OTC) hand sanitizer drug products\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on equipment also used to manufacture industrial chemicals, including those for cleaning, polymer production, and paint additives. It is unacceptable as a matter of CGMP to manufacture drugs using the same equipment that you use to manufacture these non-pharmaceutical products due to the risk of cross-contamination. Additionally, your drug component and bulk drug product transfer pipes were found open to the outside environment. Your firm lacked procedures to clean the transfer pipes and external storage tanks.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Confirmation whether you will discontinue manufacturing drugs on shared equipment in your facility. If you intend to continue to manufacture both pharmaceutical and non-pharmaceutical products at your facility, provide a plan to show how you will separate the areas in which you will maintain dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\u003C\u002Fli>\n\t\u003Cli>A risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\u003C\u002Fli>\n\t\u003Cli>For drug product dedicated equipment, a comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment, facility piping, or storage tankers that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm relied on certificates of analysis (COA) from unqualified suppliers for your ethanol for specifications such as purity, strength, and quality. By not adequately analyzing your components for identity, purity, strength, and quality, you failed to ensure your incoming components meet appropriate specifications.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, you only identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> ethanol suppliers and manufacturers in use. However, in response to FDA’s August 31, 2022 request for records and other information pursuant to section 704(a)(4) of the FD&amp;C Act, you identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> additional suppliers of ethanol.\u003C\u002Fp>\n\n\u003Cp>Furthermore, separate ethanol lots appear to have been co-mingled in a storage tanker for use in hand sanitizer manufacture. The supplier and ethanol lot number are not recorded in your manufacturing records which only list the ethanol source as “bulk.” The lack of supplier testing verification, co-mingling of component lots, and inadequate batch traceability poses a significant risk to consumers and hinders your ability to adequately respond to any ethanol related investigations and product recalls.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Confirmation that ethanol you use as a drug substance meets, at a minimum, the standards delineated in the USP monograph for ethanol.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>Procedures for controlling incoming raw materials including, but not limited to, ensuring that they are not co-mingled. In addition, provide an analysis of storage tanks that held ethanol and bulk hand sanitizer, and whether material from those tanks could have been contaminated via co-mingling or inadequate cleaning.\u003C\u002Fli>\n\t\u003Cli>A list of all ethanol grades, lots, and manufacturers used from January 2022 to the present.\u003C\u002Fli>\n\t\u003Cli>An action plan for any hand sanitizer drug product released to the market manufactured with ethanol that does not comply with USP standards. This plan should include a list of batches, volume distributed, manufacture and expiry dates, and test results.\u003C\u002Fli>\n\t\u003Cli>Controls for maintaining traceability of ethanol lots used in drug product manufacture, including procedures and an updated Master Batch Record.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish acceptance criteria for the sampling and testing conducted by the quality control unit that are adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release (21 CFR 211.165(d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm sampled in process material for the purpose of batch release testing which likewise did not include all appropriate tests to ensure that the finished drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Specifically, batches were \u003Cstrong>(b)(4)\u003C\u002Fstrong> removal from the bulk hand sanitizer and your batch release testing did not include known impurities, such as for methanol and benzene.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbiological specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) failed to provide adequate oversight of the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Written procedures for equipment and facility cleaning, monitoring, and cleaning of your water system, vendor qualification, packaging and labeling operations, process validation, and the release of drug products (21 CFR 211.22(d)).\u003C\u002Fli>\n\t\u003Cli>Adequate investigation into high colony counts in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system used to generate component \u003Cstrong>(b)(4)\u003C\u002Fstrong> water for your drug products. (21 CFR 211.192).\u003C\u002Fli>\n\t\u003Cli>Validation of manufacturing processes before release of material to the market (21 CFR 100(a)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The CGMP regulations assign responsibilities to the QU which include approving or rejecting incoming materials, in-process materials, and drug products; ensuring that controls are implemented and completed satisfactorily during manufacturing operations; and reviewing production records and investigating any unexplained discrepancies. You have not demonstrated that you have a QU capable of these responsibilities.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to orapharm1_responses@fda.hhs.gov. Your written notification should refer to the Warning Letter, CMS # 648378 and reference: FEI 2517008.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact Compliance Officer CAPT Liatte Closs at liatte.closs@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOPQO Division I\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nMr. Bryan Benner, Director of Quality\u003Cbr>\nRoyal Chemical Company\u003Cbr>\n1336 Crowe Rd\u003Cbr>\nE Stroudsburg, PA 18301\u003Cbr>\nBryan.Benner@RoyalChemical.com\u003C\u002Fp>\n\n\u003Cp>Mr. Dave DeBord, COO\u003Cbr>\nRoyal Chemical Company\u003Cbr>\n1336 Crowe Rd\u003Cbr>\nE Stroudsburg, PA 18301\u003Cbr>\ndave.debord@royalchemical.com\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (\u003Cstrong>86 Fed Reg at 56960\u003C\u002Fstrong>). This guidance communicated the agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because Royal Chemical Company hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Matt Dailey\n\nRecipient Title\n\nCEO & President\n\nChemical Services Group, Inc.\u002FRoyal Chemical Company\n\n8679 South Freeway Drive\n\nMacedonia, OH 44056-1535\n\nUnited States\n\nmatt.dailey@royalchemical.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWARNING LETTER\n\nCMS # 648378\n\nApril 5, 2023\n\nDear Mr. Dailey:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Royal Chemical Company, FEI 2517008, at 1336 Crowe Road, East Stroudsburg, Pennsylvania 18301, from October 31 to November 8, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your November 22, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nYour firm manufactured over-the-counter (OTC) hand sanitizer drug products1 on equipment also used to manufacture industrial chemicals, including those for cleaning, polymer production, and paint additives. It is unacceptable as a matter of CGMP to manufacture drugs using the same equipment that you use to manufacture these non-pharmaceutical products due to the risk of cross-contamination. Additionally, your drug component and bulk drug product transfer pipes were found open to the outside environment. Your firm lacked procedures to clean the transfer pipes and external storage tanks.\n\nIn response to this letter, provide:\n\nConfirmation whether you will discontinue manufacturing drugs on shared equipment in your facility. If you intend to continue to manufacture both pharmaceutical and non-pharmaceutical products at your facility, provide a plan to show how you will separate the areas in which you will maintain dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\n\nA risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\n\nFor drug product dedicated equipment, a comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment, facility piping, or storage tankers that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\nA summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n2. Your firm failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(2)).\n\nYour firm relied on certificates of analysis (COA) from unqualified suppliers for your ethanol for specifications such as purity, strength, and quality. By not adequately analyzing your components for identity, purity, strength, and quality, you failed to ensure your incoming components meet appropriate specifications.\n\nAdditionally, during the inspection, you only identified (b)(4) ethanol suppliers and manufacturers in use. However, in response to FDA’s August 31, 2022 request for records and other information pursuant to section 704(a)(4) of the FD&C Act, you identified (b)(4) additional suppliers of ethanol.\n\nFurthermore, separate ethanol lots appear to have been co-mingled in a storage tanker for use in hand sanitizer manufacture. The supplier and ethanol lot number are not recorded in your manufacturing records which only list the ethanol source as “bulk.” The lack of supplier testing verification, co-mingling of component lots, and inadequate batch traceability poses a significant risk to consumers and hinders your ability to adequately respond to any ethanol related investigations and product recalls.\n\nIn response to this letter, provide:\n\nConfirmation that ethanol you use as a drug substance meets, at a minimum, the standards delineated in the USP monograph for ethanol.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nProcedures for controlling incoming raw materials including, but not limited to, ensuring that they are not co-mingled. In addition, provide an analysis of storage tanks that held ethanol and bulk hand sanitizer, and whether material from those tanks could have been contaminated via co-mingling or inadequate cleaning.\n\nA list of all ethanol grades, lots, and manufacturers used from January 2022 to the present.\n\nAn action plan for any hand sanitizer drug product released to the market manufactured with ethanol that does not comply with USP standards. This plan should include a list of batches, volume distributed, manufacture and expiry dates, and test results.\n\nControls for maintaining traceability of ethanol lots used in drug product manufacture, including procedures and an updated Master Batch Record.\n\n3. Your firm failed to establish acceptance criteria for the sampling and testing conducted by the quality control unit that are adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release (21 CFR 211.165(d)).\n\nYour firm sampled in process material for the purpose of batch release testing which likewise did not include all appropriate tests to ensure that the finished drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Specifically, batches were (b)(4) removal from the bulk hand sanitizer and your batch release testing did not include known impurities, such as for methanol and benzene.\n\nIn response to this letter, provide:\n\nA list of chemical and microbiological specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\n\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) failed to provide adequate oversight of the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\n\nWritten procedures for equipment and facility cleaning, monitoring, and cleaning of your water system, vendor qualification, packaging and labeling operations, process validation, and the release of drug products (21 CFR 211.22(d)).\n\nAdequate investigation into high colony counts in your (b)(4) system used to generate component (b)(4) water for your drug products. (21 CFR 211.192).\n\nValidation of manufacturing processes before release of material to the market (21 CFR 100(a)).\n\nThe CGMP regulations assign responsibilities to the QU which include approving or rejecting incoming materials, in-process materials, and drug products; ensuring that controls are implemented and completed satisfactorily during manufacturing operations; and reviewing production records and investigating any unexplained discrepancies. You have not demonstrated that you have a QU capable of these responsibilities.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.2 Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to orapharm1_responses@fda.hhs.gov. Your written notification should refer to the Warning Letter, CMS # 648378 and reference: FEI 2517008.\n\nIf you have any questions, contact Compliance Officer CAPT Liatte Closs at liatte.closs@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nU.S. Food and Drug Administration\n\nOPQO Division I\n\nCC:\n\nMr. Bryan Benner, Director of Quality\n\nRoyal Chemical Company\n\n1336 Crowe Rd\n\nE Stroudsburg, PA 18301\n\nBryan.Benner@RoyalChemical.com\n\nMr. Dave DeBord, COO\n\nRoyal Chemical Company\n\n1336 Crowe Rd\n\nE Stroudsburg, PA 18301\n\ndave.debord@royalchemical.com\n\n______________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because Royal Chemical Company hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Chemical Services Group, Inc.\u002FRoyal Chemical Company","chemical-services-group-incroyal-chemical-company-648378-04052023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchemical-services-group-incroyal-chemical-company-648378-04052023","2026-10-26T08:08:14.181719+00:00","2023-04-18","648378","Mr. Matt Dailey","2026-08-20T01:09:28.248+00:00","2023-04-05",13,{"510k":270,"classification":271,"enforcement":272,"event":273,"event_backfill":274,"pma":275,"warning_letter":276},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]